Author: "Hospital Clínico San Carlos" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Hospital Clínico San Carlos"' showing total 8,235 results

Start Over Author "Hospital Clínico San Carlos"

8,235 results on '"Hospital Clínico San Carlos"'

1. No-biopsy Approach in Celiac Disease: Cut-off Points for IgA Anti-tissue Transglutaminase Assays

Author: Hospital Universitari Mutua Terrassa, Hospital Sant Joan de Deu, Hospital Universitario Ramon y Cajal, Hospital Universitario Lucus Augusti, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, and Marta Molero, Doctor
Published: 2024

2. Therapy Strategies After LAA Occluder Device Embolization (LAAODE)

Author: Kerstin Piayda, CardioVascular Center Frankfurt, Frankfurt, Germany, Kolja Sievert, CardioVascular Center Frankfurt, Frankfurt, Germany, Roberto Galea, Universitätsspital Bern, Bern, Switzerland, Moniek Maarse, St. Antonius Ziekenhuis, Nieuwegein, Netherlands, Sheba Medical Center, Andrey Osadchiy, City Hospital #40, St. Petersburg, Russia, Andrey Kalemberg, National Research Center, Moscow, Russia, Jung-Sun Kim, Yonsei University Hospital, Seoul, South Korea, Kasper Korsholm, Aarhus University Hospital, Aarhus, Denmark, Sajjad A Sabir, Cooper University Hospital, NJ, USA, Ashish Pershad, Banner Health, Phoenix, Arizona, USA, Markus Sandri, Herzzentrum Leipzig, Leipzig, Germany, Jens-Erik Nielsen-Kudsk, University Hospital Aarhus, Aarhus, Denmark, George Mark, The Heart House/Cooper University Camden, NJ, USA, Dhiraj Gupta, Liverpool Heart and Chest Hospital, Liverpool, UK, Pradhum Ram, Emory University, USA, Ole de Backer, Rigshospitalet Copenhagen, Denmark, Norbert Klein, Klinikum St. Georg, Leipzig, Germany, Josep Rodes, Laval Hospital, Quebec, Canada, Shazia Afzal, Heinrich-Heine University, University Hospital, Duesseldorf, Xavier Millán Alvarez, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, James E. Harvey, WellSpan Health, York, PA, USA, Wern Yew Ding, University of Liverpool, Liverpool, UK, Adel Aminian, Centre hospitalier universitaire de Charleroi, Brussels, Belgium, Pamela Moceri, Hopital Pasteur 1, Nice, France, Ibrahim Akin, Universitätsmedizin Mannheim, Germany, Jacques Mansourati, Hôpital de la Cavale Blanche, Brest, France, Eloi Marijon, Hôpital Européen Georges-Pompidou HEGP, Paris, France, Ignacio Amat Santos, University Clinical Hospital of Valladolid, Valladolid, Spain, Hana Vaknin Assa, Beilinson Hospital, Israel, Thomas Robert Schmidt, Herzzentrum Dresden GmbH Universitätsklinik, Dresden, Germany, Ran Kornowski, Rabin Medical Center, Petah Tiqwa, Israel, Giacomo Boccuzzi, Ospedale san Giovanni Bosco, Torino, Italy, Christopher R. Ellis, Vanderbilt University, Nashville, TN, USA, Henning Ebelt, Katholisches Krankenhaus St. Nepomuk, Erfurt, Germany, Brian Clapp, Guy's and St Thomas' NHS Foundation Trust, London, UK, Sonja Lehmann, Hôpital Fribourgeois, Freiburg, Swizerland, Oh-Hyun Lee, Yonsai University Hospital, Yongin, Korea, Wendy Schell, Cooper University Hospital, NJ, USA, Domenico della Rocca, St David's Medical Center, Austin, Texas, USA, Pablo Pinon Esteban, Hospital Universitario A Coruña, Spain, Jose Gabriel Galache Osuna, Miguel Servet University Hospital, Zaragoza, Spain, Enio Guerios, Hospital Pilar, Curitiba, Brazil, Nicolas Amabile, Institut Mutualiste Montsouris, Paris, France, Ignacio Cruz Gonzalez, University Hospital of Salamanca, Castillay Leon, Spain, Weita Chen, Taipei Municipal Wanfang Hospital, Taipei, Taiwan, Sandeep Kumar Goyal, Piedmont Heart Institute Buckhead, Atlanta, GA, USA, Francesco Gianni, Maria Cecilia Hospital, Cotignola, Italy, Máximo Rivero Ayerza, Ziekenhuis Oost Limburg, Genk, Belgium, Carsten Skurk, Charité, Universitätsmedizin Berlin, Berlin, Germany, Martin Langel, Klinikum St. Georg, Leipzig, Germany, Livia Gheorghe, Hospital de la Santa Creu I Santa Pau, Barcelona, Spain, Lino Santos, Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal, Mark Spence, Royal Victoria Hospital, Belfast Trust, Belfast, UK, Luis Nombela-Franco, Hospital Clínico San Carlos, Madrid, Spain, Francesco Nappi, Centre Cardiologique du Nord de Saint-Denis, Paris, France, Matteo Montorfano, Ospedale San Raffaele, Segrate, Milan, Italy, Juan Fernández-Armenta, Hospital Universitario Puerta del Mar, Cádiz, Spain, Michael Kühne, Universitätsspital Basel, Basel, Swizerland, Jesper van der Pals, Lund University Hospital, Lund, Sweden., Can Yücel Karabay, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Center, Istanbul, Turkey, Marco Ancona, San Raffaele Scientific Institute, Milan, Italy, Ghassan Moubarak, Clinique Ambroise Paré, Neuilly-sur-Seine, France, Tom De Potter, OLV Hospital, Aalst, Belgium, Mathieu Lempereur, CHU de Liège, Belgium, Joelle Kefer, Cliniques universitaires Saint-Luc, Bruxelles, Belgium, Evgeny Merkulov, Scientific Research Center, Moscow, Russia, Liesbeth Rosseel, ASZ Aalst, Belgium, Antti Saraste, Heart Center, Turku University Hospital, Turku, Finland, Ahmet Güner, Mehmet Akif Ersoy Hospital, Turkey, Achille Gaspardone, San Eugenio Hospital ASL Roma, Italy, and Prof. Dr. Horst Sievert, Principle Investigator
Published: 2022

3. Diversity of DNA Sequences from Pathogenic and Potentially Pathogenic Eukaryotic Microorganisms in Protected Granite Mountain Rocks

Author: Ministerio de Economía y Competitividad (España), Universidad Complutense de Madrid, Comunidad de Madrid, Fonds National Suisse de la Recherche Scientifique, Hospital Clínico San Carlos (España), Cos-Gandoy, Amaya de [0000-0003-4799-0147], Pérez-Uz, Blanca [0000-0002-3926-7031], Williams, Richard [0000-0002-3263-2657], Sánchez-Jiménez, Abel [0000-0002-7978-3436], Martín-Cereceda, Mercedes [0000-0001-7473-3061], Velasco-González, Ismael, Lara, Enrique, Singer, David, Cos-Gandoy, Amaya de, García-Rodríguez, Manuel, Murciano, Antonio, Pérez-Uz, Blanca, Williams, Richard, Sánchez-Jiménez, Abel, Martín-Cereceda, Mercedes, Ministerio de Economía y Competitividad (España), Universidad Complutense de Madrid, Comunidad de Madrid, Fonds National Suisse de la Recherche Scientifique, Hospital Clínico San Carlos (España), Cos-Gandoy, Amaya de [0000-0003-4799-0147], Pérez-Uz, Blanca [0000-0002-3926-7031], Williams, Richard [0000-0002-3263-2657], Sánchez-Jiménez, Abel [0000-0002-7978-3436], Martín-Cereceda, Mercedes [0000-0001-7473-3061], Velasco-González, Ismael, Lara, Enrique, Singer, David, Cos-Gandoy, Amaya de, García-Rodríguez, Manuel, Murciano, Antonio, Pérez-Uz, Blanca, Williams, Richard, Sánchez-Jiménez, Abel, and Martín-Cereceda, Mercedes
Abstract: Rain-fed mountain granite rock basins are temporary habitats conditioned by a fluctuating environment and the unpredictability of precipitation or flooding rates. These small highland freshwater habitats remain largely unexplored at the microbial level. The aim of this work is to report the presence in these habitats of genetic sequences of microbial eukaryotes that are pathogens and potential pathogens of humans, wildlife, cattle, crops as well as of other microorganisms. We sequenced the hypervariable region v4 of the 18S rDNA gene from environmental DNA of sediments taken from 21 rock basins in a National Park in Spain. More than a fifth (21%) of the eukaryotic Operational Taxonomic Units (OTUs) found are ascribed to pathogenic (within 11 Phyla) and potential pathogenic (within 1 phylum, the Chytridiomycota) microorganisms. Some OTUs retrieved are of agro-economic and public health importance (e.g., Pythium spp., Lagenidium spp., Candida spp. and Vermamoeba vermiformis). In 86% of the basins, the most abundant OTUs were affiliated to Chytridiomycota, a broad fungal group including saprozoic and parasitic taxa. Two OTUs affiliated to chytrids were significantly correlated with high concentrations of heavy metals. The high proportion of chytrid-like microbial sequences found emphasises the role of these freshwater habitats for adding knowledge regarding the ecological trade-offs of the still rather unknown Chytridiomycota. Our results show that rain-fed rock basins may be model habitats for the study and surveillance of microbial community dynamics and genetics of (mainly opportunistic) microbial pathogens.
Published: 2023

4. Enfermedades transmitidas por mosquito AEDES SPP. En España: resultados de la vigilancia de Dengue, enfermedad por virus CHikungunya y Zika según los casos notificados a la Red Nacional de Vigilancia Epidemiológica de 2014 a 2018

Author: Herranz-Hernández, Rafael, Hospital Clínico San Carlos, Díaz-García, Olivia, Centro Nacional de Epidemiología. Instituto de Salud Carlos III, Gómez-Barroso, Diana, Centro Nacional de Epidemiología. Instituto de Salud Carlos III. CIBER de epidemiología y salud pública., and Fernández- Martínez, Beatriz
Subjects: Dengue, Zika, vigilancia epidemiológica, salud pública, España
Published: 2021

5. ACE2 is on the X chromosome: could this explain COVID-19 gender differences?

Author: Hospital Clínico San Carlos (España), Hernández, Félix [0000-0001-8753-8249], Culebras, Esther, Hernández, Félix, Hospital Clínico San Carlos (España), Hernández, Félix [0000-0001-8753-8249], Culebras, Esther, and Hernández, Félix
Abstract: This commentary refers to ‘Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors’, by I.E. Sama et al., 2020;41:1810–1817. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease termed coronavirus disease 2019 (COVID-19) shows a fatality rate greater in men compared with women.1 To explain this, some hypotheses have been raised, from genes that regulate the immune system encoded on the X chromosome to smoking behaviour,2 to expression levels1 or variants for angiotensin-converting enzyme 2 (ACE2), the receptor for SARS-CoV-2.3However, we would like to point out that the ACE2 gene is located on the X chromosome (location: Xp22.2; nucleotides 15 494 402–15 602 148, GRCh38.hg38 version). To our knowledge, the importance of ACE2 localization on the X chromosome has not been explored previously. Often, to have two copies ameliorates the deleterious effects of X-linked diseases and, as a consequence, most X-linked syndromes produce male diseases.
Published: 2020

6. Amphiphilic acrylic nanoparticles containing the poloxamer star bayfit® 10WF15 as ophthalmic drug carriers

Author: Agencia Estatal de Investigación (España), Universidad Complutense de Madrid, European Commission, Hospital Clínico San Carlos (España), Ministerio de Ciencia, Innovación y Universidades (España), Gómez-Ballesteros, Miguel, Andrés-Guerrero, Vanessa, Parra, Francisco, Marinich, Jorge, Heras, Beatriz de las, Molina-Martínez, Irene Teresa, Vázquez-Lasa, Blanca, San Román, Julio, Herrero Vanrell, María del Rocio, Agencia Estatal de Investigación (España), Universidad Complutense de Madrid, European Commission, Hospital Clínico San Carlos (España), Ministerio de Ciencia, Innovación y Universidades (España), Gómez-Ballesteros, Miguel, Andrés-Guerrero, Vanessa, Parra, Francisco, Marinich, Jorge, Heras, Beatriz de las, Molina-Martínez, Irene Teresa, Vázquez-Lasa, Blanca, San Román, Julio, and Herrero Vanrell, María del Rocio
Abstract: Topical application of drops containing ocular drugs is the preferred non-invasive route to treat diseases that affect the anterior segment of the eye. However, the formulation of eye drops is a major challenge for pharmacists since the access of drugs to ocular tissues is restricted by several barriers. Acetazolamide (ACZ) is a carbonic anhydrase inhibitor used orally for the treatment of ocular hypertension in glaucoma. However, large ACZ doses are needed which results in systemic side effects. Recently, we synthesized copolymers based on 2-hydroxyethyl methacrylate (HEMA) and a functionalized three-arm poloxamer star (Bayfit-MA). The new material (HEMA/Bayfit-MA) was engineered to be transformed into nanoparticles without the use of surfactants, which represents a significant step forward in developing new ophthalmic drug delivery platforms. Acetazolamide-loaded nanocarriers (ACZ-NPs) were prepared via dialysis (224 ± 19 nm, −17.2 ± 0.4 mV). The in vitro release rate of ACZ was constant over 24 h (cumulative delivery of ACZ: 83.3 ± 8.4%). Following standard specifications, ACZ-NPs were not cytotoxic in vitro in cornea, conjunctiva, and macrophages. In normotensive rabbits, ACZ-NPs generated a significant intraocular pressure reduction compared to a conventional solution of ACZ (16.4% versus 9.6%) with the same dose of the hypotensive drug (20 µg). In comparison to previously reported studies, this formulation reduced intraocular pressure with a lower dose of ACZ. In summary, HEMA:Bayfit-MA nanoparticles may be a promising system for ocular topical treatments, showing an enhanced ocular bioavailability of ACZ after a single instillation on the ocular surface.
Published: 2019

7. Interplay between gut microbiota metabolism and inflammation in HIV infection

Author: Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Generalitat Valenciana, Red Española de Investigación en SIDA, Consejo Nacional de Ciencia y Tecnología (México), Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Ministerio de Ciencia e Innovación (España), Hospital Clínico San Carlos (España), Serrano-Villar, Sergio [0000-0002-5447-3554], Rattei, Tomas [0000-0002-0592-7791], Latorre, Amparo [0000-0002-9146-7284], Moya, Andrés [0000-0002-2867-1119], Vázquez-Castellanos, Jorge F., Serrano-Villar, Sergio, Jiménez-Hernández, Nuria, Soto del Rio, María Dolores, Gayo, Sara, Rojo, David, Ferrer, Manuel, Barbas, Coral, Moreno, Santiago, Estrada, Vicente, Rattei, Thomas, Latorre, Amparo, Moya, Andrés, Gosalbes, María José, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Generalitat Valenciana, Red Española de Investigación en SIDA, Consejo Nacional de Ciencia y Tecnología (México), Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Ministerio de Ciencia e Innovación (España), Hospital Clínico San Carlos (España), Serrano-Villar, Sergio [0000-0002-5447-3554], Rattei, Tomas [0000-0002-0592-7791], Latorre, Amparo [0000-0002-9146-7284], Moya, Andrés [0000-0002-2867-1119], Vázquez-Castellanos, Jorge F., Serrano-Villar, Sergio, Jiménez-Hernández, Nuria, Soto del Rio, María Dolores, Gayo, Sara, Rojo, David, Ferrer, Manuel, Barbas, Coral, Moreno, Santiago, Estrada, Vicente, Rattei, Thomas, Latorre, Amparo, Moya, Andrés, and Gosalbes, María José
Abstract: HIV infection causes a disruption of gut-associated lymphoid tissue, driving a shift in the composition of gut microbiota. A deeper understanding of the metabolic changes and how they affect the interplay with the host is needed. Here, we assessed functional modifications of HIV-associated microbiota by combining metagenomic and metatranscriptomic analyses. The transcriptionally active microbiota was well-adapted to the inflamed environment, overexpressing pathways related to resistance to oxidative stress. Furthermore, gut inflammation was maintained by the Gram-negative nature of the HIV-associated microbiota and underexpression of anti-inflammatory processes, such as short chain fatty acid biosynthesis or indole production. We performed co-occurrence and metabolic network analyses that showed relevance in the microbiota structure of both taxonomic and metabolic HIV-associated biomarkers. The Bayesian network revealed the most determinant pathways for maintaining the structure stability of the bacterial community. In addition, we identified the taxa's contribution to metabolic activities and their interactions with host health.
Published: 2018

8. Is it feasible a cure of the large brain vascular malformations?

Author: Rodríguez Boto, Gregorio and Servicio de Neurocirugía. Hospital Clínico San Carlos. Departamento de Cirugía. Facultad de Medicina. Universidad Complutense de Madrid.
Subjects: Arteriovenous malformation, Medical sciences
Abstract: Introducción: el tratamiento definitivo de las malformaciones arteriovenosas (MAVs) supratentoriales complejas (grados III, IV y V en la clasificación de Spetzler & Martin) se ha reservado, clásicamente, para aquellos pacientes con cuadros clínicos progresivos o que habían presentado hemorragia cerebral. Objetivo: publicar nuestra experiencia en el tratamiento de estas MAVs complejas por medio de la embolización en fases con Onyx y la resección microquirúrgica en un segundo tiempo. Pacientes: trece pacientes consecutivos (6 hombres y 7 mujeres) con MAVs supratentoriales, grados III, IV y V en la clasificación de Spetzler & Martin, fueron tratados entre Enero de 2009 y Junio de 2010. La edad media al principio de la terapia fue de 34 años. Todos los pacientes estaban sintomáticos: hemorragia cerebral (5 pacientes), crisis epilépticas (5 casos), cefalea (2 pacientes) y/o déficit neurológico (2 casos). El tamaño medio de las MAVs fue de 48 mm y el volumen medio previo a la embolización de 47 ml. De acuerdo a la clasificación de Spetzler & Martin, 7 pacientes presentaban MAVs grado III, 4 sujetos MAVs grado IV y 2 pacientes MAVs grado V. Resultados: el número medio de procedimientos endovasculares mediante embolización fue de 3 y la obliteración volumétrica media previa a la cirugía del 79,2%. El tiempo medio que transcurrió entre dos procedimientos embolizadores fue de 24 días. Un paciente mostró una complicación no incapacitante tras este tratamiento endovascular. El tiempo medio entre el último procedimiento embolizador y la cirugía fue de 42 días. El volumen medio de transfusión intraoperatorio fue de 471,4 ml. Dos pacientes desarrollaron complicaciones incapacitantes tras la intervención quirúrgica y otro paciente, una complicación no incapacitante. La angiografía de control postquirúrgica demostró la resección completa de las MAVs en todos los pacientes. La puntuación en la Escala de Rankin modificada a los 6 meses de seguimiento fue de 0 en 10 pacientes, 1 en 1 paciente y 2 en 2 pacientes. Por tanto, todos los pacientes son a día de hoy, independientes para sus actividades de la vida diaria. Solo un paciente se encuentra funcionalmente peor tras completar el tratamiento. La angiografía de control al año de seguimiento se ha realizado en 11 pacientes y ha confirmado la ausencia de permeabilidad de las MAVs y por tanto, la curación definitiva de estos pacientes pese a la existencia de material de Onyx intravascular de carácter residual. Conclusión: la embolización con Onyx en diversas fases seguida de la resección microquirúrgica de las MAVs supratentoriales complejas, consigue la curación en el 100% de los pacientes con una mortalidad del 0%, un 15,4% de complicaciones incapacitantes y un 15,4% de complicaciones no incapacitantes. Estos resultados son superiores a la historia natural de la propia enfermedad. Finalmente, hemos demostrado que no es necesaria la resección de la totalidad del Onyx intravascular para lograr la exclusión completa de la MAV y por tanto, la curación del paciente., Introduction: definitive treatment of complex supratentorial arteriovenous malformations (AVMs) (Spetzler-Martin grades III, IV and V) has been classically assigned to ruptured or progressively symptomatic cases. Aim: to report our initial experience in the treatment of complex AVMs by means of staged embolization with Onyx followed by microsurgery. Patients: thirteen consecutive patients (6 males and 7 females) with Spetzler-Martin grades III, IV and V supratentorial AVMs were treated between January 2009 and June 2010. Mean age at the beginning of the therapy was 34. All patients were symptomatic: intracranial haemorrhage (5), seizures (5), headache (2) and/or neurological deficit (2 cases). Mean AVM size was 48 mm and mean volume prior to embolization was 47 ml. According to the Spetzler-Martin grading scale seven patients were classified as grade III, four patients as grade IV and two patients as grade V. Results: mean number of endovascular procedures was 3, and mean volumetric obliteration prior to surgery was 79.2%. Mean time between two embolizations was 24 days. One patient showed a non-disabling complication after endovascular procedures. Mean time between the last embolization and surgery was 42 days. Mean blood transfusion volume was 471.4 ml. Two patients showed disabling complications after surgery and one patient showed a non-disabling complication. Follow-up angiography showed complete removal of permeable AVM in all patients. Modified Rankin Scale score at 6-month follow-up was 0 in 10 patients, 1 in 1 patient and 2 in 2 patients. All patients were, therefore, non-dependent concerning daily life activity. Only one patient was functionally worse after the treatment but also cured. One-year follow-up angiography has been performed in 11 patients so far showing an absence of permeable AVM in spite of the remainder intravascular Onyx. Conclusion: preoperative embolization staging with Onyx followed by microsurgery has made possible 100% cure of complex AVMs with 0% mortality, 15.4% disabling complications and 15.4% non-disabling complications. These results are superior to the natural history of the own disease. Complete onyx resection is not essential in order to achieve the cure of the patient.
Published: 2013

9. ¿Es factible la curación de las grandes malformaciones vasculares cerebrales?

Author: Rodríguez Boto, Gregorio and Servicio de Neurocirugía. Hospital Clínico San Carlos. Departamento de Cirugía. Facultad de Medicina. Universidad Complutense de Madrid.
Subjects: Arteriovenous malformation, Medical sciences
Abstract: Introducción: el tratamiento definitivo de las malformaciones arteriovenosas (MAVs) supratentoriales complejas (grados III, IV y V en la clasificación de Spetzler & Martin) se ha reservado, clásicamente, para aquellos pacientes con cuadros clínicos progresivos o que habían presentado hemorragia cerebral. Objetivo: publicar nuestra experiencia en el tratamiento de estas MAVs complejas por medio de la embolización en fases con Onyx y la resección microquirúrgica en un segundo tiempo. Pacientes: trece pacientes consecutivos (6 hombres y 7 mujeres) con MAVs supratentoriales, grados III, IV y V en la clasificación de Spetzler & Martin, fueron tratados entre Enero de 2009 y Junio de 2010. La edad media al principio de la terapia fue de 34 años. Todos los pacientes estaban sintomáticos: hemorragia cerebral (5 pacientes), crisis epilépticas (5 casos), cefalea (2 pacientes) y/o déficit neurológico (2 casos). El tamaño medio de las MAVs fue de 48 mm y el volumen medio previo a la embolización de 47 ml. De acuerdo a la clasificación de Spetzler & Martin, 7 pacientes presentaban MAVs grado III, 4 sujetos MAVs grado IV y 2 pacientes MAVs grado V. Resultados: el número medio de procedimientos endovasculares mediante embolización fue de 3 y la obliteración volumétrica media previa a la cirugía del 79,2%. El tiempo medio que transcurrió entre dos procedimientos embolizadores fue de 24 días. Un paciente mostró una complicación no incapacitante tras este tratamiento endovascular. El tiempo medio entre el último procedimiento embolizador y la cirugía fue de 42 días. El volumen medio de transfusión intraoperatorio fue de 471,4 ml. Dos pacientes desarrollaron complicaciones incapacitantes tras la intervención quirúrgica y otro paciente, una complicación no incapacitante. La angiografía de control postquirúrgica demostró la resección completa de las MAVs en todos los pacientes. La puntuación en la Escala de Rankin modificada a los 6 meses de seguimiento fue de 0 en 10 pacientes, 1 en 1 paciente y 2 en 2 pacientes. Por tanto, todos los pacientes son a día de hoy, independientes para sus actividades de la vida diaria. Solo un paciente se encuentra funcionalmente peor tras completar el tratamiento. La angiografía de control al año de seguimiento se ha realizado en 11 pacientes y ha confirmado la ausencia de permeabilidad de las MAVs y por tanto, la curación definitiva de estos pacientes pese a la existencia de material de Onyx intravascular de carácter residual. Conclusión: la embolización con Onyx en diversas fases seguida de la resección microquirúrgica de las MAVs supratentoriales complejas, consigue la curación en el 100% de los pacientes con una mortalidad del 0%, un 15,4% de complicaciones incapacitantes y un 15,4% de complicaciones no incapacitantes. Estos resultados son superiores a la historia natural de la propia enfermedad. Finalmente, hemos demostrado que no es necesaria la resección de la totalidad del Onyx intravascular para lograr la exclusión completa de la MAV y por tanto, la curación del paciente. Introduction: definitive treatment of complex supratentorial arteriovenous malformations (AVMs) (Spetzler-Martin grades III, IV and V) has been classically assigned to ruptured or progressively symptomatic cases. Aim: to report our initial experience in the treatment of complex AVMs by means of staged embolization with Onyx followed by microsurgery. Patients: thirteen consecutive patients (6 males and 7 females) with Spetzler-Martin grades III, IV and V supratentorial AVMs were treated between January 2009 and June 2010. Mean age at the beginning of the therapy was 34. All patients were symptomatic: intracranial haemorrhage (5), seizures (5), headache (2) and/or neurological deficit (2 cases). Mean AVM size was 48 mm and mean volume prior to embolization was 47 ml. According to the Spetzler-Martin grading scale seven patients were classified as grade III, four patients as grade IV and two patients as grade V. Results: mean number of endovascular procedures was 3, and mean volumetric obliteration prior to surgery was 79.2%. Mean time between two embolizations was 24 days. One patient showed a non-disabling complication after endovascular procedures. Mean time between the last embolization and surgery was 42 days. Mean blood transfusion volume was 471.4 ml. Two patients showed disabling complications after surgery and one patient showed a non-disabling complication. Follow-up angiography showed complete removal of permeable AVM in all patients. Modified Rankin Scale score at 6-month follow-up was 0 in 10 patients, 1 in 1 patient and 2 in 2 patients. All patients were, therefore, non-dependent concerning daily life activity. Only one patient was functionally worse after the treatment but also cured. One-year follow-up angiography has been performed in 11 patients so far showing an absence of permeable AVM in spite of the remainder intravascular Onyx. Conclusion: preoperative embolization staging with Onyx followed by microsurgery has made possible 100% cure of complex AVMs with 0% mortality, 15.4% disabling complications and 15.4% non-disabling complications. These results are superior to the natural history of the own disease. Complete onyx resection is not essential in order to achieve the cure of the patient.
Published: 2013

10. Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19

Author: Mulet, Alba, Carbonell, Juan Antonio, Soriano, Joan B, Nuñez Gil, Ivan Javier, Viana-Llamas, María C., RAPOSEIRAS-ROUBIN, SERGIO, Uribarri, Aitor, Institut Català de la Salut, [Mulet A] Pulmonary Department, Hospital Clínico Universitario Valencia, INCLIVA, Valencia, Spain. [Núñez-Gil IJ] Cardiology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Carbonell JA] Bioinformatics and Biostatistics Unit, INCLIVA, Valencia, Spain. [Soriano JB] Faculty of Medicine, Universitat de les Illes Balears, Palma, Spain. Centro de Investigación en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. [Viana-Llamas MC] Intensive Medicine Department, Hospital Universitario Guadalajara, Guadalajara, Spain. [Raposeiras-Roubin S] National Center for Cardiovascular Research (CNIC), Department of Cardiology, Álvaro Cunqueiro University Hospital, Vigo, Spain. [Uribarri A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Pulmons - Malalties - Prognosi, Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Interstitial [DISEASES], enfermedades respiratorias::enfermedades pulmonares::enfermedades pulmonares intersticiales [ENFERMEDADES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Diagnosis::Prognosis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], COVID-19 (Malaltia), diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Abstract: COVID-19; Interstitial lung diseases; Mortality COVID-19; Malalties pulmonars intersticials; Mortalitat COVID-19; Enfermedades pulmonares intersticiales; Mortalidad Background: Concern has risen about the effects of COVID-19 in interstitial lung disease (ILD) patients. The aim of our study was to determine clinical characteristics and prognostic factors of ILD patients admitted for COVID-19. Methods: Ancillary analysis of an international, multicenter COVID-19 registry (HOPE: Health Outcome Predictive Evaluation) was performed. The subgroup of ILD patients was selected and compared with the rest of the cohort. Results: A total of 114 patients with ILDs were evaluated. Mean ± SD age was 72.4 ± 13.6 years, and 65.8% were men. ILD patients were older, had more comorbidities, received more home oxygen therapy and more frequently had respiratory failure upon admission than non-ILD patients (all p < 0.05). In laboratory findings, ILD patients more frequently had elevated LDH, C-reactive protein, and D-dimer levels (all p < 0.05). A multivariate analysis showed that chronic kidney disease and respiratory insufficiency on admission were predictors of ventilatory support, and that older age, kidney disease and elevated LDH were predictors of death. Conclusions: Our data show that ILD patients admitted for COVID-19 are older, have more comorbidities, more frequently require ventilatory support and have higher mortality than those without ILDs. Older age, kidney disease and LDH were independent predictors of mortality in this population.
Published: 2023

11. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry

Author: Abumayyaleh, Mohammad, Nuñez Gil, Ivan Javier, Viana-Llamas, María C., RAPOSEIRAS-ROUBIN, SERGIO, Romero, Rodolfo, Alfonso, Emilio, Uribarri, Aitor, Institut Català de la Salut, [Abumayyaleh M] Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, Mannheim, Germany. [Núñez Gil IJ] Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación, Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Viana-LLamas MC] Hospital Universitario Guadalajara, Guadalajara, Spain. [Raposeiras Roubin S] University Hospital Álvaro Cunqueiro, Vigo, Spain. [Romero R] Hospital Universitario Getafe, Getafe, Universidad Europea, Madrid, Spain. [Alfonso-Rodríguez E] Hospital University of Bellvitge, Barcelona, Spain. [Uribarri A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigacion Biomedica en Red para Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Diabetis, enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus [ENFERMEDADES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], COVID-19 (Malaltia), Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [DISEASES]
Abstract: SARS-CoV-2; Reinfection; Respiratory complications SARS-CoV-2; Reinfección; Complicaciones respiratorias SARS-CoV-2; Reinfecció; Complicacions respiratòries Background: Diabetes mellitus (DM) is one of the most frequent comorbidities in patients suffering from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a higher rate of severe course of coronavirus disease (COVID-19). However, data about post-COVID-19 syndrome (PCS) in patients with DM are limited. Methods: This multicenter, propensity score-matched study compared long-term follow-up data about cardiovascular, neuropsychiatric, respiratory, gastrointestinal, and other symptoms in 8,719 patients with DM to those without DM. The 1:1 propensity score matching (PSM) according to age and sex resulted in 1,548 matched pairs. Results: Diabetics and nondiabetics had a mean age of 72.6 ± 12.7 years old. At follow-up, cardiovascular symptoms such as dyspnea and increased resting heart rate occurred less in patients with DM (13.2% vs. 16.4%; p = 0.01) than those without DM (2.8% vs. 5.6%; p = 0.05), respectively. The incidence of newly diagnosed arterial hypertension was slightly lower in DM patients as compared to non-DM patients (0.5% vs. 1.6%; p = 0.18). Abnormal spirometry was observed more in patients with DM than those without DM (18.8% vs. 13; p = 0.24). Paranoia was diagnosed more frequently in patients with DM than in non-DM patients at follow-up time (4% vs. 1.2%; p = 0.009). The incidence of newly diagnosed renal insufficiency was higher in patients suffering from DM as compared to patients without DM (4.8% vs. 2.6%; p = 0.09). The rate of readmission was comparable in patients with and without DM (19.7% vs. 18.3%; p = 0.61). The reinfection rate with COVID-19 was comparable in both groups (2.9% in diabetics vs. 2.3% in nondiabetics; p = 0.55). Long-term mortality was higher in DM patients than in non-DM patients (33.9% vs. 29.1%; p = 0.005). Conclusions: The mortality rate was higher in patients with DM type II as compared to those without DM. Readmission and reinfection rates with COVID-19 were comparable in both groups. The incidence of cardiovascular symptoms was higher in patients without DM.
Published: 2023

12. Failure of early non-invasive ventilation in preterm infants with respiratory distress syndrome in current care practice in Spanish level-III neonatal intensive care units – a prospective observational study

Author: Boix Alonso, Héctor, Fernandez Garcia, Cristina, Serrano Martín, María del Mar, Arruza, Luis, Concheiro-Guisan, Ana, Gimeno, Ana, Institut Català de la Salut, [Boix H] Division of Neonatology, Hospital Universitario Dexeus, Barcelona, Spain. [Fernández C] Servei de Neonatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Serrano Martín MM] Division of Neonatology, Regional University Hospital of Malaga, Málaga, Spain. [Arruza L] Department of Neonatology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Concheiro A] Department of Neonatology, Álvaro Cunqueiro University Hospital, Vigo, Spain. [Gimeno A] Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Pulmons - Malalties - Tractament, Therapeutics::Therapeutics::Emergency Treatment::Resuscitation::Therapeutics::Respiration, Artificial [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Other subheadings::Other subheadings::/adverse effects [Other subheadings], enfermedades respiratorias::enfermedades pulmonares::síndrome disneico respiratorio del recién nacido [ENFERMEDADES], Other subheadings::/therapy [Other subheadings], terapéutica::terapéutica::tratamiento de urgencia::resucitación::terapéutica::respiración artificial [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Respiració artificial - Complicacions, Otros calificadores::/terapia [Otros calificadores], Respiratory Tract Diseases::Lung Diseases::Respiratory Distress Syndrome, Newborn [DISEASES]
Abstract: Non-invasive respiratory ventilation; Preterm infant; Respiratory distress syndrome Ventilación respiratoria no invasiva; Bebé prematuro; Síndrome de dificultad respiratoria Ventilació respiratòria no invasiva; Nadó prematur; Síndrome de dificultat respiratòria Introduction: Despite advances in respiratory distress syndrome (RDS) management over the past decade, non-invasive ventilation (NIV) failure is frequent and associated with adverse outcomes. There are insufficient data on the failure of different NIV strategies currently used in clinical practice in preterm infants. Methods: This was a prospective, multicenter, observational study of very preterm infants [gestational age (GA)
Published: 2023

13. Positive airway pressure longer than 24 h is associated with histopathological volutrauma in severe COVID-19 pneumonia—an ESGFOR based narrative case-control review

Author: Veroniek Saegeman, Marta C. Cohen, Lydia Abasolo, Jordi Rello, Benjamin Fernandez-Gutierrez, Amparo Fernandez-Rodriguez, Institut Català de la Salut, [Saegeman V] Department of Microbiology and Infection Control, Vitaz, Sint-Niklaas, Belgium. Department of Infection Control, University Hospitals, Leuven, Belgium. [Cohen MC] Histopathology Department, Sheffield Children’s NHS FT, Sheffield, UK. [Abasolo L] Rheumatology Department, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), Hospital Clínico San Carlos, Madrid, Spain. [Rello J] Grup de Recerca Clínica/Innovació en la Pneumònia i Sèpsia (CRIPS), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. Clinical Research, CHRU Nimes, Nimes, France. [Fernandez-Gutierrez B] Rheumatology Department, Hospital Clinico San Carlos, Madrid, Spain. [Fernandez-Rodriguez A] Microbiology Laboratory, Biology Department, Instituto Nacional de Toxicología y Ciencias Forenses, Las Rozas de Madrid, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Therapeutics::Airway Management::Respiration, Artificial [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Pneumònia vírica, terapéutica::manejo de la via aérea::respiración artificial [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], enfermedades respiratorias::enfermedades pulmonares::neumonía [ENFERMEDADES], Other subheadings::Other subheadings::/adverse effects [Other subheadings], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Respiració artificial - Complicacions, Respiratory Tract Diseases::Lung Diseases::Pneumonia [DISEASES], COVID-19 (Malaltia) - Complicacions
Abstract: SARS-CoV-2; Post-mortem microbiology; Volutrauma SARS-CoV-2; Microbiología post mortem; Volutrauma SARS-CoV-2; Microbiologia post mortem; Volutrauma Background and Objective: A thorough understanding of the pathogenic mechanisms elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still requires further research. Until recently, only a restricted number of autopsies have been performed, therefore limiting the accurate knowledge of the lung injury associated with SARS-CoV-2. A multidisciplinary European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group of Forensic and Post-mortem Microbiology-ESGFOR team conducted a non-systematic narrative literature review among coronavirus 2019 disease (COVID-19) pneumonia cases assessing the histopathological (HP) effects of positive airways pressure. HP lung features were recorded and compared between mechanically ventilated (>24 hours) and control (ventilation 24 hours as an independent variable associated with DAD (OR =5.40, 95% CI: 1.48–19.62), fibrosis (OR =3.88, 95% CI: 1.25–12.08), vascular damage (OR =5.49, 95% CI: 1.78–16.95) and association of DAD plus fibrosis plus vascular damage (OR =6.99, 95% CI: 2.04–23.97). Conclusions: We identified that patients mechanically ventilated >24 hours had a significantly higher rate of pulmonary injury on histopathology independently of age and gender. Our findings emphasize the importance of maintaining a protective ventilator strategy when subjects with COVID-19 pneumonia undergo intubation.
Published: 2022

14. Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients

Author: Judith Abarca-Zabalía, Pilar López-Cotarelo, Manuel Comabella, Yolanda Aladro, Teresa Agudo-Jiménez, Belen Pilo, Elena Urcelay, Adela González-Jiménez, Laura Espino-Paisán, Institut Català de la Salut, [López-Cotarelo P, González-Jiménez A] Laboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Agudo-Jiménez T, Abarca-Zabalía J] Laboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Aladro Y, Pilo B] Neurology Department, Hospital Universitario de Getafe, Madrid, Spain. [Comabella M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Red Española de Esclerosis Múltiple (REEM), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Male, Esclerosi múltiple - Aspectes genètics, T-Lymphocytes, Gene Expression, Autoimmunity, Basal (phylogenetics), fenómenos genéticos::variación genética::polimorfismo genético::polimorfismo de nucleótido único [FENÓMENOS Y PROCESOS], B-Lymphocytes, Multidisciplinary, Genètica humana, medicine.diagnostic_test, Otros calificadores::Otros calificadores::/genética [Otros calificadores], CD69, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], Middle Aged, Genetic Phenomena::Genetic Variation [PHENOMENA AND PROCESSES], enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Medicine, Female, Adult, medicine.medical_specialty, Multiple Sclerosis, Science, Biology, Peripheral blood mononuclear cell, Polymorphism, Single Nucleotide, Article, Immune system, Western blot, Downregulation and upregulation, Internal medicine, fenómenos genéticos::variación genética [FENÓMENOS Y PROCESOS], medicine, Other subheadings::Other subheadings::/genetics [Other subheadings], Immunogenetics, Humans, Allele, Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide [PHENOMENA AND PROCESSES], Multiple sclerosis, Polimorfisme genètic, Genetic Variation, Membrane Proteins, medicine.disease, Gene regulation in immune cells, Endocrinology, Genetic markers, Carrier Proteins, Neurological disorders
Abstract: Autoinmunidad; Marcadores genéticos; Trastornos neurológicos Autoimmunitat; Marcadors genètics; Trastorns neurològics Autoimmunity; Genetic markers; Neurological disorders One of the 233 polymorphisms associated with multiple sclerosis (MS) susceptibility lies within the NDFIP1 gene, and it was previously identified as eQTL in healthy controls. NDFIP1 shows interesting immune functions and is involved in the development of the central nervous system. We aimed at studying the NDFIP1 variant on activation and metabolism of immune cells. NDFIP1 mRNA and protein expression were assessed in PBMCs by qPCR and western blot in 87 MS patients and 84 healthy controls genotyped for rs4912622. Immune activation after PHA stimulation was evaluated by CD69 upregulation, and metabolic function of both basal and PHA-activated lymphocytes was studied by Seahorse Xfp-Analyzer. In minor-allele homozygous controls but not in patients, we found higher NDFIP1 expression, significantly reduced protein levels, and CD69 upregulation in B- and T-cells. PBMCs from minor-allele homozygous controls showed significantly higher basal mitochondrial respiration and ATP production compared to major-allele carriers, while minor-allele homozygous patients showed significantly lower metabolic activity than carriers of the major allele. In conclusion, we describe associations in minor-allele homozygous controls with lower levels of NDFIP1 protein, CD69 upregulation, and raised mitochondrial activity, which are not replicated in MS patients, suggesting a NDFIP1 differential effect in health and disease. This work was supported by the projects PI16/01259 and PI20/01634, integrated in the Plan Nacional de I + D + I, AES 2013–2016 and 2017–2020; funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) "A way to make Europe”. LEP is recipient of a contract from “REEM: Red Española de Esclerosis Múltiple” (RETICS-REEM RD16/0015/0013; www.reem.es). AGJ and JAZ hold contracts from the program “Promoción de empleo joven y garantía juvenil-CAM” (PEJ2018-003125-A and PEJD-2019-PRE/SAL-16662).
Published: 2021

15. Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis

Author: Carmen Picón, Amalia Tejeda-Velarde, José Ignacio Fernández-Velasco, Manuel Comabella, Roberto Álvarez-Lafuente, Ester Quintana, Susana Sainz de la Maza, Enric Monreal, Noelia Villarrubia, José Carlos Álvarez-Cermeño, María Inmaculada Domínguez-Mozo, Lluís Ramió-Torrentà, Eulalia Rodríguez-Martín, Ernesto Roldán, Yolanda Aladro, Silvia Medina, Mercedes Espiño, Jaime Masjuan, Clara Matute-Blanch, Marta Muñoz-San Martín, Carmen Espejo, Carmen Guaza, Alfonso Muriel, Lucienne Costa-Frossard, Luisa María Villar, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), European Commission, Institut Català de la Salut, [Picón C] Department of Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacón Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. Department of Brain Science, Imperial College London, London, United Kingdom. [Tejeda-Velarde A, Fernández-Velasco JI] Department of Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacón Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Comabella M, Matute-Blanch C, Espejo C] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Álvarez-Lafuente R] Department of Neurology, Hospital Clínico San Carlos, Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), REEM, Madrid, Spain. [Quintana E] Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Dr. Josep Trueta, Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Medical Sciences Department, Universitat de Girona, REEM, Girona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Male, 0301 basic medicine, T-Lymphocytes, Antibodies, Viral, multiple sclerosis, B7-H1 Antigen, 0302 clinical medicine, Immunology and Allergy, Otros calificadores::Otros calificadores::/inmunología [Otros calificadores], innate immunity, Original Research, B-Lymphocytes, fenómenos fisiológicos::crecimiento y desarrollo::envejecimiento::inmunosenescencia [FENÓMENOS Y PROCESOS], Physiological Phenomena::Growth and Development::Aging::Immunosenescence [PHENOMENA AND PROCESSES], Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], adaptive immunity, Immunosenescence, Middle Aged, Acquired immune system, Activins, medicine.anatomical_structure, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Biomarker (medicine), Female, medicine.symptom, Adult, Adolescent, T cell, Immunology, Inflammation, CHI3L1, Envelliment - Aspectes immunològics, Multiple sclerosis, Young Adult, 03 medical and health sciences, Other subheadings::Other subheadings::/immunology [Other subheadings], medicine, Humans, Chitinase-3-Like Protein 1, Aged, business.industry, Oligoclonal Bands, aging, RC581-607, medicine.disease, 030104 developmental biology, inflammation, Multivariate Analysis, Linear Models, Immunologic diseases. Allergy, business, Esclerosi múltiple - Tractament, Biomarkers, 030217 neurology & neurosurgery, CD8
Abstract: Patients with multiple sclerosis (MS) suffer with age an early immunosenescence process, which influence the treatment response and increase the risk of infections. We explored whether lipid-specific oligoclonal IgM bands (LS-OCMB) associated with highly inflammatory MS modify the immunological profile induced by age in MS. This cross-sectional study included 263 MS patients who were classified according to the presence (M+, n=72) and absence (M-, n=191) of LS-OCMB. CSF cellular subsets and molecules implicated in immunosenescence were explored. In M- patients, aging induced remarkable decreases in absolute CSF counts of CD4+ and CD8+ T lymphocytes, including Th1 and Th17 cells, and of B cells, including those secreting TNF-alpha. It also increased serum anti-CMV IgG antibody titers (indicative of immunosenescence) and CSF CHI3L1 levels (related to astrocyte activation). In contrast, M+ patients showed an age-associated increase of TIM-3 (a biomarker of T cell exhaustion) and increased values of CHI3L1, independently of age. Finally, in both groups, age induced an increase in CSF levels of PD-L1 (an inductor of T cell tolerance) and activin A (part of the senescence-associated secretome and related to inflammaging). These changes were independent of the disease duration. Finally, this resulted in augmented disability. In summary, all MS patients experience with age a modest induction of T-cell tolerance and an activation of the innate immunity, resulting in increased disability. Additionally, M- patients show clear decreases in CSF lymphocyte numbers, which could increase the risk of infections. Thus, age and immunological status are important for tailoring effective therapies in MS., This work was supported by grants FIS-PI15/00513, FIS-PI18/00572 and RD16/0015/0001 from the Instituto de Salud Carlos III. Ministerio de Ciencia e Innovación, Spain and FEDER: "Una manera de hacer Europa".
Published: 2021
Full Text: View/download PDF

16. Choice of CTO scores to predict procedural success in clinical practice. A comparison of 4 different CTO PCI scores in a comprehensive national registry including expert and learning CTO operators

Author: Javier Martín-Moreiras, Ignacio J. Amat-Santos, Juan Caballero Borrego, Jesús Jiménez-Mazuecos, Gema Miñana, Julio Núñez, Pablo Salinas, Sergio Rojas, José M. de la Torre Hernández, Guillermo Galeote, Manuel Fuentes, Eva Rumiz, Sandra Santos-Martínez, Fernando Lozano, Soledad Ojeda, José Antonio Fernández-Díaz, Javier Cuesta, Daniela Dubois, Javier Lacunza, Javier Goicolea, Javier Escaned, Alejandro Diego-Nieto, Alfonso Jurado, Sergio Rodríguez-Leiras, Manel Sabaté, Victoria Martin-Yuste, Francisco J Morales-Ponce, Juan Sanchis, Nieves Gonzalo, Miriam Jiménez-Fernández, Raúl Millán, Alejandro Gutiérrez, María M. López, Juan Rondan, Manuel Pan, Francisco Bosa Ojeda, Víctor H Moreno, Beatriz Vaquerizo, Fernando Rivero, J. Robles, Dae-Hyun Lee, Mohsen Mohandes, [Salinas,P, Gonzalo,N, Moreno,VH, Escaned,J] Cardiology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Fuentes,M] Servicio de Medicina Preventiva, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. [Santos-Martinez,S, Amat-Santos,IJ] Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Fernandez-Diaz,JA, Goicolea,J] Interventional Cardiology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Bosa Ojeda,F] Servicio de Cardiología, H. Tenerife, Tenerife, Spain. [Caballero Borrego,J, Jiménez-Fernández,M] Servicio de Cardiología, HU. San Cecilio, Granada, Spain. [Cuesta,J, Rivero,F] Servicio de Cardiología, H. de la Princesa, Madrid, Spain. [de la Torre Hernández,JM, Lee,DH] Servicio de Cardiología, H. Valdecilla, Santander, Spain. [Diego-Nieto,A, Martin-Moreiras,J] Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca, IBSAL, CIBERCV, Salamanca, España. [Dubois,D, Millán,R, Vaquerizo,B] Servicio de Cardiología, H. del Mar, Barcelona, Spain. [Galeote,G, Jurado,A] Servicio de Cardiología, H. la Paz, Madrid, Spain. [Gutiérrez,A] Servicio de Cardiología, H. Jerez, Jerez, Spain. [Jiménez-Mazuecos,J] Servicio de Cardiología, H. Albacete, Albacete, Spain. [Jurado,A, Lozano,F] Servicio de Cardiología, H. Ciudad Real, Ciudad Real, Spain. [Lacunza,J] Servicio de Cardiología, H. de la Arrixaca, Murcia, Spain. [López,M] Servicio de Cardiología, H. León, León, Spain. [Martin-Yuste,V, Sabaté,M] CIBER CV, IDIBAPS, Instituto Cardiovascular, Servicio de Cardiología, H. Clinic Barcelona, Spain. [Miñana,G, Núñez,J, Sanchís,J] Servicio de Cardiología, H. Clínico de Valencia. Universidad de Valencia, CIBERCV, Valencia, Spain. [Mohandes,M, Rojas,S] Servicio de Cardiología, H. Joan XXIII, Tarragona, Spain. [Morales-Ponce,FJ] Servicio de Cardiología, H. Puerto Real, Puerto Real, Spain. [Ojeda,S, and Pan,M] Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), University of Córdoba, Córdoba, Spain. [Robles,J] Servicio de Cardiología, H. Burgos, Burgos, Spain. [Rodríguez-Leiras,S] Servicio de Cardiología, H. Virgen de la Macarena, Málaga, Spain. [Rondán,J] Servicio de Cardiología, H. Cabueñes, Gijón, Spain. [Rumiz,E] Servicio de Cardiología, H. General de Valencia, Valencia, Spain.
Subjects: Male, Calibración, Cardiovascular Procedures, Physiology, medicine.medical_treatment, Myocardial Infarction, Social Sciences, Vasos coronarios, Cardiovascular Medicine, Severity of Illness Index, Percutaneous coronary intervention, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Calibration [Medical Subject Headings], Learning and Memory, Medical Conditions, Medicine and Health Sciences, Psychology, Registries, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Coronary Artery Bypass Grafting, Multidisciplinary, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Vascular Surgical Procedures::Endovascular Procedures::Percutaneous Coronary Intervention [Medical Subject Headings], Intervención coronaria percutánea, Middle Aged, Prognosis, Interventional Cardiology, Clinical Practice, Treatment Outcome, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Health Surveys::Health Status Indicators::Patient Acuity::Severity of Illness Index [Medical Subject Headings], Cardiovascular Diseases, Integrated discrimination improvement, Area Under Curve, Cohort, Calibration, Medicine, Female, Research Article, Learning Curves, medicine.medical_specialty, Coronary Stenting, Science, Cardiology, MEDLINE, Check Tags::Male [Medical Subject Headings], Surgical and Invasive Medical Procedures, Coronary artery, Risk Assessment, Total occlusion, Calcification, Percutaneous Coronary Intervention, medicine, Humans, Learning, Registros, Aged, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], business.industry, Angioplasty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Assessment [Medical Subject Headings], Cognitive Psychology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Area Under Curve [Medical Subject Headings], Biology and Life Sciences, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Cardiovascular Disease Risk, Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Coronary Disease::Coronary Occlusion [Medical Subject Headings], Coronary Occlusion, Check Tags::Female [Medical Subject Headings], Stent Implantation, Conventional PCI, Physical therapy, Cognitive Science, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], National registry, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings], Physiological Processes, business, Coronary Angioplasty, Neuroscience
Abstract: Background We aimed to compare the performance of the recent CASTLE score to J-CTO, CL and PROGRESS CTO scores in a comprehensive database of percutaneous coronary intervention of chronic total occlusion procedures. Methods Scores were calculated using raw data from 1,342 chronic total occlusion procedures included in REBECO Registry that includes learning and expert operators. Calibration, discrimination and reclassification were evaluated and compared. Results Mean score values were: CASTLE 1.60±1.10, J-CTO 2.15±1.24, PROGRESS 1.68±0.94 and CL 2.52±1.52 points. The overall percutaneous coronary intervention success rate was 77.8%. Calibration was good for CASTLE and CL, but not for J-CTO or PROGRESS scores. Discrimination: the area under the curve (AUC) of CASTLE (0.633) was significantly higher than PROGRESS (0.557) and similar to J-CTO (0.628) and CL (0.652). Reclassification: CASTLE, as assessed by integrated discrimination improvement, was superior to PROGRESS (integrated discrimination improvement +0.036, p Conclusion Procedural percutaneous coronary intervention difficulty is not consistently depicted by available chronic total occlusion scores and is influenced by the characteristics of each chronic total occlusion cohort. In our study population, including expert and learning operators, the CASTLE score had slightly better overall performance along with CL score. However, we found only intermediate performance in the c-statistic predicting chronic total occlusion success among all scores.
Published: 2021

17. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

Author: J. Sastre, P. García-Alfonso, J.M. Viéitez, M.T. Cano, F. Rivera, J.J. Reina-Zoilo, A. Salud-Salvia, G. Quintero, L. Robles-Díaz, M.J. Safont, A. La Casta, S. Gil, E. Polo, E. Asensio-Martínez, B. García-Paredes, R.L. López, M. Guillot, M. Valladares-Ayerbes, E. Aranda, E. Díaz-Rubio, P. Jiménez, E. Aranda Aguilar, A. Gómez, S. Gil Calle, A. Salud, M. Valladares, B. Graña, J.J. Reina, E. González Flores, M. Salgado, E. Grande, C. Guillén, R. Garcia Carbonero, M.J. Flor, S. Arévalo, R. López López, H. Manzano, X. Hernández Yagüe, A. Arrivi, E. Falcó, J. Gallego, P. Escudero, I. Cabezas, A. Juárez, E. Gálvez, C. Grávalos, L. Robles, R. Dueñas, J.M. Campos, A. Albert, P. Salinas, C. Montagut, M. Provencio, A. Ruiz Casado, J. Muñoz, M. Gil Raga, M.R. Chilet, F.J. González González, B. Massutí, A. López, J. Aparicio, M. Marín, J. Alfaro, M. Zanui, D. Gutiérrez Abad, A.M. García Tapiador, C. García-Girón, J. Molina Saera, E. Torres Sánchez, I. López, C. Bosch, J. Valero, P. Martínez de Prado, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), [Sastre,J, García-Paredes,B, Díaz-Rubio,E] Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC). [García-Alfonso,P] Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid. [Viéitez,JM] Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, [Cano,MT, Aranda,E] Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba. [Rivera,F] Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander. [Reina-Zoilo,JJ] Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Seville. [Salud-Salvia,A] Hospital Universitario Arnau de Vilanova de Lleida, Lleida. [Quintero,G] Medical Oncology, Hospital Lucus Augusti, Lugo. [Robles-Díaz,L] Medical Oncology, Hospital 12 de Octubre, Madrid. [Safont,MJ] Medical Oncology, Hospital General Universitario de Valencia, Valencia. [La Casta,A] Medical Oncology, Hospital de Donostia, Guipúzcoa. [Gil,S] Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Malaga. [Polo,E] Medical Oncology, Hospital Miguel Servet, Zaragoza. [Asensio-Martínez,E] Medical Oncology, Hospital General Universitario de Elche, Alicante. [López,RL] Medical Oncology, University Clinical Hospital and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela. [Guillot,M] Medical Oncology, Hospital Son Espases, Palma de Mallorca. [Valladares-Ayerbes,M] Medical Oncology, Complejo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain., This work was supported by Roche Farma S.A (no grant number). Medical writing support was funded by Roche Farma S.A and provided by H. Lamb and L. Miller of Miller Medical Communications Ltd., and UAM. Departamento de Medicina
Subjects: Oncology, Cancer Research, Colorectal cancer, Terapia dirigida, Cetuximab, Phases of clinical research, Chemicals and Drugs::Heterocyclic Compounds::Alkaloids::Camptothecin [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings], Targeted therapy, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Neoplasias colorrectales, Antineoplastic Combined Chemotherapy Protocols, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidinones::Uracil::Fluorouracil [Medical Subject Headings], Original Research, Hazard ratio, Neoplastic Cells, Circulating, targeted therapy, Bevacizumab, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Phosphatidylinositol 3-Kinases::Phosphatidylinositol 3-Kinase::Class I Phosphatidylinositol 3-Kinases [Medical Subject Headings], FOLFIRI, Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [Medical Subject Headings], Colorectal Neoplasms, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Asthenia [Medical Subject Headings], medicine.drug, Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells, Circulating [Medical Subject Headings], Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Medicina, Class I Phosphatidylinositol 3-Kinases, colorectal cancer, Neutropenia, Neoplastic cells circulating, BRAF, Internal medicine, medicine, Humans, neoplasms, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [Medical Subject Headings], business.industry, Chemicals and Drugs::Enzymes and Coenzymes::Coenzymes::Tetrahydrofolates::Formyltetrahydrofolates::Leucovorin [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], PIK3CA, medicine.disease, digestive system diseases, Irinotecan, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Digestive::Diarrhea [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::MAP Kinase Kinase Kinases::raf Kinases::Proto-Oncogene Proteins B-raf [Medical Subject Headings], Camptothecin, business, Células neoplásicas circulantes, RAS
Abstract: Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM, Background We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). Patients and methods VISNÚ-2 was a multicentre, randomised, phase II study. Patients with RAS wild-type mCRC and 1), and allocated to bevacizumab (5 mg/kg every 2 weeks) or cetuximab (400 mg/m2 then 250 mg/m2 weekly) plus FOLFIRI [irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 (bolus) then 2400 mg/m2 (46-h continuous infusion) every 2 weeks]. The primary endpoint was progression-free survival (PFS). All analyses were exploratory. Results Two hundred and forty patients with BRAF/PIK3CA wild-type (n = 196) or BRAF- and/or PIK3CA-mutated tumours (n = 44) were enrolled. Median PFS was 12.7 and 8.8 months in patients with BRAF/PIK3CA wild-type and BRAF/PIK3CA-mutated tumours, respectively [hazard ratio (HR) = 1.22; 95% confidence interval (CI) 0.80-1.85; P = 0.3602]. In the BRAF- and/or PIK3CA-mutated cohort, median PFS was 2.8, 8.8 and 15.0 months in patients with BRAF/PI3KCA-mutated (n = 8), BRAF-mutated/PI3KCA wild-type (n = 16) and BRAF wild-type/PI3KCA-mutated (n = 20) tumours, respectively (P = 0.0002). PFS was similar with bevacizumab plus FOLFIRI versus cetuximab plus FOLFIRI in BRAF/PIK3CA wild-type (HR = 0.99; 95% CI 0.67-1.45; P = 0.9486) and BRAF/PIK3CA-mutated tumours (HR = 1.11; 95% CI 0.53-2.35; P = 0.7820). The most common grade 3/4 treatment-related adverse events were neutropenia, diarrhoea and asthenia in both treatment groups. Conclusions BRAF/PIK3CA status influences outcomes in patients with RAS wild-type mCRC but does not appear to assist with the selection of first-line targeted therapy, This work was supported by Roche Farma S.A (no grant number). Medical writing support was funded by Roche Farma S.A and provided by H. Lamb and L. Miller of Miller Medical Communications Ltd.
Published: 2021

18. A ventromedial prefrontal dysrhythmia in obsessive-compulsive disorder is attenuated by nucleus accumbens deep brain stimulation

Author: Diego Lozano-Soldevilla, Juan A. Barcia, Vanesa Soto-León, Antonio Oliviero, Blanca Reneses-Prieto, Svenja Treu, Fernando Lopez-Sosa, Javier J. Gonzalez-Rosa, Bryan A. Strange, [Treu,S, Gonzalez-Rosa,JJ, Lozano-Soldevilla,D, Lopez-Sosa,F, Strange,BA] Laboratory for Clinical Neuroscience, Centre for Biomedical Technology, Universidad Politécnica de Madrid, Spain. [Gonzalez-Rosa,JJ, Lopez-Sosa,F] University of Cadiz, Institute of Biomedical Research Cadiz (INiBICA), Cadiz, Spain. [Soto-Leon,V, Oliviero,A] Hospital Nacional de Parapléjicos, FENNSI Group, Hospital Nacional de Parapléjicos, Toledo, Spain. [Reneses-Prieto,B] Department of Psychiatry, Hospital Clínico San Carlos, Instituto de Investigacion Sanitaria San Carlos, Universidad Complutense de Madrid, Spain. [Barcia,JA] Department of Neurosurgery, Hospital Clínico San Carlos, Instituto de Investigacion Sanitaria San Carlos, Universidad Complutense de Madrid, Spain., This work was supported by Project grants SAF2015-65982-R from the Spanish Ministry of Economy and Competitiveness to BS and PSI2014-58654-JIN to JGR, an FPI Predoctoral Fellowship (BES2016-079470) to ST, and BIAL Foundation Grant 119/12 to BS. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC-2018-COG 819814)., and Psicología
Subjects: Obsessive-Compulsive Disorder, medicine.medical_treatment, Deep Brain Stimulation, Nucleus Accumbens, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Coupling, 0302 clinical medicine, Obsessive-compulsive disorder, Deep brain stimulation, EEG, media_common, General Neuroscience, European research, 05 social sciences, Núcleo accumbens, Frontal Lobe, Corteza prefrontal, Estimulación encefálica profunda, Nucleus accumbens, Christian ministry, Psychology, RC321-571, Ventromedial frontal cross-frequency coupling, Electroencefalografía, Anatomy::Nervous System::Central Nervous System::Brain::Prosencephalon::Telencephalon::Cerebrum::Cerebral Cortex::Frontal Lobe [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Electric Stimulation Therapy::Deep Brain Stimulation [Medical Subject Headings], Phenomena and Processes::Physiological Phenomena::Electrophysiological Phenomena [Medical Subject Headings], medicine.medical_specialty, Biophysics, Anatomy::Nervous System::Central Nervous System::Brain::Prosencephalon::Telencephalon::Cerebrum::Basal Ganglia::Nucleus Accumbens [Medical Subject Headings], Neurosciences. Biological psychiatry. Neuropsychiatry, behavioral disciplines and activities, 050105 experimental psychology, 03 medical and health sciences, Obsessive compulsive, medicine, Psychiatry and Psychology::Mental Disorders::Anxiety Disorders::Obsessive-Compulsive Disorder [Medical Subject Headings], media_common.cataloged_instance, Humans, 0501 psychology and cognitive sciences, European union, Psychiatry, Trastorno obsesivo compulsivo, Electrophysiological Phenomena, Neurology (clinical), Ventromedial frontal cross-frequency, 030217 neurology & neurosurgery, Acoplamiento neurovascular
Abstract: Background: Obsessive-compulsive disorder (OCD) has consistently been linked to abnormal frontostriatal activity. The electrophysiological disruption in this circuit, however, remains to be characterized. Objective/hypothesis: The primary goal of this study was to investigate the neuronal synchronization in OCD patients. We predicted aberrant oscillatory activity in frontal regions compared to healthy control subjects, which would be alleviated by deep brain stimulation (DBS) of the nucleus accumbens (NAc). Methods: We compared scalp EEG recordings from nine patients with OCD treated with NAc-DBS with recordings from healthy controls, matched for age and gender. Within the patient group, EEG activity was compared with DBS turned off vs. stimulation at typical clinical settings (3.5 V, frequency of stimulation 130 Hz, pulse width 60 ms). In addition, intracranial EEG was recorded directly from depth macro electrodes in the NAc in four OCD patients. Results: Cross-frequency coupling between the phase of alpha/low beta oscillations and amplitude of high gamma was significantly increased over midline frontal and parietal electrodes in patients when stimulation was turned off, compared to controls. Critically, in patients, beta (16-25 Hz)-gamma (110-166 Hz) phase amplitude coupling source localized to the ventromedial prefrontal cortex, and was reduced when NAc-DBS was active. In contrast, intracranial EEG recordings showed no beta-gamma phase amplitude coupling. The contribution of non-sinusoidal beta waveforms to this coupling are reported. Conclusion: We reveal an increased beta-gamma phase amplitude coupling in fronto-central scalp sensors in patients suffering from OCD, compared to healthy controls, which may derive from ventromedial prefrontal regions implicated in OCD and is normalized by DBS of the nucleus accumbens. This aberrant cross-frequency coupling could represent a biomarker of OCD, as well as a target for novel therapeutic approaches. (C) 2021 The Authors. Published by Elsevier Inc., This work was supported by Project grants SAF2015-65982-R from the Spanish Ministry of Economy and Competitiveness to BS and PSI2014-58654-JIN to JGR, an FPI Predoctoral Fellowship (BES-2016-079470) to ST, and BIAL Foundation Grant 119/12 to BS. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (ERC-2018-COG 819814).
Published: 2020

19. Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study)

Author: Baldassarre Doronzo, Christian Templin, Francesco Tomassini, Mauro Rinaldi, Andrea Montabone, Zenon Huczek, Enrico Cerrato, Maurizio D'Amico, Carlo Di Mario, Radosław Parma, Giuseppe Venuti, Nicola Ryan, Giorgio Quadri, Thomas F. Lüscher, Iván J. Núñez-Gil, Giacomo Boccuzzi, Alaide Chieffo, Antonia Bassignana, Imad Sheiban, Bernardo Cortese, Fabrizio D'Ascenzo, Sebastiano Gili, Javier Escaned, Andrea Rognoni, Pierluigi Omedè, Michele Autelli, Gérard Helft, Davide Capodanno, Grzegorz Smolka, Michele De Benedictis, Mario Iannaccone, Alessio Mattesini, Ferdinando Varbella, Wojciech Wojakowski, Umberto Barbero, Yoichi Imori, Wojciech Wańha, Daniela Trabattoni, Leonardo De Luca, Delio Tedeschi, Civil Hospital SS. Annunziata [Savigliano, Italy] (CH2SA), Nippon Medical School [Tokyo, Japon], Ospedale di Rivoli [Rivoli, Italy] (OR), San Luigi Gonzaga University Hospital [Turin, Italy] (SLGUH Orbassano), Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano = University of Milan (UNIMI)-Università degli Studi di Milano = University of Milan (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Università degli Studi di Milano = University of Milan (UNIMI), Hospital Clínico San Carlos [Madrid, Spain], AOU Policlinico Vittorio-Emanuele [Catania, Italia], Careggi University Hospital [Florence, Italie], Medical University of Silesia (SUM), University Hospital 'Maggiore della Carità' [Novara, Italy], Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), University of Warsaw (UW), Clinica Pederzoli [Peschiera del Garda, Italy] (CP), Ospedale San Giovanni Bosco [Turin, Italy] (OSGB), University hospital of Zurich [Zurich], Medical University of Warsaw - Poland, ASST Fatebenefratelli-Sacco [Milan, Italy], IRCCS San Raffaele Scientific Institute [Milan, Italie], Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino, Civic Hospital of Brescia, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), and Lesnik, Philippe
Subjects: Male, lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Coronary Artery Disease, 030204 cardiovascular system & hematology, Prosthesis Design, Percutaneous coronary intervention, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Absorbable Implants, medicine, Left main, Humans, Registries, 030212 general & internal medicine, Myocardial infarction, cardiovascular diseases, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Coronary Stenosis, Stent, Drug-Eluting Stents, Middle Aged, medicine.disease, Drug eluting stents, Struts thickness, [SDV] Life Sciences [q-bio], Stenosis, Treatment Outcome, Coronary bifurcation, lcsh:RC666-701, Drug-eluting stent, Conventional PCI, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Mace, Research Article
Abstract: Background There are limited data regarding the impact of bioresorbable polymer drug eluting stent (BP-DES) compared to durable polymer drug eluting stent (DP-DES) in patients treated with percutaneous coronary intervention using ultrathin stents in left main or bifurcations. Methods In the RAIN registry (ClinicalTrials NCT03544294, june 2018 retrospectively registered) patients with a ULM or bifurcation stenosis treated with PCI using ultrathin stents (struts thinner than 81 μm) were enrolled. The primary endpoint was the rate of target lesion revascularization (TLR); major adverse cardiovascular events (MACE, a composite of all-cause death, myocardial infarction, TLR and stent thrombosis) and its components, along with target vessel revascularization (TVR) were the secondary ones. A propensity score with matching analysis to compare patients treated with BP-DES versus DP-DES was also assessed. Results From 3001 enrolled patients, after propensity score analysis 1400 patients (700 for each group) were selected. Among them, 352 had ULM disease and 1048 had non-LM bifurcations. At 16 months (12–22), rates of TLR (3.7% vs 2.9%, p = 0.22) and MACE were similar (12.3% vs. 11.6%, p = 0.74) as well as for the other endpoints. Sensitivity analysis of outcomes after a two-stents strategy, showed better outcome in term of MACE (20.4% vs 10%, p = 0.03) and TVR (12% vs 4.6%, p = 0.05) and a trend towards lower TLR in patients treated with BP-DES. Conclusion In patients with bifurcations or ULM treated with ultrathin stents BP-DES seems to perform similarly to DP-DES: the trends toward improved clinical outcomes in patients treated with the BP-DES might potentially be of value for speculating the stent choice in selected high-risk subgroups of patients at increased risk of ischemic events. Trial registration ClinicalTrials.gov Identifier: NCT03544294. Retrospectively registered June 1, 2018.
Published: 2020
Full Text: View/download PDF

20. Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

Author: Jiménez de Ory, Santiago, Ramos, José Tomas, Fortuny, Claudia, González-Tomé, María Isabel, Mellado, Maria José, Moreno, David, Gavilán, César, Menasalvas, Ana Isabel, Piqueras, Ana Isabel, Frick, M Antoinette, Muñoz-Fernández, Maria Angeles, Navarro, Maria Luisa, CoRISpe Cohort Working Group, Red Española de Investigación en SIDA, Instituto de Salud Carlos III, European Commission, Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo, National Institutes of Health (US), Wellcome Trust, Howard Hughes Medical Institute, [Jiménez de Ory S] Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón (IisGM), Madrid, Spain. CoRISpe, Madrid, Spain. [Ramos JT] Servicio de Pediatría, Hospital Clínico San Carlos, Madrid, Spain. Universidad Complutense de Madrid, Madrid, Spain. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Fortuny C] Unidad de Enfermedades Infecciosas, Servicio de Pediatría, Hospital Sant Joan de Déu, Esplugues del Llobregat, Spain. Universitat de Barcelona, Barcelona, Spain. [González-Tomé MI] Servicio de Infecciosas Pediátricas, Hospital Universitario Doce de Octubre, Madrid, Spain. Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain. Universidad Complutense de Madrid, Madrid, Spain. [Mellado MJ] Pediatrics, Immunodeficiencies and Infectious Diseases Unit, Hospital Universitario La Paz, Madrid, Spain. Translational Research Network in Pediatric Infectious Diseases (RITIP), Madrid, Spain. [Moreno D] Department of Pediatrics, Regional Maternal-Child University Hospital, Malaga, Spain. IBIMA Multidisciplinary Group for Pediatric Research, Malaga, Spain, Malaga University, Malaga, Spain. [Frick MA] Unitat de Medicina tropical i Salut internacional, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Servei de Pediatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: 0301 basic medicine, RNA viruses, Male, Perinatal transmission, European People, Spanish People, Epidemiology, Maternal Health, Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, Pathology and Laboratory Medicine, Severity of Illness Index, Perinatal hiv, Geographical locations, Labor and Delivery, Families, 0302 clinical medicine, Immunodeficiency Viruses, Pregnancy, Risk Factors, Medicine, Ethnicities, Public Health Surveillance, 030212 general & internal medicine, Medical diagnosis, Hispanic People, Multidisciplinary, Transmission (medicine), virus diseases, Obstetrics and Gynecology, HIV diagnosis and management, 3. Good health, Europe, Geographic Locations::Europe::Spain [GEOGRAPHICALS], HIV epidemiology, Medical Microbiology, Viral Pathogens, Viruses, Ubicaciones Geográficas::Europa (Continente)::España [DENOMINACIONES GEOGRÁFICAS], Female, Pathogens, Sexual contact, Research Article, virosis::virosis::enfermedades de transmisión sexual::enfermedades virales de transmisión sexual::infecciones por VIH [ENFERMEDADES], Pediatric hiv, Science, 030106 microbiology, Mothers, Infections::Sexually Transmitted Diseases::Sexually Transmitted Diseases, Viral::HIV Infections [DISEASES], Microbiology, History, 21st Century, 03 medical and health sciences, Retroviruses, Humans, European Union, Microbial Pathogens, Retrospective Studies, Medicine and health sciences, business.industry, Lentivirus, Organisms, Biology and Life Sciences, HIV, Retrospective cohort study, History, 20th Century, Diagnostic medicine, Infectious Disease Transmission, Vertical, Spain, técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de casos y controles::estudios retrospectivos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Birth, Women's Health, Infeccions per VIH, Population Groupings, Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], People and places, business, Estudi de casos - Espanya, Demography
Abstract: [Background] There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015., [Methods] A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997–2000; P2: 2001–2005; P3: 2006–2010; P4: 2011–2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated., [Results] A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively., [Conclusions] A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact., This work has been partially funded by Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035, RD12/0017/0037 and RD16/0025/0019), project as part of the Plan R+D+I (2008–2011; 2013–2016) and cofinanced by ISCIII- Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER), RIS-EPICLIN-19/2015, Fondo para la Investigación Sanitaria of the Spanish Ministry of Science and Innovation (FIS PI13/00422, PI16/01863), CYTED (214RT0482) and EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008–2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. COST CA17140 Cancer Nanomedicine-Front The Bench to Bebside. We thank the Spanish HIV HGM BioBank supported by ISC III project RETIC PT13/0010/0028 and PT17/0015/0042. No funding for this work was received from National Institutes of Health (NIH), Wellcome Trust and Howard Hughes Medical Institute (HHMI).
Published: 2019

21. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Author: Sergio Vázquez, Jose Miguel Cuevas Sanz, A. González-del-Alba, Alvaro Pinto, Jacobo Muñoz del Toro, Ángela García García-Porrero, Ángel Francisco Zazo Rodríguez, Javier Puente, Eduardo Useros Rodríguez, Núria Sala-González, María José Méndez-Vidal, [Puente,J] Medical Oncology, Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC. Madrid, Spain. [González-del-Alba,A] Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. [Sala-Gonzalez,N] Medical Oncology, ICO Girona, Hospital Josep Trueta, Girona, Spain. [Méndez-Vidal,MJ] Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC). Reina Sofía Hospital. University of Córdoba, Cordoba, Spain. [Pinto,A] Medical Oncology, University Hospital La Paz - IdiPAZ, Madrid, Spain. [Rodríguez,A] Medical Oncology, Hospital Universitario de León, León, Spain. [Cuevas Sanz,JM] Medical Oncology, Hospital Universitario de la Ribera, Alcira, Spain. [Muñoz del Toro,JR, Useros Rodríguez,E, García García-Porrero,A] Medical Department, Janssen-Cilag S.A., Madrid, Spain. [Vázquez,S] Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain., and This study was funded by Janssen Cilag S.A.
Subjects: Oncology, Male, Neoplasias de la próstata, astenia, medicine.medical_treatment, Docetaxel, law.invention, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, estudios prospectivos, Antineoplastic Combined Chemotherapy Protocols, dolor, Prospective Studies, mediana edad, Aged, 80 and over, anciano, Cabazitaxel, protocolos de quimioterapia antineoplásica combinada, Hazard ratio, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Progression-Free Survival, Prostatic Neoplasms, Castration-Resistant, 030220 oncology & carcinogenesis, Taxoids, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Asthenia [Medical Subject Headings], medicine.medical_specialty, Antineoplastic Agents, Hormonal, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis [Medical Subject Headings], Antineoplastic Agents, Adenocarcinoma, lcsh:RC254-282, 03 medical and health sciences, Sequence, Genetics, Humans, Aged, Diseases::Male Urogenital Diseases::Genital Diseases, Male::Genital Neoplasms, Male [Medical Subject Headings], Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Pain [Medical Subject Headings], medicine.disease, Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone [Medical Subject Headings], Regimen, 030104 developmental biology, chemistry, Persons::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings], Asthenia, Quimioterapia, l-lactato deshidrogenasa, 0301 basic medicine, Cancer Research, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models, Statistical::Proportional Hazards Models [Medical Subject Headings], modelos de riesgos proporcionales, humanos, Abiraterone Acetate, Kaplan-Meier Estimate, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Alcohol Oxidoreductases::Lactate Dehydrogenases::L-Lactate Dehydrogenase [Medical Subject Headings], Prostate cancer, chemistry.chemical_compound, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Alicyclic::Cycloparaffins::Cyclodecanes::Taxoids [Medical Subject Headings], Randomized controlled trial, law, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [Medical Subject Headings], antineoplásicos, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], resultado del tratamiento, Abiraterone acetate, Age Factors, Anemia, Middle Aged, Treatment Outcome, Drug therapy, Prostatic neoplasms, Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Age Factors [Medical Subject Headings], Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia [Medical Subject Headings], taxoides, medicine.drug, Research Article, estimación de Kaplan-Meier, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Pain, Acetato de abiraterona, Internal medicine, medicine, Chemotherapy, análisis multifactorial, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], Proportional Hazards Models, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Kaplan-Meier Estimate [Medical Subject Headings], L-Lactate Dehydrogenase, business.industry, Prostatic Neoplasms, Metastatic castration-resistant prostate cancer, Spain, Multivariate Analysis, neoplasias de la próstata, Prednisone, prednisona, business
Abstract: Background To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to compare the efficacy and safety of the treatments most frequently administered. Methods Observational, prospective study conducted in patients with histologically or cytologically confirmed prostate adenocarcinoma; documented metastatic castration-resistant disease; progression after first-line, docetaxel-based chemotherapy with or without other agents. Results Of the 150 patients recruited into the study, 100 patients were prescribed abiraterone acetate plus prednisone (AAP), 44 patients received cabazitaxel plus prednisone (CP), and 6 patients received other treatments. Age (odds ratio [OR] 1.06, 95% [confidence interval] CI 1.01 to 1.11) and not elevated lactate dehydrogenase (LDH) levels (OR 0.33, 95% CI 0.14 to 0.76) were independently associated with the administration of AAP. Treatment with AAP was associated with significantly longer clinical/radiographic progression-free survival (hazard ratio [HR] 0.57, 95% CI 0.38 to 0.85) and overall survival (OS; HR 0.40, 95% CI 0.21 to 0.76) compared to CP, while no significant differences between the treatments were found regarding biochemical progression-free survival (PFS; HR 0.78 [95% CI 0.49 to 1.24]). However, in a post-hoc Cox regression analysis adjusted for potential confounders there were not differences between AAP and CP in any of the time-to-event outcomes, including overall survival. We observed no new safety signals related to either regimen. Conclusion Second-line AAP for patients with mCRPC is the most common treatment strategy after progression with a docetaxel-based regimen. When controlling for potential confounders, patients receiving this treatment showed no differences in PFS and OS in comparison to those receiving CP, although these latter results should be confirmed in randomized controlled trials., This study was funded by Janssen Cilag S.A. Janssen-Cilag S.A. was involved in the design of the study, interpretation of data, and in writing the manuscript. Quality control and statistical analyses were performed by a contract research organization that was funded by Janssen-Cilag S.A.
Published: 2019

22. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

Author: Luigi Mori, Sara González, Elia Grau, Dieter Niederacher, Alexandra C. Kölbl, Ares Solanes, Cassandra B. Nichols, Marine Guillaud-Bataille, Ulrike Schoenwiese, Katherine L. Nathanson, Alfons Meindl, Ellen Honisch, Hans Ehrencrona, Ute Enders, Anke Waha, Trinidad Caldés, Inge Søkilde Pedersen, Ana Blanco, Emma Tudini, Conxi Lázaro, Paolo Radice, Torben A Kruse, María Concepción Alonso-Cerezo, Chantal Farra, Shan Wang-Gohrke, Wilko Weichert, Heli Nevanlinna, Setareh Moghadasi, Bernd Auber, Carla Bruzzone, Aliana Guerrieri-Gonzaga, Sabine Grill, Raymonda Varon, Nicolas Derive, Ana Vega, Nicolai Maass, Åke Borg, Cora M. Aalfs, Nadia Naldi, Silvia Iglesias, Kai Ren Ong, Encarna B. Gomez Garcia, Karl Hackmann, Emma R. Woodward, Norbert Arnold, David E. Goldgar, Bernard Peissel, Karolin Bucksch, Berardino Porfirio, Françoise Révillion, Angel Izquierdo, Isabell Witzel, Sebastian Wagner, Silke Zachariae, Elisa Alducci, Mads Thomassen, Jesús del Valle, Valentina Zampiga, Kerstin Rhiem, Lidia Moserle, Edenir Inêz Palmero, Maaike P.G. Vreeswijk, Christoph Mundhenke, Laura Papi, Alejandro Moles-Fernández, Paula Rofes, Ulrike Faust, Andrea Gehrig, Sandrine M. Caputo, Logan C. Walker, Fiona Lalloo, Ute Felbor, Joan Brunet, Henriette Roed Nielsen, Sean V. Tavtigian, Beatrice Bortesi, Thomas Hansen, Maria Grazia Tibiletti, Estela Carrasco, Lisa Wiesmüller, Viviana Gismondi, Sophie Krieger, Pedro Pérez-Segura, Esther Pohl-Rescigno, Emanuela Lucci-Cordisco, Barbara Wappenschmidt, Rui Manuel Reis, Gabriele Lorenzo Capone, Ileana Carnevali, Christi J. van Asperen, KCon Fab Investigators, Jochen Seggewiß, Rhiannon J. Walters, Irmgard Debatin, Susan M. Domchek, Marco Montagna, Francesca Gensini, Kristiina Aittomäki, Véronique Dutrannoy, Arcangela De Nicolo, Giulia Cagnoli, Elisa J. Cops, Henrique de Campos Reis Galvão, Giulia Cini, Barbara Riboli, Eva Tornero, Paul A. James, Judith Balmaña, Anne-Marie Gerdes, Heide Hellebrand, Miriam Fine, Mathias Stiller, Aldo Germani, Diana Eccles, Britta Blümcke, Dominique Stoppa-Lyonnet, Elena Leinert, Alexandra Lewis, Daniela Rivera, Verena Hübbel, Fergus J. Couch, Gunnar Schmidt, Katharina Keupp, Bernhard H. F. Weber, Tilman Heinrich, Mariarosaria Calvello, Michael Dean, Udo Jeschke, Vanessa Lattimore, Linda A.M. Janssen, Siranoush Manoukian, Eva Gross, Kelly J. Sullivan, Doris Steinemann, Susanne Ledig, Alessandra Viel, Christoph Engel, Ana Sánchez de Abajo, Nina Ditsch, Sandra Bonache, Maria A. Caligo, Katharina Pfeifer, Thomas Haaf, Christian Sutter, Eric Hahnen, Laura Matricardi, Marc Tischkowitz, Alex Teulé, Katherine M. Tucker, Jutta Giesecke, Silvia Tognazzo, Gemma Montalban, Carolina Gómez, Anders Kvist, Joanna Lim, Alison H. Trainer, Rachel Susman, Judit Horvath, Amanda B. Spurdle, Mirjam Larsen, Therese Törngren, Mónica Salinas, Nicholas Pachter, Rachel Austin, Nicola K. Poplawski, C Zeder-Göß, Juliane Ramser, Julia Ritter, Anne Sophie Vesper, Paola Concolino, D. Gareth Evans, Clemens R. Müller, Matilde Navarro, Sara Torres-Esquius, Claus R. Bartram, Laura Cortesi, Jacopo Azzollini, Marion Harris, Edward M. Clarke, Marion Kiechle, Lídia Feliubadaló, Almuth Caliebe, Karen N. Herold, Charlotte Kvist Lautrup, Anne S. Quante, Gardenia Vargas-Parra, Michael T. Parsons, Pietro Cavalli, Hongyan Li, Rodrigo Augusto Depieri Michelli, Irene Feroce, Achim Wöckel, Kerstin Wieland, Silke Kaulfuß, Soo Hwang Teo, Angela Velasco, Capucine Delnatte, Marta Pineda, Marion van Mackelenbergh, Eva Montes, Angela Toss, Rita K. Schmutzler, William D. Foulkes, Alvaro N.A. Monteiro, Jan Hauke, Monica Marabelli, Miguel de la Hoya, Sara Gutiérrez-Enríquez, Esther Darder, Simona Agata, Amanda E. Toland, Bernardo Bonanni, Liliana Varesco, Orland Diez, Andreas Rump, Virginie Caux-Moncoutier, Gaetana Gambino, Markus Loeffler, Claude Houdayer, Elena Barbieri, Adrià López-Fernández, et. al., Universidade do Minho, QIMR Berghofer Medical Research Institute, Chinese Academy of Geological Sciences [Beijing] (CAGS), Ministry of Land and Resources (MLR), Department of Gynaecology and Obstetrics, University Hospital of Cologne [Cologne]-Centre of Familial Breast and Ovarian Cancer-Centre for Integrated Oncology (CIO), Programa de Càncer Hereditari, Unitat de Diagnòstic Molecular, Laboratori de Recerca Translacional, Institut Català d'Oncologia-IDIBELL, Department of Clinical Genetics, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Helsinki University Central Hospital, University Hospital of Schleswig-Holstein-Christian-Albrechts-Universität zu Kiel (CAU), Università degli Studi di Milano [Milano] (UNIMI), Medical Oncology Department, Vall d'Hebron University Hospital [Barcelona], Institute of Human Genetics, Universität Heidelberg [Heidelberg], Fundación Pública Galega de Medicina Xenómica-SERGAS & Grupo de Medicina Xenómica-USC, CIBER-ER, Division of Cancer Prevention and Genetics, Department of Oncology, Clinical Sciences, Lund University [Lund]-Skåne University Hospital, Genetic Counseling and Hereditary Cancer Programme, Catalan Institute of Oncology, Molecular Oncology Laboratory, Hospital Clínico San Carlos, Institut Curie [Paris], Programa de Consell Genètic en Càncer, Institut Català d'Oncologia, Girona-IdIBGi, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Centre René Gauducheau, CRLCC René Gauducheau, Institut de biochimie et génétique cellulaires (IBGC), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Oncogenetics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Ludwig-Maximilians-Universität München (LMU), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Genetics, University of Southampton, Departament of Genetics and Pathology, Uppsala University-Rudbeck Laboratory, Department of Genomic Medicine, University of Manchester [Manchester], Department of Medical Genetics, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU)-Centre of Familial Breast and Ovarian Cancer, Obstetrics and Gynaecology, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Institüt für Humangenetik [Würzburg], Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Institute of Chemistry [Budapest], Faculty of Sciences [Budapest], Eötvös Loránd University (ELTE)-Eötvös Loránd University (ELTE), Service de Biochimie et de Biologie Moléculaire [CHU Trousseau], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), I. Frauenklinik, Klinikum der Ludwig-Maximilians-Universitaet, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Biochemistry, Pharmacology and Genetics, Odense University Hospital, Department of Oncology, Lund University [Lund]-Clinical Sciences, Genetic Medicine, Manchester Academic Health Sciences Centre-Central Manchester University Hospitals, Institute for Medical Informatics, Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Unit of Medical Genetics, Fondazione IRCCS Istituto Nazionale Tumouri (INT), Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, University Medical Center Kiel, Department of Obstetrics and Gynecology, University Hospital Düsseldorf-Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Medical Genetics Unit, Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Department of Biochemistry, Section of Molecular Diagnostics, Laboratoire d'Oncologie Moléculaire Humaine, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER-Université Lille Nord de France (COMUE)-UNICANCER, Institute of Cell and Molecular Pathology, Medizinische Hochschule Hannover (MHH), University of California [Santa Cruz] (UCSC), University of California, Heidelberg University Hospital [Heidelberg], International Agency for Cancer Research (IACR), Programa de Consejo Genético en Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet, Programa de Diagnòstic Molecular de Càncer Hereditari, Laboratori de Recerca Translacional, Institut Català d'Oncologia-IDIBELL, Hospital Duran i Reynals, Hospitalet de Llobregat, Unit of Hereditary Cancers, Istituto Nazionale per la Ricerca sul Cancro, CIBER de Enfermedades Raras (CIBERER), Unit of Experimental Oncology 1, Centro di Riferimento Oncologico, University of Otago [Dunedin, Nouvelle-Zélande], Institute of Pathology, Department of Gynecology, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), King‘s College London, Molecular Diagnostic Unit, IDIBELL-Catalan Institute of Oncology, Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale Tumouri (INT)-Fondazione Istituto FIRC di Oncologia Molecolare, Institute for Medical Informatics, Statistics and Epidemiology [Leipzig] (IMISE), Universität Leipzig [Leipzig], Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, Clinical Center University of Cologne, Medicum, Research Programs Unit, Genome-Scale Biology (GSB) Research Program, Kristiina Aittomäki / Principal Investigator, HUSLAB, Department of Medical and Clinical Genetics, HUS Gynecology and Obstetrics, University Management, University of Helsinki, Università degli Studi di Milano = University of Milan (UNIMI), Universität Heidelberg [Heidelberg] = Heidelberg University, Department of Genetics and Pathology, Uppsala University, Julius-Maximilians-Universität Würzburg (JMU)-Centre of Familial Breast and Ovarian Cancer, Julius-Maximilians-Universität Würzburg (JMU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Università degli Studi di Firenze = University of Florence (UniFI), Université de Lille-UNICANCER-Université de Lille-UNICANCER, University of California [Santa Cruz] (UC Santa Cruz), University of California (UC), Universität Leipzig, University of Cologne, RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: DA KG Polikliniek (9), and Klinische Genetica
Subjects: Male, Multifactorial Inheritance, BRCA1, BRCA2, classification, clinical, multifactorial, quantitative, uncertain significance, variant, Alternative Splicing, BRCA1 Protein, BRCA2 Protein, Computational Biology, Early Detection of Cancer, Female, Genetic Predisposition to Disease, Humans, Likelihood Functions, Neoplasms, Mutation, Missense, Medicina Básica [Ciências Médicas], Settore MED/03 - GENETICA MEDICA, GUIDELINES, Genetic analysis, CLINGEN, SEQUENCE VARIANTS, Missense mutation, FUNCTIONAL ASSAYS, Genetics (clinical), BRCA1, BRCA2, quantitative, clinical, classification, multifactorial, variant, uncertain significance, 0303 health sciences, education.field_of_study, 030305 genetics & heredity, 1184 Genetics, developmental biology, physiology, SPLICING ANALYSIS, OVARIAN, BRCA2 Protein/genetics, 3. Good health, ddc, Mutation (genetic algorithm), Ciências Médicas::Medicina Básica, Medical genetics, Special Articles, medicine.medical_specialty, Posterior probability, Population, Computational biology, Biology, INTEGRATED EVALUATION, 03 medical and health sciences, Special Article, medicine, Genetics, BREAST-CANCER, Genetic variability, ddc:610, education, 030304 developmental biology, Tumors, Science & Technology, Proteins, Computational Biology/methods, RISKS, Mutation, BRCA1 Protein/genetics, 3111 Biomedicine, Missense, Proteïnes, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Genètica, Neoplasms/diagnosis
Abstract: The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification., Ohio State University Comprehensive Cancer Center Barretos Cancer Hospital. Grant Number: FINEP ‐ CT‐INFRA (02/2010) Breast Cancer Foundation of New Zealand Canadian Institutes of Health Research. Grant Number: PSR‐SIIRI‐701 Cancer Research UK. Grant Numbers: C8197/A16565, C5047/A8384, C1281/A12014, C12292/A11174, C1287/A10710, C1287/A10118, C1287/A16563, C5047/A10692, C5047/A15007 Department of Defence, USA. Grant Number: W81XWH‐10‐1‐0341 Helsinki University Hospital Research fund Scientific Foundation Asociación Española Contra el Cáncer Leiden University Medical Centre. Grant Number: Grant 30.925 Generalitat de Catalunya. Grant Numbers: PERIS_MedPerCan, URDCat, 2017SGR1282, 2017SGR496 Royal Society of New Zealand Cancer Council Victoria Netherlands Organization for Scientific Research (NWO). Grant Number: Grant 017.008.022 Breast Cancer Research Foundation Cancer Foundation of Western Australia EU H2020. Grant Number: 634935 Fundación Mutua Madrileña Seventh Framework Programme. Grant Numbers: 634935, 223175, 633784 Cancer Council South Australia Government of Galicia. Grant Number: Consolidation and structuring program: IN607B Cancer Council Tasmania Italian Association of Cancer Research. Grant Number: 15547 Queensland Cancer Fund AstraZeneca National Institute of Health (USA). Grant Numbers: 1U19 CA148065‐01, CA128978, CA192393, 1U19 CA148537, P50 CA1162091, CA116167, 1U19 CA148112 Newcastle University Dutch Cancer Society KWF. Grant Numbers: KWF/Pink Ribbon‐11704, UL2012‐5649 National Institute for Health Research. Grant Number: Manchester Biomedical Research centre (IS‐BRC‐1215 National Council of Technological and Scientific Development (CNPq) Instituto de Salud Carlos III. Grant Numbers: FIS PI15/00355, FIS PI13/01711, CIBERONC, FIS PI16/01218, PI16/00563 French National Institute of Cancer National Breast Cancer Foundation National Health and Medical Research Council. Grant Numbers: ID1061778, ID1104808 Carlos III National Health Centro de Investigación Biomédica en Red de Enferemdades Raras. Grant Number: ACCI 2016: ER17P1AC7112/2018 Cancer Council NSW Deutsche Krebshilfe. Grant Numbers: (#110837, #70111850 Fondazione Pisa. Grant Number: Grant “Clinical characterization of BRCA 1/2 Mis
Published: 2019
Full Text: View/download PDF

23. Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

Author: Carlos Taxonera, Dolores Martín Arranz, Juan Luis Mendoza, José Lázaro Pérez-Calle, Fernando Bermejo, Concepción Núñez, Virginia Pascual, Javier P. Gisbert, María Gómez-García, Elena Urcelay, Javier Martín, Cristina González-Artacho, Luz Maria Medrano, Antonio López-Sanromán, Manuel Barreiro-de Acosta, [Medrano,LM, Pascual,V, Núñez,C, Urcelay,E] Immunology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Taxonera,C, Mendoza,JL] Gastroenterology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [González-Artacho,C, Gómez-García,M] Gastroenterology Department, Virgen de las Nieves Hospital, Granada, Spain. [Barreiro-de Acosta,M] Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. [Perez-Calle,JL] Gastroenterology Department, Alcorcón Hospital, Madrid, Spain. [Bermejo,F] Gastroenterology Department, Fuenlabrada Hospital, Madrid, Spain. [López-Sanromán,A] Gastroenterology Department, Fuenlabrada Hospital, Madrid, Spain. [Martín Arranz,D] Gastroenterology Department, La Paz Hospital, Madrid, Spain. [Gisber,JP] Gastroenterology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla, Granada, Spain., and Financial support for the study was provided by Fundación Mutua Madrileña.
Subjects: Male, Polimorfismo genético, Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Large::Colon [Medical Subject Headings], Cell Cycle Proteins, Disease, Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Small::Ileum [Medical Subject Headings], Genetic analysis, Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Crohn Disease, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intercellular Signaling Peptides and Proteins::Tumor Necrosis Factors::Tumor Necrosis Factor-alpha [Medical Subject Headings], Genotype, Young adult, Crohn's disease, Marcadores biológicos, Interleukin-11, Humanos, Antirheumatic Agents, Female, Haplotipos, Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings], Interleucina-11, lcsh:RB1-214, medicine.drug, Adult, Article Subject, Adolescent, Colon, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-11 [Medical Subject Headings], Immunology, Biology, Young Adult, Íleon, Chemicals and Drugs::Biological Factors::Biological Markers [Medical Subject Headings], lcsh:Pathology, medicine, Calgranulin B, Humans, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal [Medical Subject Headings], Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases::Crohn Disease [Medical Subject Headings], Calgranulin A, Enfermedad de Crohn, Genotyping, Haplotype, Cell Biology, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings], medicine.disease, Infliximab, Factor de necrosis tumoral alfa, Anticuerpos monoclonales, Clinical Study, Genotipo, Cell Adhesion Molecules
Abstract: Substantial proportion of Crohn’s disease (CD) patients shows no response or a limited response to treatment with infliximab (IFX) and to identify biomarkers of response would be of great clinical and economic benefit. The expression profile of five genes (S100A8-S100A9, G0S2, TNFAIP6, andIL11) reportedly predicted response to IFX and we aimed at investigating their etiologic role through genetic association analysis. Patients with active CD (350) who received at least three induction doses of IFX were included and classified according to IFX response. A tagging strategy was used to select genetic polymorphisms that cover the variability present in the chromosomal regions encoding the identified genes with altered expression. Following genotyping, differences between responders and nonresponders to IFX were observed in haplotypes of the studied regions:S100A8-S100A9(rs11205276*G/rs3014866*C/rs724781*C/rs3006488*A;P=0.05);G0S2(rs4844486*A/rs1473683*T;P=0.15);TNFAIP6(rs11677200*C/rs2342910*A/rs3755480*G/rs10432475*A;P=0.10); andIL11(rs1126760*C/rs1042506*G;P=0.07). These differences were amplified in patients with colonic and ileocolonic location for all but theTNFAIP6haplotype, which evidenced significant difference in ileal CD patients. Our results support the role of the reported expression signature as predictive of anti-TNF outcome in CD patients and suggest an etiological role of those top-five genes in the IFX response pathway.
Published: 2015
Full Text: View/download PDF

24. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease

Author: José Miguel Rodríguez González-Moro, Cristóbal Esteban, Borja G. Cosío, Bernardino Alcázar-Navarrete, José Antonio Quintano Jiménez, Cruz González, Aurelio Arnedillo, Juan Antonio Trigueros, Adolfo Baloira, Myriam Calle, Marc Miravitlles, Institut Català de la Salut, [Miravitlles M] Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Cosío BG] CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. Department of Respiratory Medicine, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain. [Arnedillo A] Pneumology, Allergy and Thoracic Surgery Department, Hospital Universitario Puerta del Mar, Cádiz, Spain. Medicine Department, University of Cádiz, Cádiz, Spain. [Calle M] Pulmonary Department, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain. Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. [Alcázar-Navarrete B] Respiratory Department, AIG de Medicina, Hospital de Alta Resolución de Loja, Agencia Sanitaria Hospital de Poniente, Loja, Granada, Spain. [González C] Department of Respiratory Medicine, Hospital Clínico Universitario Valencia, Spain. Instituto de Investigación Sanitaria (INCLIVA) Valencia, Valencia, Spain., Vall d'Hebron Barcelona Hospital Campus, [Miravitlles, Marc] Hosp Univ Vall dHebron, Pneumol Dept, P Vall dHebron 119-129, Barcelona 08035, Spain, [Cosio, Borja G.] CIBER Enfermedades Resp CIBERES, Barcelona, Spain, [Cosio, Borja G.] Hosp Univ Son Espases IdISBa, Dept Resp Med, Palma De Mallorca, Spain, [Arnedillo, Aurelio] Hosp Univ Puerta Mar, Pneumol Allergy & Thorac Surg Dept, Cadiz, Spain, [Arnedillo, Aurelio] Univ Cadiz, Med Dept, Cadiz, Spain, [Calle, Myriam] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Car Carlos Id, Pulm Dept, Madrid, Spain, [Calle, Myriam] Univ Complutense Madrid, Fac Med, Dept Med, Madrid, Spain, [Alcazar-Navarrete, Bernardino] Agencia Sanitaria Hosp Poniente, Hosp Alta Resoluc Loja, Resp Dept, AIG Med, Granada, Spain, [Gonzalez, Cruz] Hosp Clin Univ, Dept Resp Med, Valencia, Spain, [Gonzalez, Cruz] Inst Invest Sanitaria INCLIVA Valencia, Valencia, Spain, [Esteban, Cristobal] Hosp Galdakao Usansolo, Pneumol Dept, Biscay, Spain, [Esteban, Cristobal] Red Invest Serv Sanitarios & Enfermed Cron REDISS, Bilbao, Spain, [Antonio Trigueros, Juan] Auton Hlth Serv, Hlth Ctr Menasalbas, Toledo, Spain, [Rodriguez Gonzalez-Moro, Jose Miguel] Hosp Univ Principe Asturias, Pneumol Dept, Madrid, Spain, [Quintano Jimenez, Jose Antonio] Ctr Salud Lucena I, Cordoba, Spain, [Baloira, Adolfo] Complejo Hosp Univ Pontevedra, Serv Neurol, Pontevedra, Spain, and Novartis
Subjects: humanos, Review, Disease, broncodilatadores, Fluticasone propionate, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Adrenal Cortex Hormones, Broncodilatadors, 030212 general & internal medicine, Randomized Controlled Trials as Topic, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores], COPD, Withholding Treatment, Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones [CHEMICALS AND DRUGS], Inhaled corticosteroids, ensayos clínicos controlados aleatorizados como asunto, Chronic obstructive pulmonary disease, Copd overlap syndrome, Double-blind, Management, Bronchodilator Agents, enfermedades respiratorias::enfermedades pulmonares::enfermedades pulmonares obstructivas::enfermedad pulmonar obstructiva crónica [ENFERMEDADES], Algorithm, Salmeterol-fluticasone, Other subheadings::Other subheadings::/administration & dosage [Other subheadings], Risk, medicine.medical_specialty, Pulmonary disease, Exacerbations, 03 medical and health sciences, Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Peripheral Nervous System Agents::Autonomic Agents::Bronchodilator Agents [CHEMICALS AND DRUGS], Administration, Inhalation, medicine, Humans, hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas de la corteza suprarrenal [COMPUESTOS QUÍMICOS Y DROGAS], Intensive care medicine, Adverse effect, acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::fármacos del sistema nervioso periférico::fármacos del sistema nervioso autónomo::broncodilatadores [COMPUESTOS QUÍMICOS Y DROGAS], Adrenergic beta-2 Receptor Agonists, lcsh:RC705-779, Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores], Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Pulmonary Disease, Chronic Obstructive [DISEASES], business.industry, Pulmons - Malalties obstructives, neumonía, Pneumonia, lcsh:Diseases of the respiratory system, medicine.disease, Corticosteroides, Asthma, agonistas de receptores adrenérgicos beta-2, Lung function, suspensión del tratamiento, Discontinuation, 030228 respiratory system, Salmeterol/fluticasone propionate, Blood eosinophils, business, hormonas de la corteza suprarrenal
Abstract: According to the current clinical practice guidelines for chronic obstructive pulmonary disease (COPD), the addition of inhaled corticosteroids (ICS) to long-acting beta(2) agonist therapy is recommended in patients with moderate-to-severe disease and an increased risk of exacerbations. However, ICS are largely overprescribed in clinical practice, and most patients are unlikely to benefit from long-term ICS therapy. Evidence from recent randomized-controlled trials supports the hypothesis that ICS can be safely and effectively discontinued in patients with stable COPD and in whom ICS therapy may not be indicated, without detrimental effects on lung function, health status, or risk of exacerbations. This article summarizes the evidence supporting the discontinuation of ICS therapy, and proposes an algorithm for the implementation of ICS withdrawal in patients with COPD in clinical practice. Given the increased risk of potentially serious adverse effects and complications with ICS therapy (including pneumonia), the use of ICS should be limited to the minority of patients in whom the treatment effects outweigh the risks., This article is a summary of a workshop held in Barcelona, Spain on February 14 2017. The workshop was supported by unrestricted grant from Novartis. The sponsor had no role in the discussion, preparation of manuscript and decision to submit the manuscript for publication.
Published: 2017

25. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

Author: Berta Laquente, M. E. Gallardo, A. Calsina, S. Arévalo, I. Gonzalez, B. G. de Paredes, I. Alés, A. M. López, Rosa Alvarez, Fernando Lopez-Rios, Juan José Reina, Josefa Plaza, Elena Escalera Martín, Manuel Hidalgo, Ovidio Hernando, M. Salgado, Carmen Guillén-Ponce, J. Blázquez, José Montans, R. Yaya, Teresa Macarulla, Alfredo Carrato, C. Lopez, Alfonso Sanjuanbenito, R. Vera, P. Jiménez, Teresa Bascarán Fernández, A. Muñoz, Javier Gallego, I. Peiró, Luis Iglesias Díez, Alfonso Martínez, R. Pazo, Juan José Martínez, R. Díaz, E. de Madaria, Jorge Adeva, A. Carmona, [Hidalgo,M] Spanish National Cancer Centre, Madrid, Spain. Beth Israel Deaconess Medical Center, Boston, USA. [Álvarez,R] Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid, Spain. [Gallego,J] University Hospital of Elche, Elche, Spain. [Guillén-Ponce,C, Carrato,A] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Laquente,B] Institut Catalá d’Oncologia, Duran y Reynals Hospital, Hospitalet Llobregat, Barcelona, Spain. [Macarulla,T] Vall d’Hebrón University Hospital, Barcelona, Spain. [Muñoz,A] University Hospital Gregorio Marañón, Madrid, Spain. [Salgado,M] University Hospital of Ourense, Ourense, Spain. [Vera,R] Complejo Hospitalario de Navarra, Pamplona, Spain. [Adeva,J] University Hospital 12 de Octubre, Madrid, Spain. [Alés,I] Hospital Carlos Haya, Málaga, Spain. [Arévalo,S] University Hospital Donostia, San Sebastián, Spain. [Blázquez,J] Department of Radiology, University Hospital Ramón y Cajal, Madrid, Spain.MD Anderson Hospital, Madrid, Spain. [Calsina,A] Department of Palliative Care, Hospital Germans Trias I Pujol, Institut Catalá d’Oncologia, Badalona, Spain. [Carmona,A] Department of Medical Oncology and Hematology, University Hospital Morales Messeguer, Murcia, Spain. [de Madaria,E] Department of Gastroenterology, Hospital General Universitario de Alicante, Alicante, Spain. [Díaz,R] Department of Medical Oncology, Hospital Universitari I Politécnic La Fe, Valencia, Spain. [Díez,L] Department of Surgery, Hospital Clínico San Carlos, Madrid, Spain. [Fernández,T] Department of Medical Oncology, Hospital Son Llàtzer, Palma de Mallorca, Spain. [de Paredes,BG] Hospital Clínico San Carlos, Madrid, Spain. [Gallardo,ME] Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain. [González,I] Complejo Hospitalario de Granada, Granada, Spain. [Hernando,O] Department of Radiotherapy, University Hospital HM Sanchinarro, Madrid, Spain. University Hospital HM Puerta del Sur, Madrid, Spain. [Jiménez,P] Department of Medical Oncology, Hospital Universitario Central de Asturias, Asturias, Spain. [López,A] Hospital Universitario de Burgos, Burgos, Spain. [López,C] Hospital Universitario Marqués de Valdecilla, Santander, Spain. [López-Ríos,F, and Plaza,JC] Department of Pathology, University Hospital HM Sanchinarro, Madrid, Spain. [Martín,E] Department of Surgery, Hospital Universitario de la Princesa, Madrid, Spain. [Martínez,J] Department of Medical Oncology, University Hospital Virgen de las Nieves, Granada, Spain. [Martínez,A] Hospital del Mar, Barcelona, Spain. [Montans,J] Department of Pathology, Centro Anatomopatológico, Madrid, Spain. [Pazo,R] Department of Medical Oncology, University Hospital Miguel Servet, Saragossa, Spain. [Peiró,I] Department of Endocrinology, Instituto Catalán de Oncología, Hospital Duran I Reynals, Hospitalet de Llobregat, Barcelona, Spain. [Reina,JJ] Department of Medical Oncology, University Hospital Virgen de la Macarena, Seville, Spain. [Sanjuanbenito,A] Department of Surgery, University Hospital Ramón y Cajal, Madrid, Spain. [Yaya,R] Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Subjects: Diseases::Digestive System Diseases::Pancreatic Diseases::Pancreatic Neoplasms::Carcinoma, Pancreatic Ductal [Medical Subject Headings], Cancer Research, medicine.medical_treatment, humanos, Disease, Guideline, oncología médica, estudios de seguimiento, Medical Oncology, Treatment and control groups, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, guías de práctica clínica como asunto, Consensus guidelines, Diagnosis, Pancreatic cancer, Treatment, neoplasias pancreáticas, Diagnosis, Publication Type::Publication Formats::Guideline [Medical Subject Headings], Tratamiento, Medical diagnosis, àncrees -- Càncer -- Tractament, Guías, General Medicine, Humanos, Diagnosis treatment, Oncology, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, 030211 gastroenterology & hepatology, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genetic Code::Reading Frames [Medical Subject Headings], Early stage disease, Carcinoma ductal pancreático, Carcinoma, Pancreatic Ductal, medicine.medical_specialty, Tratamento, guía, Special Article, 03 medical and health sciences, Pancreatic cancer, medicine, Humans, Sistemas de lectura, Consensus guidelines, Chemotherapy, business.industry, General surgery, Carcinoma, medicine.disease, Surgery, Clinical trial, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [Medical Subject Headings], Cáncer de páncreas, Treatment, Pancreatic Neoplasms, Spain, business, Follow-Up Studies
Abstract: The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to stablish practical guidelines for the diagnoses, staging and management of these patients. This paper summarizes the main conclusions of the working group. Patients with suspected pancreatic ductal adenocarcinoma should be rapidly evaluated and referred to high-volume centers. Multidisciplinary supervision is critical for proper diagnoses, staging and to frame a treatment plan. Surgical resection together with chemotherapy offers the highest chance for cure in early stage disease. Patients with advanced disease should be classified in treatment groups to guide systemic treatment. New chemotherapeutic regimens have resulted in improved survival. Symptomatic management is critical in this disease. Enrollment in a clinical trial is, in general, recommended., The support for medical writing was supported by Fundacion ECO.
Published: 2016

26. Combined genetic and splicing analysis of BRCA1 c.[594-2A > C; 641A > G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms

Author: Barbara Wappenschmidt, Fergus J. Couch, Norbert Arnold, Claude Houdayer, Manjeet K. Bolla, Omar Soukarieh, Sean V. Tavtigian, Irene L. Andrulis, Alexandra Becker, Alexandra Martins, Qin Wang, Sara Margolin, Paolo Radice, Janet E. Olson, Mitul Shah, Juul T. Wijnen, Amanda B. Spurdle, Nichola Johnson, Carole Brewer, Harald Surowy, Graham G. Giles, Ana Blanco, Kamila Czene, Thomas Hansen, Wendy S. Rubinstein, Anja Rudolph, Christian F. Singer, Antonis C. Antoniou, Douglas F. Easton, Fiona M. Blows, Michael T. Parsons, kConFab Investigators, Annika Lindblom, Nicola K. Poplawski, Melissa C. Southey, Emily Hallberg, Vanessa Lattimore, Yvette van Ierland, Logan C. Walker, Joe Dennis, Gord Glendon, Ana Vega, Diether Niederacher, Laurent Castera, David E. Goldgar, Ulrike Faust, Roger L. Milne, Marta Santamariña, Lesley McGuffog, Jan Hauke, Christi J. van Asperen, Michela Raponi, Irene López-Perolio, Diana Baralle, Tina Pesaran, Huong Meeks, Peter J. Hulick, Miguel de la Hoya, Philip Whiley, Raquel Behar, Jenny Chang-Claude, Elizabeth C. Chao, Henrik Flyger, Doris Steinemann, Pham Phuong Mai, Stig E. Bojesen, Maaike P.G. Vreeswijk, Sandrine M. Caputo, Jan Sullivan, Julian Peto, Barbara Burwinkel, Laura Galastri, Per Hall, Kyriaki Michailidou, Bernd Dworniczak, Molecular Oncology Laboratory, Hospital Clínico San Carlos, Génétique du cancer et des maladies neuropsychiatriques (GMFC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Fundación Pública Galega Medicina Xenómica-SERGAS & Grupo de Medicina Xenómica--USC, CIBER de Enfermedades Raras (CIBERER), Division of Genetics and Population Health, Queensland Institute of Medical Research, Genetics, University of Southampton, University of Otago [Dunedin, Nouvelle-Zélande], Department of Clinical Genetics and GROM, School for Oncology and Developmental Biology, Human Genetics Division [Southampton], Division of Molecular Gyneco-Oncology, Department of Gynaecology and Obstetrics, Institut Laue-Langevin (ILL), University of Melbourne, Division of Oncology, Department of Gynaecology and Obstetrics, University Hospital Schleswig–Holstein, Institute of Cell and Molecular Pathology, Medizinische Hochschule Hannover (MHH), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), DIEP/DSV (DIEP/DSV), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Ambry Genetics [Aliso Viejo, CA, USA], Department of Clinical Genetics, Royal Devon & Exeter Hospital, Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia, Leiden University Medical Center (LUMC), Universiteit Leiden-Universiteit Leiden, Division of Special Gynecology, Medizinische Universität Wien = Medical University of Vienna-Department of OB/GYN, Metabolic Unit, Dept Clinical Chemistry, Division of Cancer Epidemiology and Genetics, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH), Non-Communicable Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine (LSHTM), Molecular Epidemiology Research Group, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Department of Breast Surgery, Herlev and Gentofte Hospital, Karolinska University Hospital [Stockholm], Division of Cancer Epidemiology, Unit of Genetic Susceptibility to Cancer, Department of Experimental Oncology and Molecular Medici, Cancer Epidemiology Centre, Cancer Council Victoria, Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto-Cancer Care Ontario, Ontario Cancer Genetics Network, Cancer Care Ontario, Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet [Stockholm], University of Science and Technology Beijing [Beijing] (USTB), Strangeways Research Laboratory, University of Cambridge [UK] (CAM)-Department of Public Health and Primary Care-Centre for Cancer Genetic Epidemiology, Cancer Research U.K. Genetic Epidemiology Unit, Department of Laboratory Medicine and Pathology, Mayo Clinic, Department of Oncological Sciences, University of Utah-Huntsman Cancer Institute, Center for Human and Clinical Genetics, Université de Pau et des Pays de l'Adour (UPPA), International Agency for Cancer Research (IACR), ILL, Service de Biochimie et de Biologie Moléculaire [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Wang, Jean [0000-0002-9139-0627], Dennis, Joe [0000-0003-4591-1214], Antoniou, Antonis [0000-0001-9223-3116], Easton, Douglas [0000-0003-2444-3247], Apollo - University of Cambridge Repository, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: 0301 basic medicine, Adult, RNA Splicing, [SDV]Life Sciences [q-bio], DNA Mutational Analysis, Breast Neoplasms, Biology, 03 medical and health sciences, Exon, Genetics, Humans, Allele, Molecular Biology, Gene, Genetics (clinical), ComputingMilieux_MISCELLANEOUS, Aged, Ovarian Neoplasms, Messenger RNA, BRCA1 Protein, Tumor Suppressor Proteins, Alternative splicing, RNA, General Medicine, Articles, Exons, Middle Aged, Splicing regulatory element, 3. Good health, Gene Expression Regulation, Neoplastic, Alternative Splicing, 030104 developmental biology, RNA splicing, Mutation, Female, RNA Splice Sites
Abstract: A recent analysis using family history weighting and co-observation classification modeling indicated that BRCA1 c.594-2A>C (IVS9-2A>C), previously described to cause exon 10 skipping (a truncating alteration), displays characteristics inconsistent with those of a high risk pathogenic BRCA1 variant. We used large-scale genetic and clinical resources from the ENIGMA, CIMBA and BCAC consortia to assess pathogenicity of c.594-2A>C. The combined odds for causality considering case-control, segregation, and breast tumor pathology information was 3.23x10-8. Our data indicate that c.594-2A>C is always in cis with c.641A>G.The spliceogenic effect of c.[594-2A>C;641A>G] was characterized using RNA analysis of human samples and splicing minigenes. As expected, c.[594-2A>C; 641A>G] caused exon 10 skipping, albeit not due to c.594-2A>C impairing the acceptor site but rather by c.641A>G modifying exon 10 splicing regulatory element(s). Multiple blood-based RNA assays indicated that the variant allele did not produce detectable levels of full-length transcripts, with a per allele BRCA1 expression profile comprised of ?70-80% truncating transcripts, and ?20-30% of in-frame ?9,10 transcripts predicted to encode a BRCA1 protein with tumor suppression function.We confirm that BRCA1c.[594-2A>C;641A>G] should not be considered a high-risk pathogenic variant. Importantly, results from our detailed mRNA analysis suggest that BRCA-associated cancer risk is likely not markedly increased for individuals who carry a truncating variant in BRCA1 exons 9 or 10, or any other BRCA1 allele that permits 20-30% of tumor suppressor function. More generally, our findings highlight the importance of assessing naturally occurring alternative splicing for clinical evaluation of variants in disease-causing genes.
Published: 2016
Full Text: View/download PDF

27. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

Author: A. M. Alonso Torres, A. G. Arévalo Bernabé, N. Becerril Ríos, M. F. Hellín Gil, J. M. Martínez Sesmero, V. Meca Lallana, Ll. Ramió-Torrentà, A. Rodríguez-Antigüedad, L. Gómez Maldonado, I. Triana Junco, M. Gómez-Barrera, N. Espinoza Cámac, I. Oyagüez, Institut Català de la Salut, [Alonso Torres AM] Neurology Department, Hospital Universitario de Málaga, Málaga, Spain. [Arévalo Bernabé AG] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Becerril Ríos N] Specialised Nurse, Hospital Virgen Macarena, Sevilla, Spain. [Hellín Gil MF] Specialised Nurse, Hospital Virgen Arrixaca, Murcia, Spain. [Martínez Sesmero JM] Pharmacy Department, Hospital Clínico San Carlos, Madrid, Spain. [Meca Lallana V] Neurology Department, Hospital Universitario La Princesa, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Pharmacology, Assistència sanitària - Cost, Anticossos monoclonals - Ús terapèutic, Health Care Economics and Organizations::Economics::Costs and Cost Analysis [HEALTH CARE], Health Policy, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Injeccions hipodèrmiques, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [CHEMICALS AND DRUGS], terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], economía y organizaciones para la atención de la salud::economía::costes y análisis de costes [ATENCIÓN DE SALUD], enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Pharmacology (medical), Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections, Subcutaneous [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados [COMPUESTOS QUÍMICOS Y DROGAS], Esclerosi múltiple - Tractament
Abstract: Análisis de costes; Administración subcutánea; Esclerosis múltiple Anàlisi de costos; Administració subcutània; Esclerosi múltiple Cost-analysis; Subcutaneous administration; Multiple sclerosis Introduction A subcutaneous (SC) formulation of natalizumab has been recently authorised for multiple sclerosis patients. This study aimed to assess the implications of the new SC formulation, and to compare the annual treatment costs of SC versus intravenous (IV) natalizumab therapy from both the Spanish healthcare system (direct health cost) and the patient (indirect cost) perspectives. Methods A patient care pathway map and a cost-minimisation analysis were developed to estimate SC and IV natalizumab annual costs over a 2-year time horizon. Considering the patient care pathway and according to natalizumab experience (IV) or estimation (SC), a national expert panel involving neurologists, pharmacists, and nurses provided information/data regarding resource consumption for drug and patient preparation, administration, and documentation. One hour of observation was applied to the first six (SC) or 12 (IV) doses, and 5 min for successive doses. The Day hospital (infusion suite) facilities at a reference hospital were considered for IV administrations and the first six SC injections. For successive SC injections, either a reference hospital or regional hospital in a consulting room was considered. Productivity time associated with travel (56 min to reference hospital, 24 min to regional hospital) and waiting time pre- and post-treatment (SC 15 min, IV 25 min) were assessed for patients and caregivers (accompanying 20% of SC and 35% of IV administrations). National salaries for healthcare professionals were used for cost estimation (€, year 2021). Results At years 1 and 2, total time and cost savings (excluding drug acquisition cost) per patient, driven by saving on administration and patient and caregiver productivity for SC at a reference hospital versus IV at a reference hospital, were 116 h (a reduction of 54.6%) and €3682.82 (a reduction of 66.2%). In the case of natalizumab SC at a regional hospital, the total time and cost saving were 129 h (a reduction of 60.6%) and €3883.47 (a reduction of 69.8%). Conclusions Besides the potential benefits of convenient administration and improving work–life balance, as suggested by the expert panel, natalizumab SC was associated with cost savings for the healthcare system by avoiding drug preparation, reducing administration time, and freeing up infusion suite capacity. Additional cost savings could be derived with regional hospital administration of natalizumab SC by reducing productivity loss.
Published: 2023

28. Impact of Left Ventricular Ejection Fraction on Procedural and Long-Term Outcomes of Bifurcation Percutaneous Coronary Intervention

Author: Guglielmo Gallone, Jeehoon Kang, Francesco Bruno, Jung-Kyu Han, Ovidio De Filippo, Han-Mo Yang, Mattia Doronzo, Kyung-Woo Park, Gianluca Mittone, Hyun-Jae Kang, Radoslaw Parma, Hyeon-Cheol Gwon, Enrico Cerrato, Woo Jung Chun, Grzegorz Smolka, Seung-Ho Hur, Gerard Helft, Seung Hwan Han, Saverio Muscoli, Young Bin Song, Filippo Figini, Ki Hong Choi, Giacomo Boccuzzi, Soon-Jun Hong, Daniela Trabattoni, Chang-Wook Nam, Massimo Giammaria, Hyo-Soo Kim, Federico Conrotto, Javier Escaned, Carlo Di Mario, Fabrizio D'Ascenzo, Bon-Kwon Koo, Gaetano Maria de Ferrari, Università degli studi di Torino = University of Turin (UNITO), Seoul National University Hospital, Medical University of Silesia (SUM), Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Ospedale di Rivoli [Rivoli, Italy] (OR), Keimyung University, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Gachon University Gil Medical Center [Incheon, Republic of Korea], University of Rome 'Tor Vergeta', Università degli Studi di Roma Tor Vergata [Roma], Clinica Pederzoli [Peschiera del Garda, Italy] (CP), Ospedale S.Giovanni Bosco, Korea University [Seoul], Monzino Cardiology Center [Milan, Italy] (M2C), Maria Vittoria Hospital [Turin], Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano = University of Milan (UNIMI)-Università degli Studi di Milano = University of Milan (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Careggi University Hospital [Florence, Italie], and Lesnik, Philippe
Subjects: [SDV] Life Sciences [q-bio], Ventricular Dysfunction, Left, Percutaneous Coronary Intervention, Treatment Outcome, [SDV]Life Sciences [q-bio], Humans, Drug-Eluting Stents, Stroke Volume, Coronary Artery Disease, Registries, Cardiology and Cardiovascular Medicine, Ventricular Function, Left, Retrospective Studies
Abstract: International audience; The association of left ventricular ejection fraction (LVEF) with procedural and long-term outcomes after state-of-the-art percutaneous coronary intervention (PCI) of bifurcation lesions remains unsettled. A total of 5,333 patients who underwent contemporary coronary bifurcation PCI were included in the intercontinental retrospective combined insights from the unified RAIN (veRy thin stents for patients with left mAIn or bifurcatioN in real life) and COBIS (COronary BIfurcation Stenting) III bifurcation registries. Of 5,003 patients (93.8%) with known baseline LVEF, 244 (4.9%) had LVEF
Published: 2022
Full Text: View/download PDF

29. Optical coherence tomography in coronary atherosclerosis assessment and intervention

Author: Makoto Araki, Seung-Jung Park, Harold L. Dauerman, Shiro Uemura, Jung-Sun Kim, Carlo Di Mario, Thomas W. Johnson, Giulio Guagliumi, Adnan Kastrati, Michael Joner, Niels Ramsing Holm, Fernando Alfonso, William Wijns, Tom Adriaenssens, Holger Nef, Gilles Rioufol, Nicolas Amabile, Geraud Souteyrand, Nicolas Meneveau, Edouard Gerbaud, Maksymilian P. Opolski, Nieves Gonzalo, Guillermo J. Tearney, Brett Bouma, Aaron D. Aguirre, Gary S. Mintz, Gregg W. Stone, Christos V. Bourantas, Lorenz Räber, Sebastiano Gili, Kyoichi Mizuno, Shigeki Kimura, Toshiro Shinke, Myeong-Ki Hong, Yangsoo Jang, Jin Man Cho, Bryan P. Yan, Italo Porto, Giampaolo Niccoli, Rocco A. Montone, Vikas Thondapu, Michail I. Papafaklis, Lampros K. Michalis, Harmony Reynolds, Jacqueline Saw, Peter Libby, Giora Weisz, Mario Iannaccone, Tommaso Gori, Konstantinos Toutouzas, Taishi Yonetsu, Yoshiyasu Minami, Masamichi Takano, O. Christopher Raffel, Osamu Kurihara, Tsunenari Soeda, Tomoyo Sugiyama, Hyung Oh Kim, Tetsumin Lee, Takumi Higuma, Akihiro Nakajima, Erika Yamamoto, Krzysztof L. Bryniarski, Luca Di Vito, Rocco Vergallo, Francesco Fracassi, Michele Russo, Lena M. Seegers, Iris McNulty, Sangjoon Park, Marc Feldman, Javier Escaned, Francesco Prati, Eloisa Arbustini, Fausto J. Pinto, Ron Waksman, Hector M. Garcia-Garcia, Akiko Maehara, Ziad Ali, Aloke V. Finn, Renu Virmani, Annapoorna S. Kini, Joost Daemen, Teruyoshi Kume, Kiyoshi Hibi, Atsushi Tanaka, Takashi Akasaka, Takashi Kubo, Satoshi Yasuda, Kevin Croce, Juan F. Granada, Amir Lerman, Abhiram Prasad, Evelyn Regar, Yoshihiko Saito, Mullasari Ajit Sankardas, Vijayakumar Subban, Neil J. Weissman, Yundai Chen, Bo Yu, Stephen J. Nicholls, Peter Barlis, Nick E. J. West, Armin Arbab-Zadeh, Jong Chul Ye, Jouke Dijkstra, Hang Lee, Jagat Narula, Filippo Crea, Sunao Nakamura, Tsunekazu Kakuta, James Fujimoto, Valentin Fuster, Ik-Kyung Jang, CarMeN, laboratoire, Massachusetts General Hospital [Boston, MA, USA], Harvard Medical School [Boston] (HMS), Asan Medical Center [Seoul, South Korea] (AMC), University of Vermont [Burlington], Kawasaki Medical School [Okayama, Japan] (KMS), Yonsei University College of Medicine [Seoul, South Korea] (YUCM), Azienda Ospedaliero-Universitaria Careggi [Firenze] (AOUC), University Hospitals Bristol, Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], Technische Universität München = Technical University of Munich (TUM), Munich Heart Alliance [Munich, Allemagne] (MHA), German Heart Center = Deutsches Herzzentrum München [Munich, Germany] (GHC), Aarhus University Hospital [Skejby, Denmark] (AUH), Hospital Universitario de La Princesa, National University of Ireland [Galway] (NUI Galway), University Hospitals Leuven [Leuven], Technische Hochschule Mittelhessen - University of Applied Sciences [Giessen] (THM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), Université de Lyon, Institut Mutualiste de Montsouris (IMM), CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute of Cardiology [Warsaw, Poland] (NIC), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Massachusetts General Hospital [Boston], Cardiovascular Research Foundation [New York, NY, USA] (CRF), Icahn School of Medicine at Mount Sinai [New York] (MSSM), Barts Health NHS Trust [London, UK], Queen Mary University of London (QMUL), Bern University Hospital [Berne] (Inselspital), Centro Cardiologico Monzino [Milan, Italy] (2CM), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Mitsukoshi Health and Welfare Foundation [Tokyo, Japan] (MHWF), Yokohama Minami Kyosai Hospital [Kanagawa, Japan] (YMKH), Showa University Hospital [Tokyo, Japan] (SUH), Kyung Hee University [Seoul, South Korea] (KHU), The Chinese University of Hong Kong [Hong Kong], Università degli studi di Genova = University of Genoa (UniGe), Università degli studi di Parma = University of Parma (UNIPR), Catholic University of the Sacred Heart [Rome, Italy] (CUSH), University Hospital [Ioannina, Greece] (UH), New York University School of Medicine (NYU Grossman School of Medicine), Vancouver General Hospital [Vancouver, British Columbia, Canada] (VGH), University of British Columbia (UBC), Brigham and Women’s Hospital [Boston, MA], New York Presbyterian Hospital, Columbia University Medical Center (CUMC), Columbia University [New York], Ospedale San Giovanni Bosco [Turin, Italy] (OSGB), Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), National and Kapodistrian University of Athens (NKUA), Tokyo Medical and Dental University [Japan] (TMDU), Kitasato University, Nippon Medical School Chiba Hokusoh Hospital [Chiba, Japan] (NMSC2H), The Prince Charles Hospital, Nara Medical University [Nara, Japan] (NMU), Tsuchiura Kyodo General Hospital [Ibaraki, Japan] (TKGH), Japanese Red Cross Musashino Hospital [Tokyo], St. Marianna University School of Medicine [Kanagawa, Japan], Kyoto University Graduate School of Medicine [Kyoto, Japan] (KUGSM), Jagiellonian University - Medical College (JUMC), Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Mazzoni Hospital [Ascoli Piceno, Italy] (MH), Korea Advanced Institute of Science and Technology (KAIST), University of Texas Health Science Center, The University of Texas Health Science Center at Houston (UTHealth), Saint Camillus International University of Health Sciences [Rome, Italy] (SCIUHS), Fondazione IRCCS Policlinico San Matteo [Pavia], Università degli Studi di Pavia = University of Pavia (UNIPV), Universidade de Lisboa = University of Lisbon (ULISBOA), MedStar Washington Hospital Center [Washington, DC, USA] (MedStar WHC), CV Path Institute [Gaithersburg, MD, USA] (CV-PI), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Yokohama City University (YCU), Wakayama University, Tohoku University [Sendai], Mayo Clinic [Rochester, MN, USA], Mayo Clinic [Rochester], University hospital of Zurich [Zurich], Gifu University Graduate School of Medicine, Madras Medical Mission [Chennai, India] (3M), MedStar Health Research Institute [Washington, DC, USA] (MedStar-HRI), Chinese People's Liberation Army General Hospital [Beijing, China] (CPLAGH), Harbin Medical University [China] (HMU), Monash university, University of Melbourne, Royal Papworth Hospital [Cambridge, UK] (RPH), Johns Hopkins University (JHU), Leiden University Medical Center (LUMC), The Open University of Japan [Chiba] (OUJ), and Massachusetts Institute of Technology (MIT)
Subjects: [SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], Cardiology and Cardiovascular Medicine
Abstract: Optical coherence tomography (OCT) has been widely adopted in research on coronary atherosclerosis and adopted clinically to optimize percutaneous coronary intervention. In this Review, Jang and colleagues summarize this rapidly progressing field, with the aim of standardizing the use of OCT in coronary atherosclerosis.Since optical coherence tomography (OCT) was first performed in humans two decades ago, this imaging modality has been widely adopted in research on coronary atherosclerosis and adopted clinically for the optimization of percutaneous coronary intervention. In the past 10 years, substantial advances have been made in the understanding of in vivo vascular biology using OCT. Identification by OCT of culprit plaque pathology could potentially lead to a major shift in the management of patients with acute coronary syndromes. Detection by OCT of healed coronary plaque has been important in our understanding of the mechanisms involved in plaque destabilization and healing with the rapid progression of atherosclerosis. Accurate detection by OCT of sequelae from percutaneous coronary interventions that might be missed by angiography could improve clinical outcomes. In addition, OCT has become an essential diagnostic modality for myocardial infarction with non-obstructive coronary arteries. Insight into neoatherosclerosis from OCT could improve our understanding of the mechanisms of very late stent thrombosis. The appropriate use of OCT depends on accurate interpretation and understanding of the clinical significance of OCT findings. In this Review, we summarize the state of the art in cardiac OCT and facilitate the uniform use of this modality in coronary atherosclerosis. Contributions have been made by clinicians and investigators worldwide with extensive experience in OCT, with the aim that this document will serve as a standard reference for future research and clinical application.
Published: 2022
Full Text: View/download PDF

30. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and COVID-19 infection

Author: Rosa Burgos, José Manuel García-Almeida, Pilar Matía-Martín, Samara Palma, Alejandro Sanz-Paris, Ana Zugasti, José Joaquín Alfaro, Ana Artero Fullana, Alfonso Calañas Continente, María Jesús Chicetru, Katherine García Malpartida, Ángela González Faes, Víctor González Sánchez, María Lainez López, Antonio Jesús Martínez Ortega, Juana Oliva Roldán, Clara Serrano Moreno, Pablo Suárez Llanos, Institut Català de la Salut, [Burgos R] Unitat de Suport Nutricional, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [García-Almeida JM] Unidad de Gestión Clínica de Endocrinología Y Nutrición, Hospital Virgen de La Victoria, Málaga, Spain. [Matía-Martín P] Departamento de Endocrinología Y Nutrición, Hospital Clínico San Carlos, Madrid, Spain. [Palma S] Unidad de Nutrición Clínica Y Dietética, Hospital Universitario de La Paz, Madrid, Spain. [Sanz-Paris A] Nutrition Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain. Instituto de Investigación Sanitaria (IIS) Aragón, 50009 Zaragoza, Spain. [Zugasti A] Unidad de Nutrición Clínica, Hospital Universitario de Navarra, 31008 Pamplona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Diabetis, SARS-CoV-2, Endocrinology, Diabetes and Metabolism, Diabetes, Malnutrition, trastornos nutricionales, COVID-19, terapia, COVID-19 (Malaltia), Malnutrició, Nutrition Disorders, Medical nutrition, Endocrinology, therapy, Hyperglycemia, Diabetes Mellitus, Humans
Abstract: COVID-19; Diabetes; Medical nutrition COVID-19; Diabetes; Nutrición médica COVID-19; Diabetis; Nutrició mèdica Diabetes mellitus and/or hyperglycemia are highly prevalent medical conditions in patients hospitalized for coronavirus disease 2019 (COVID-19) and are associated with adverse outcomes. In addition, COVID-19 itself can provoke fluctuating and high glucose levels that can be difficult to manage upon hospitalization. Hospitalized patients with COVID-19 are at high risk of malnutrition due to an increase in nutritional requirements and a severe acute inflammatory response. The management of patients with diabetes/hyperglycemia and COVID-19 is challenging and requires a specific nutritional approach, the purpose of which is to fulfill the nutritional requirements while maintaining an optimal glycemic control. In this study, an expert group of nutritional endocrinologists carried out a qualitative literature review and provided recommendations based on evidence and guidelines, when available, or on their own experience. The optimal care based on these recommendations was compared with the routine bedside care as reported by a panel of physicians (mainly, endocrinologists, geriatricians, and internists) treating patients with diabetes/hyperglycemia and COVID-19 in their daily practice. Early screening and diagnosis, a diabetes-specific therapeutic approach, and a close malnutrition monitoring are essential to improve the clinical outcomes of these patients. In conclusion, the proposed recommendations are intended to provide a useful guide on the clinical management of malnutrition in patients with COVID-19 and diabetes/hyperglycemia, in order to improve their outcomes and accelerate their recovery. The comparison of the recommended optimal care with routine clinical practice could aid to identify gaps in knowledge, implementation difficulties, and areas for improvement in the management of malnutrition in this population. This study was funded by Abbott. Abbott Nutrition was the sponsor of the study, but it didn’t participate in the design, research, data collection and data review.
Published: 2022
Full Text: View/download PDF

31. Cefalea: embarazo y lactancia. Recomendaciones del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología (GECSEN)

Author: A.C. López-Veloso, N. Mas-Sala, Nuria González-García, Sonia Santos-Lasaosa, J. Díaz de Terán, A.B. Gago-Veiga, M. Ruiz-Piñero, J. Viguera-Romero, Patricia Pozo-Rosich, A. Minguez-Olaondo, UAM. Departamento de Medicina, Institut Català de la Salut, [González-García N] Unidad de Cefaleas, Hospital Clínico San Carlos, Madrid, Spain. [Díaz de Terán J] Unidad de Cefaleas, Servicio de Neurología, Hospital Universitario La Paz, IdiPAZ, Instituto de Investigación Sanitaria, Madrid, Spain. [López-Veloso AC] Servicio de Neurología, Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain. [Mas-Sala N] Servicio de Neurología, Hospital Universitario Sant Joan de Déu, Fundación Althaia, Manresa, Barcelona, Spain. [Mínguez-Olaondo A] Servicio de Neurología, Hospital Universitario Donostia, Donostia, Spain. Servicio de Neurología, Clínica Universidad de Navarra, Pamplona, Spain. [Ruiz-Piñero M] Servicio de Neurología, Hospital Universitario San Juan de Alicante, Alicante, Spain. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalea, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Medicina, Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Pain::Headache [DISEASES], Embaràs, Breastfeeding, Headache, Alletament, Birth defects, 03 medical and health sciences, 0302 clinical medicine, afecciones patológicas, signos y síntomas::signos y síntomas::manifestaciones neurológicas::dolor::cefalea [ENFERMEDADES], Postpartum, Pregnancy, Adverse events, Cefalàlgia, Neurology (clinical), Migraine, 030217 neurology & neurosurgery
Abstract: Introduction: Headache is one of the most common neurological complaints, and is most frequent during reproductive age. As a result, we are routinely faced with pregnant or breastfeeding women with this symptom in clinical practice. It is important to know which pharmacological choices are the safest, which should not be used, and when we should suspect secondary headache. To this end, the Spanish Society of Neurology's Headache Study Grouphas prepared a series of consensus recommendations on the diagnostic and therapeutic algorithms that should be followed during pregnancy and breastfeeding. Development: This guide was prepared by a group of young neurologists with special interest and experience in headache, in collaboration with the Group's Executive Committee. Recommendations focus on which drugs should be used for the most frequent primary headaches, both during the acute phase and for prevention. The second part addresses when secondary headache should be suspected and which diagnostic tests should be performed in the event of possible secondary headache during pregnancy and breastfeeding. Conclusions: We hope this guide will be practical and useful in daily clinical practice and that it will help update and improve understanding of headache management during pregnancy and breastfeeding, enabling physicians to more confidently treat these patients., Introducción: La cefalea es uno de los motivos de consulta más comunes en neurología, siendo más frecuente durante la edad reproductiva. Por ello, es habitual encontrar en nuestras consultas pacientes embarazadas o en periodo de lactancia con dicha queja. Es importante conocer las opciones farmacológicas más seguras, cuáles no se deben emplear, así como cuándo sospechar cefaleas secundarias. Por este motivo, el Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología ha elaborado una guía con las recomendaciones consensuadas acerca de los algoritmos diagnósticos y terapéuticos que se deben emplear durante el embarazo y la lactancia
Published: 2022
Full Text: View/download PDF

32. Extended use of dual antiplatelet therapy among older adults with acute coronary syndromes and associated variables: a cohort study

Author: Albert Ariza-Solé, Gemma Mateus-Porta, Francesc Formiga, Sergio Garcia-Blas, Clara Bonanad, Iván Núñez-Gil, Carlos Vergara-Uzcategui, Pablo Díez-Villanueva, Jordi Bañeras, Clara Badia-Molins, Jaime Aboal, José Carreras-Mora, Ana Gabaldón-Pérez, José Antonio Parada-Barcia, Manuel Martínez-Sellés, Josep Comín-Colet, Sergio Raposeiras-Roubin, Institut Català de la Salut, [Ariza-Solé A, Mateus-Porta G] Cardiology Department, Bioheart Grup de Malalties Cardiovasculars, Hospital Universitari de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge—IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Formiga F] Geriatrics Unit. Internal Medicine Department, Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat, Barcelona, Spain. [Garcia-Blas S, Bonanad C] Cardiology Department, Department of Medicine, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. [Núñez-Gil I] Cardiology Department, Hospital Clínico San Carlos, Madrid, Spain. [Bañeras J, Badia-Molins C] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos hematológicos::inhibidores de la agregación plaquetaria [COMPUESTOS QUÍMICOS Y DROGAS], Malalties coronàries - Tractament, Hemorrhage, Hematology, Other subheadings::/therapy [Other subheadings], Hemorràgia, Malalties coronàries, Persones grans, Coronary diseases, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Platelet Aggregation Inhibitors [CHEMICALS AND DRUGS], enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::síndrome coronario agudo [ENFERMEDADES], Older people, Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Acute Coronary Syndrome [DISEASES], Plaquetes sanguínies - Inhibidors - Ús terapèutic, Otros calificadores::/terapia [Otros calificadores]
Abstract: Background Current guidelines recommend extending the use of dual antiplatelet therapy (DAPT) beyond 1 year in patients with an acute coronary syndrome (ACS) and a high risk of ischaemia and low risk of bleeding. No data exist about the implementation of this strategy in older adults from routine clinical practice. Methods We conducted a Spanish multicentre, retrospective, observational registry-based study that included patients with ACS but no thrombotic or bleeding events during the first year of DAPT after discharge and no indication for oral anticoagulants. High bleeding risk was defined according to the Academic Research Consortium definition. We assessed the proportion of cases of extended DAPT among patients 65 ≥ years that went beyond 1 year after hospitalisation for ACS and the variables associated with the strategy. Results We found that 48.1% (928/1,928) of patients were aged ≥ 65 years. DAPT was continued beyond 1 year in 32.1% (298/928) of patients ≥ 65; which was a similar proportion as with their younger counterparts. There was no significant correlation between a high bleeding risk and DAPT duration. Contrastingly, there was a strong correlation between the extent of coronary disease and DAPT duration (p Conclusion There was no correlation between age and extended use of DAPT beyond 1 year in older patients with ACS. DAPT was extended in about one-third of patients ≥ 65 years. The severity of the coronary disease, prior heart failure, left ventricle ejection fraction and prior stent thrombosis all correlated with extended DAPT.
Published: 2023

33. Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study

Author: Juan Luis Rodríguez Hermosa, Gianna Vargas Centanaro, María Estela González Castro, Marc Miravitlles, Lourdes Lázaro-Asegurado, Beatriz María Jiménez-Rodríguez, Rosanel Amaro Rodríguez, Rosaly Moreno Méndez, María Torres-Duran, José María Hernández-Pérez, Ana María Humanes-Navarro, Myriam Calle Rubio, Institut Català de la Salut, [Rodríguez Hermosa JL, Vargas Centanaro G] Pulmonology Department, Research Institute of Hospital Clínico San Carlos (IdISSC), Madrid, Spain. Department of Medicine, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain. [González Castro ME] Pneumology Department, Hospital Universitario Torrecardenas, Almería, Spain. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Lázaro-Asegurado L] Pneumology Department, Complejo Asistencial Universitario de Burgos, Burgos, Spain. [Jiménez-Rodríguez BM] Pneumology Department, Hospital Virgen de las Nieves, Granada, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: alpha-1 antitrypsin deficiency, SARS-CoV-2 infection, COVID-19 (Malaltia) - Factors de risc, Medicine (miscellaneous), severe COVID-19, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], genetic mutations, General Biochemistry, Genetics and Molecular Biology, Alfa 1-antitripsina, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], enfermedades respiratorias::enfermedades pulmonares::deficiencia de alfa 1-antitripsina [ENFERMEDADES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Respiratory Tract Diseases::Lung Diseases::alpha 1-Antitrypsin Deficiency [DISEASES], Other subheadings::Other subheadings::/complications [Other subheadings]
Abstract: Alpha-1 antitrypsin deficiency; Genetic mutations; Severe COVID-19 Deficiència d'alfa-1 antitripsina; Mutacions genètiques; COVID-19 greu Deficiencia de alfa-1 antitripsina; Mutaciones genéticas; COVID-19 grave Background: Epidemiologic studies have reported that the geographical distribution of the prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of COVID-19 were similar. Methods: A multicenter, cross-sectional, observational study to evaluate the frequency of alpha-1 antitrypsin deficiency (AATD) in patients with COVID-19 and whether it was associated with having suffered severe COVID-19. Results: 2022 patients who had laboratory-confirmed SARS-CoV-2 infection. Mutations associated with AATD were more frequent in severe COVID versus non-severe (23% vs. 18.8%, p = 0.022). The frequency of Pi*Z was 37.8/1000 in severe COVID versus 17.5/1000 in non-severe, p = 0.001. Having an A1AT level below 116 was more frequent in severe COVID versus non-severe (29.5% vs. 23.1, p = 0.003). Factors associated with a higher likelihood of severe COVID-19 were being male, older, smoking, age-associated comorbidities, and having an A1AT level below 116 mg/dL [OR 1.398, p = 0.003], and a variant of the SERPINA1 gene that could affect A1AT protein [OR 1.294, p = 0.022]. Conclusions: These observations suggest that patients with AATD should be considered at a higher risk of developing severe COVID-19. Further studies are needed on the role of A1AT in the prognosis of SARS-CoV-2 infection and its possible therapeutic role. This study was promoted by the Madrid Society of Pneumology and Thoracic Surgery (Neumomadrid). We thank Grifols for its financial support to carry out the study. The financing entities did not participate in the design of the study, data collection, analysis, publication, or preparation of this manuscript. The participation of the Vall d’Hebron University Hospital in this study has been funded by a research grant from the Fundació Catalana de Pneumologia (FUCAP) 2021.
Published: 2023

34. COVID-19's impact on care practice for alpha-1-antitrypsin deficiency patients

Author: Calle Rubio, Myriam, López-Campos, José Luis, Miravitlles, Marc, Michel de la Rosa, Francisco Javier, Hernández Pérez, José María, Montero Martínez, Carmen, Montoro Ronsano, José Bruno, Casas-Maldonado, Francisco, Rodríguez Hermosa, Juan Luis, Tabernero Huguet, Eva María, Martínez Sesmero, José Manuel, Martínez Rivera, Carlos, Callejas González, Francisco Javier, Torres Durán, María, Universitat Autònoma de Barcelona, CSL Behring, Institut Català de la Salut, [Calle Rubio M] Pulmonology Department, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. [López-Campos JL] Medical Surgical Unit for Respiratory Diseases, Biomedicine Institute of Sevilla (IBiS), Virgen del Rocío University Hospital, Seville, Spain. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Network of Centers for Biomedical Research On Respiratory Diseases (CIBERES), Carlos III Health Institute, Madrid, Spain. [Michel de la Rosa FJ] Pulmonology Department, Donostia University Hospital, San Sebastián, Spain. [Hernández Pérez JM] Network of Centers for Biomedical Research On Respiratory Diseases (CIBERES), Carlos III Health Institute, Madrid, Spain. Pulmonology Department, Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife, Spain. [Montero Martínez C] Pulmonology Department, A Coruña University Hospital, A Coruña, Spain. [Montoro Ronsano JB] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Healthcare system, Atenció centrada en el pacient, Alpha-1-antitrypsin deficiency, Health Policy, Follow-up, COVID-19, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], AATD, Recommendations, COVID-19 (Malaltia), Alfa 1-antitripsina, Pulmons - Malalties, Treatment, enfermedades respiratorias::enfermedades pulmonares::deficiencia de alfa 1-antitripsina [ENFERMEDADES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Patient management, Respiratory Tract Diseases::Lung Diseases::alpha 1-Antitrypsin Deficiency [DISEASES], administración de los servicios de salud::gestión de la atención al paciente::prestación sanitaria [ATENCIÓN DE SALUD], Diagnostic, Rare disease, Health Services Administration::Patient Care Management::Delivery of Health Care [HEALTH CARE]
Abstract: Patients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been affected by the changes in healthcare management brought about by COVID-19. This study's aim was to identify the changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose experts' recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation., This study was funded by CSL Behring.
Published: 2023

35. HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV

Author: Elena Urcelay, María Fedetz, Guillermo Izquierdo, Fuencisla Matesanz, Belén de la Hera, Angel Garcia-Martinez, Iris Camacho, Jezabel Varadé, Ana de la Encarnación, Ana Maria Arias-Leal, Maria Inmaculada Dominguez-Mozo, Roberto Alvarez-Lafuente, Rafael Arroyo, Marta Garcia-Montojo, Ignacio Casanova, Miguel Lucas, Antonio Alcina, Instituto de Salud Carlos III, Fundación Genzyme, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, Fundación LAIR, [García-Montojo,M, Domínguez-Mozo,M, Árias-Leal,A, Casanova,I, Arroyo,R] Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid. [Hera,B de la, Varadé,J, Encarnación,A de la, Camacho,I, García-Martínez,A, Urcelay,E, Alvarez-Lafuente,R] Immunology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain. [Izquierdo,G] Multiple Sclerosis Unit, Hospital Virgen Macarena, Sevilla, Spain. [Lucas,M] Molecular Biology Department, Hospital Virgen Macarena, Sevilla, Spain. [Fedetz,M, Alcina,A, Matesanz,F] Instituto de Parasitologia y Biomedicina ’Lopez-Neyra’-CSIC, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain., and Instituto de Salud Carlos III-Fondo Investigaciones Sanitarias FIS (10/01985 and 09/02074), Fundación Genzyme, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, and Fundación LAIR.
Subjects: Male, Endogenous retrovirus, Autoimmunity, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease_cause, Pathogenesis, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Retrovirus, Demyelinating disease, Gender differences, Anatomy::Cells::Cellular Structures::Chromosomes::Chromosomes, Mammalian::Chromosomes, Human::Chromosomes, Human, 6-12 and X::Chromosomes, Human, X [Medical Subject Headings], X chromosome, Genetics, Chromosome x, Predisposición genética a la enfermedad, Human endogenous retrovirus, Middle Aged, Infectious Diseases, Female, Sex, Adult, Chromosome X, Check Tags::Male [Medical Subject Headings], Retrovirus endógenos, Biology, Diseases::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [Medical Subject Headings], Risk Assessment, Multiple sclerosis, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings], Virology, medicine, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], Humans, Genetic Predisposition to Disease, Organisms::Viruses::RNA Viruses::Retroviridae::Endogenous Retroviruses [Medical Subject Headings], Chromosomes, Human, X, Polymorphism, Genetic, Research, Endogenous Retroviruses, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Assessment [Medical Subject Headings], Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings], medicine.disease, biology.organism_classification, Open reading frame, Check Tags::Female [Medical Subject Headings], HERV-W, Esclerosis múltiple, Immunology, Cromosomas humanos X, Multiple sclerosis associated retrovirus
Abstract: [Background] Multiple Sclerosis (MS) is an autoimmune demyelinating disease that occurs more frequently in women than in men. Multiple Sclerosis Associated Retrovirus (MSRV) is a member of HERV-W, a multicopy human endogenous retroviral family repeatedly implicated in MS pathogenesis. MSRV envelope protein is elevated in the serum of MS patients and induces inflammation and demyelination but, in spite of this pathogenic potential, its exact genomic origin and mechanism of generation are unknown. A possible link between the HERV-W copy on chromosome Xq22.3, that contains an almost complete open reading frame, and the gender differential prevalence in MS has been suggested., [Results] MSRV transcription levels were higher in MS patients than in controls (U-Mann–Whitney; p = 0.004). Also, they were associated with the clinical forms (Spearman; p = 0.0003) and with the Multiple Sclerosis Severity Score (MSSS) (Spearman; p = 0.016). By mapping a 3 kb region in Xq22.3, including the HERV-W locus, we identified three polymorphisms: rs6622139 (T/C), rs6622140 (G/A) and rs1290413 (G/A). After genotyping 3127 individuals (1669 patients and 1458 controls) from two different Spanish cohorts, we found that in women rs6622139 T/C was associated with MS susceptibility: [χ2; p = 0.004; OR (95% CI) = 0.50 (0.31-0.81)] and severity, since CC women presented lower MSSS scores than CT (U-Mann–Whitney; p = 0.039) or TT patients (U-Mann–Whitney; p = 0.031). Concordantly with the susceptibility conferred in women, rs6622139*T was associated with higher MSRV expression (U-Mann–Whitney; p = 0.003)., [Conclusions] Our present work supports the hypothesis of a direct involvement of HERV-W/MSRV in MS pathogenesis, identifying a genetic marker on chromosome X that could be one of the causes underlying the gender differences in MS., This work was supported by grants from: Instituto de Salud Carlos III-Fondo Investigaciones Sanitarias FIS (10/01985 and 09/02074), Fundación Genzyme, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, and Fundación LAIR.
Published: 2014

36. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

Author: Antonio Gallo, Leopoldo Pérez de Isla, Sybil Charrière, Alexandre Vimont, Rodrigo Alonso, Ovidio Muñiz-Grijalvo, José L. Díaz-Díaz, Daniel Zambón, Philippe Moulin, Eric Bruckert, Pedro Mata, Sophie Béliard, Denis Angoulvant, Sophie Beliard, Franck Boccara, Bertrand Cariou, Valérie Carreau, Alain Carrie, Sybil Charrieres, Yves Cottin, Mathilde Di Filippo, Pierre Henri Ducluzeau, Sonia Dulong, Vincent Durlach, Michel Farnier, Emile Ferrari, Dorota Ferrieres, Jean Ferrieres, Philippe Giral, Sophie Gonbert, Regis Hankard, Jocelyn Inamo, Olga Kalmykova, Michel Krempf, Julie Lemale, François Paillard, Noel Peretti, Agnes Perrin, Alain Pradignac, Jean Pierre Rabes, Vincent Rigalleau, François Schiele, Ariane Sultan, Patrick Tounian, René Valero, Bruno Verges, Cecile Yelnik, Olivier Ziegler, Rocío Aguado, Ma Pilar Álvarez-Baños, Rosa Argüeso, Francisco Arrieta, Miguel Ángel Barba, Marta Casañas, José María Cepeda, Raimundo De Andrés, Gonzalo Díaz-Soto, Jose Luis Díaz-Diaz, Marta Dieguez, Ceferino Faedo, Francisco Fuentes, Juan A. Garrido, Aurora González, Pablo González-Bustos, Ma Dolores Mañas, Marta Mauri, Juan Diego Mediavilla, Alfredo Michán, Pablo Miramontes, Ovidio Muñiz, Leire Pérez, Leopoldo Perez De Isla, Xavier Pintó, Manuel J. Romero, Patricia Rubio, Juan F. Sánchez Muñoz-Torrero, Jose I. Vidal-Pardo, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Public Health Expertise [Paris, France], Hospital Universitario Virgen del Rocío [Sevilla], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Hospital Abente y Lago, Fundación Hipercolesterolemia Familiar, and ANR-16-RHUS-0007,CHOPIN,CHOPIN(2016)
Subjects: Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Coronary Artery Disease, Disease, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Risk Assessment, Sudden death, Cohort Studies, Hyperlipoproteinemia Type II, risk prediction, 03 medical and health sciences, 0302 clinical medicine, cardiovascular disease, genetic disease, Predictive Value of Tests, Risk Factors, Interquartile range, Internal medicine, Humans, Medicine, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Vascular Calcification, Stroke, coronary artery calcium, ComputingMilieux_MISCELLANEOUS, familial hypercholesterolemia, business.industry, Proportional hazards model, nutritional and metabolic diseases, Middle Aged, Atherosclerosis, medicine.disease, 3. Good health, Coronary Calcium Score, Cardiology, Calcium, Cardiology and Cardiovascular Medicine, business, coronary imaging, Cohort study
Abstract: International audience; ObjectivesThis study aimed at investigating the additional contribution of coronary artery calcium (CAC) score to SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study) risk equation (SAFEHEART-RE) for cardiovascular risk prediction in heterozygous familial hypercholesterolemia (HeFH).BackgroundCommon cardiovascular risk equations are imprecise for HeFH. Because of the high phenotype variability of HeFH, CAC score could help to better stratify the risk of atherosclerotic cardiovascular disease (ASCVD).MethodsREFERCHOL (French Registry of Familial Hypercholesterolemia) and SAFEHEART are 2 ongoing national registries on HeFH. We analyzed data from primary prevention HeFH patients undergoing CAC quantification. We used probability-weighted Cox proportional hazards models to estimate HRs. Area under the receiver-operating characteristic curve (AUC) and net reclassification improvement (NRI) were used to compare the incremental contribution of CAC score when added to the SAFEHEART-RE for ASCVD prediction. ASCVD was defined as coronary heart disease, stroke or transient ischemic attack, peripheral artery disease, resuscitated sudden death, and cardiovascular death.ResultsWe included 1,624 patients (mean age: 48.5 ± 12.8 years; men: 45.7%) from both registries. After a median follow-up of 2.7 years (interquartile range: 0.4-5.0 years), ASCVD occurred in 81 subjects. The presence of a CAC score of >100 was associated with an HR of 32.05 (95% CI: 10.08-101.94) of developing ASCVD as compared to a CAC score of 0. Receiving-operating curve analysis showed a good performance of CAC score alone in ASCVD prediction (AUC: 0.860 [95% CI: 0.853-0.869]). The addition of log(CAC + 1) to SAFEHEART-RE resulted in a significantly improved prediction of ASCVD (AUC: 0.884 [95% CI: 0.871-0.894] for SAFEHEART-RE + log(CAC + 1) vs AUC: 0.793 [95% CI: 0.779-0.818] for SAFEHEART-RE; P < 0.001). These results were confirmed also when considering only hard cardiovascular endpoints. The addition of CAC score was associated with an estimated overall net reclassification improvement of 45.4%.ConclusionsCAC score proved its use in improving cardiovascular risk stratification and ASCVD prediction in statin-treated HeFH.
Published: 2021
Full Text: View/download PDF

37. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author: Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology
Subjects: Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract: Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion
Published: 2021
Full Text: View/download PDF

38. Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry)

Author: Young Bin Song, Jeehoon Kang, Carlo Di Mario, Javier Escaned, Imad Sheiban, Han-Mo Yang, Saverio Muscoli, Seung Ho Hur, Davide Capodanno, Bernardo Cortese, Hyo-Soo Kim, Soon-Jun Hong, Guglielmo Gallone, Joon-Hyung Doh, Federico Conrotto, Daniela Trabattoni, Radosław Parma, Gérard Helft, Chang-Wook Nam, Ovidio De Filippo, Leonardo De Luca, Hyeon-Cheol Gwon, Grzegorz Smolka, Antonio Montefusco, Giuseppe Patti, Kyung-Woo Park, Fabrizio D'Ascenzo, Seung Hwan Han, Woo Jung Chun, Jung-Kyu Han, Iacopo Colonnelli, Bon-Kwon Koo, Gaetano M. De Ferrari, Enrico Cerrato, Yoichi Imori, Andrea Saglietto, Ki Hong Choi, Veronica Dusi, Alessandra Truffa Giachet, Francesco Bruno, Mario Iannaccone, Università degli studi di Torino = University of Turin (UNITO), Seoul National University Hospital, University Hospital 'Maggiore della Carità' [Novara, Italy], Medical University of Silesia (SUM), Ospedale San Camillo-Forlanini, Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Ospedale San Giovanni Bosco [Turin, Italy] (OSGB), Keimyung University, Ospedale San Luigi Gonzaga, Gachon University Gil Medical Center [Incheon, Republic of Korea], Careggi University Hospital [Florence, Italie], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Inje University, Ospedale di Asti [Asti, Italy] (OA), Korea University Anam Hospital [Seoul], Università degli Studi di Roma Tor Vergata [Roma], AOU Policlinico Vittorio-Emanuele [Catania, Italia], IRCCS Istituto Nazionale dei Tumori [Milano], Nippon Medical School [Tokyo, Japon], Università degli Studi di Pavia = University of Pavia (UNIPV), ASST Fatebenefratelli-Sacco [Milan, Italy], Clinica Pederzoli [Peschiera del Garda, Italy] (CP), and Lesnik, Philippe
Subjects: Male, Acute coronary syndrome, medicine.medical_specialty, animal structures, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Revascularization, Drug Administration Schedule, Percutaneous Coronary Intervention, Internal medicine, Clinical endpoint, Humans, Medicine, Registries, cardiovascular diseases, Myocardial infarction, Acute Coronary Syndrome, Aged, business.industry, Dual Anti-Platelet Therapy, Percutaneous coronary intervention, Drug-Eluting Stents, Middle Aged, medicine.disease, [SDV] Life Sciences [q-bio], Treatment Outcome, Cohort, Conventional PCI, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors, Mace, Follow-Up Studies
Abstract: Optimal dual antiplatelet therapy (DAPT) duration for patients undergoing percutaneous coronary intervention (PCI) for coronary bifurcations is an unmet issue. The BIFURCAT registry was obtained by merging two registries on coronary bifurcations. Three groups were compared in a two-by-two fashion: short-term DAPT (≤ 6 months), intermediate-term DAPT (6-12 months) and extended DAPT (>12 months). Major adverse cardiac events (MACE) (a composite of all-cause death, myocardial infarction (MI), target-lesion revascularization and stent thrombosis) were the primary endpoint. Single components of MACE were the secondary endpoints. Events were appraised according to the clinical presentation: chronic coronary syndrome (CCS) versus acute coronary syndrome (ACS). 5537 patients (3231 ACS, 2306 CCS) were included. After a median follow-up of 2.1 years (IQR 0.9-2.2), extended DAPT was associated with a lower incidence of MACE compared with intermediate-term DAPT (2.8% versus 3.4%, adjusted HR 0.23 [0.1-0.54], p
Published: 2021
Full Text: View/download PDF

39. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and sarcopenia

Author: García-Almeida, José Manuel, Laínez López, María, Matía‑Martín, Pilar, Palma, Samara, Sanz París, Alejandro, Burgos Peláez, Rosa, Institut Català de la Salut, [García Almeida JM] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Laínez López M] Servicio de Endocrinología y Nutrición, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain. [Burgos R] Unitat de Suport Nutricional, Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Matía Martín P] Departamento de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, Spain. [Palma S] Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, Madrid, Spain. [Sanz Paris A] Servicio de Nutrición, Hospital Universitario Miguel Servet, Zaragoza, Spain. Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia [ENFERMEDADES], Diabetis, enfermedades del sistema nervioso::manifestaciones neurológicas::manifestaciones neuromusculares::atrofia muscular::sarcopenia [ENFERMEDADES], Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [DISEASES], Nervous System Diseases::Neurologic Manifestations::Neuromuscular Manifestations::Muscular Atrophy::Sarcopenia [DISEASES], enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición [ENFERMEDADES], Hiperglucèmia, enfermedades del sistema endocrino::diabetes mellitus [ENFERMEDADES], Atròfia muscular, Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition [DISEASES], Malnutrició, Endocrine System Diseases::Diabetes Mellitus [DISEASES]
Abstract: Hiperglucemia; Diabetes; Sarcopenia Hyperglycemia; Diabetes; Sarcopenia Hiperglucèmia; Diabetis; Sarcopènia La sarcopenia se describe como una afección multidimensional que afecta negativamente a la masa muscular, la fuerza muscular y el rendimiento físico. La prevalencia de sarcopenia en personas con diabetes es muy superior a la de la población general, especialmente en individuos que presentan un estado nutricional deficiente. Tanto la sarcopenia como la desnutrición son condiciones susceptibles de intervención para mejorar el pronóstico clínico. El presente artículo describe los resultados del consenso de expertos y las respuestas de los panelistas sobre el manejo nutricional en la práctica clínica habitual de los pacientes con diabetes/hiperglucemia hospitalizados en planta (no críticos) con sarcopenia concurrente. Sarcopenia is a multidimensional condition that negatively affects muscle mass, muscle strength, and physical performance. The prevalence of sarcopenia in people with diabetes is much higher than that of the general population, especially in individuals with poor nutritional status. Both sarcopenia and malnutrition are conditions amenable to intervention to improve clinical prognosis. This article describes the results of the expert consensus and the responses of the panelists on the nutritional management in routine clinical practice of patients with diabetes/hyperglycemia hospitalized (non-critically ill) with sarcopenia.
Published: 2022

40. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and liver cirrhosis

Author: Matía‑Martín, Pilar, González-Sánchez, Víctor, García-Almeida, José Manuel, Palma, Samara, Sanz París, Alejandro, Burgos Peláez, Rosa, Institut Català de la Salut, [Matía Martín P] Departamento de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, Spain. [González-Sánchez V] Unidad de Endocrinología y Nutrición, Hospital Universitario Fundación de Alcorcón, Madrid, Spain. [Burgos Peláez R] Unitat de Suport Nutricional, Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [García Almeida JM] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Palma S] Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, Madrid, Madrid. [Sanz Paris A] Departamento de Nutrición, Hospital Universitario Miguel Servet, Zaragoza, Spain. Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES], enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia [ENFERMEDADES], Cirrosi hepàtica, Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [DISEASES], enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición [ENFERMEDADES], Hiperglucèmia, enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES], Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES], Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 [DISEASES], Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition [DISEASES], Diabetis no-insulinodependent, Malnutrició
Abstract: Diabetes; Liver cirrhosis; Medical nutrition Diabetes; Cirrosis hepática; Tratamiento nutricional Diabetis; Cirrosi hepàtica; Tractament nutricional La cirrosis hepática es una enfermedad progresiva y crónica del hígado, de etiología diversa, que se asocia frecuentemente con intolerancia a la glucosa y en algunos casos concurre con diabetes tipo 2 (DM2). La DM2 se asocia con resultados adversos en pacientes con cirrosis, incluyendo una mayor tasa de ingresos hospitalarios, una mayor prevalencia de carcinoma hepatocelular y un mayor riesgo de mortalidad. La desnutrición es otra complicación frecuente en la cirrosis, cuya prevalencia aumenta con el grado de disfunción hepática, empeorando el pronóstico. El presente artículo describe los resultados del consenso de expertos y las respuestas de los panelistas sobre el manejo nutricional en la práctica clínica habitual de los pacientes con diabetes/hiperglucemia hospitalizados en planta (no críticos) con cirrosis hepática. Liver cirrhosis is a progressive and chronic disease of the liver, of diverse etiology, which is frequently associated with glucose intolerance and in some cases concurs with type 2 diabetes (DM2). DM2 is associated with adverse outcomes in patients with cirrhosis, including a higher rate of hospitalizations, a higher prevalence of hepatocellular carcinoma, and an increased risk of mortality. Malnutrition is another frequent complication of cirrhosis, the prevalence of which increases with the degree of liver dysfunction, worsening the prognosis. This article describes the results of the expert consensus and the responses of the panelists on the nutritional management in routine clinical practice of patients with diabetes/hyperglycemia hospitalized (non-critically ill) with liver cirrhosis.
Published: 2022

41. Malnutrition management of hospitalized patients with diabetes/hyperglycemia in the perioperative setting

Author: Palma, Samara, García Malpartida, Katherine, García-Almeida, José Manuel, Matía‑Martín, Pilar, Sanz París, Alejandro, Burgos Peláez, Rosa, Institut Català de la Salut, [Palma Milla S] Unidad de Nutrición Clínica y Dietética, Servicio de Endocrinología y Nutrición, Hospital Universitario La Paz, Madrid, Spain. [García Malpartida K] Servicio de Endocrinología y Nutrición, Hospital Universitari i Politècnic La Fe, Valencia, Spain. [Burgos Peláez R] Unitat de Suport Nutricional, Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [García Almeida JM] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Matía Martín P] Departamento de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, Spain. [Sanz Paris A] Servicio de Nutrición, Hospital Universitario Miguel Servet, Zaragoza, Spain. Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia [ENFERMEDADES], Diabetis, Surgical Procedures, Operative [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [DISEASES], enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición [ENFERMEDADES], Hiperglucèmia, Operacions quirúrgiques, enfermedades del sistema endocrino::diabetes mellitus [ENFERMEDADES], intervenciones quirúrgicas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition [DISEASES], Malnutrició, Endocrine System Diseases::Diabetes Mellitus [DISEASES]
Abstract: Diabetes; Surgery; Perioperative setting Diabetes; Cirugía; Periodo perioperatorio Diabetis; Cirurgia; Període perioperatori Las personas con diabetes tienen un riesgo elevado de requerir una intervención quirúrgica a lo largo de su vida y de tener complicaciones perioperatorias en caso de un control metabólico deficiente. La hospitalización representa un evento estresante que, unido a otros factores asociados a procedimientos diagnósticos y terapéuticos, conlleva un deterioro del estado nutricional de los pacientes. Se ha observado una asociación entre un estado nutricional deficiente y resultados adversos en pacientes quirúrgicos. El presente artículo describe los resultados del consenso de expertos y las respuestas de los panelistas sobre el manejo nutricional en la práctica clínica habitual de los pacientes con diabetes/hiperglucemia hospitalizados en planta (no críticos) en el periodo perioperatorio. People with diabetes are at high risk of requiring surgical intervention throughout their lives, and of perioperative complications in case of poor metabolic control. Hospitalization represents a stressful event that, together with other factors associated with diagnostic and therapeutic procedures, leads to a deterioration in the nutritional status of the patients. An association between poor nutritional status and adverse outcomes in surgical patients has been observed. This article describes the results of the expert consensus and the responses of the panelists on the nutritional management in routine clinical practice of patients with diabetes/hyperglycemia hospitalized (non-critically ill) in the perioperative setting.
Published: 2022

42. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and cancer cachexia

Author: Suárez-Llanos, José Pablo, García-Almeida, José Manuel, Matía‑Martín, Pilar, Palma, Samara, Sanz París, Alejandro, Burgos Peláez, Rosa, Institut Català de la Salut, [Burgos Peláez R] Unitat de Suport Nutricional, Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Suárez Llanos JP] Unidad de Nutrición Clínica y Dietética, Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain. [García Almeida JM] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Matía Martín P] Departamento de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, Spain. [Palma S] Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, Madrid, Spain. [Sanz Paris A] Servicio de Endocrinología y Nutrición, Hospital Universitario Miguel Servet, Zaragoza, Spain. Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia [ENFERMEDADES], Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [DISEASES], enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición [ENFERMEDADES], Hiperglucèmia, afecciones patológicas, signos y síntomas::signos y síntomas::peso corporal::cambios en el peso corporal::pérdida de peso::emaciación::caquexia [ENFERMEDADES], Caquèxia, enfermedades del sistema endocrino::diabetes mellitus [ENFERMEDADES], Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss::Emaciation::Cachexia [DISEASES], Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition [DISEASES], Malnutrició, Diabetis no-insulinodependent, Endocrine System Diseases::Diabetes Mellitus [DISEASES]
Abstract: Diabetes; Cáncer; Caquexia tumoral Diabetis; Càncer; Caquèxia tumoral Diabetes; Cancer; Tumoral cachexia La diabetes es una comorbilidad frecuente en pacientes con cáncer, ya que comparten factores de riesgo comunes. En la enfermedad oncológica, la presencia de caquexia tumoral representa un factor de mal pronóstico, que se ve agravado por un estado nutricional deficiente. Clínicamente, la caquexia se manifiesta como una reducción significativa del peso corporal, acompañado de cambios en la composición corporal y alteraciones en el equilibrio del sistema biológico, y causa una disfunción progresiva. El presente artículo describe los resultados del consenso de expertos y las respuestas de los panelistas sobre el manejo nutricional en la práctica clínica habitual de los pacientes con diabetes/hiperglucemia hospitalizados en planta (no críticos) con caquexia tumoral concurrente. Diabetes is a frequent comorbidity in cancer patients, since they share common risk factors. In cancer, the concurrence of cachexia represents a poor prognostic factor, which is aggravated by poor nutritional status. Clinically, cancer cachexia manifests as a significant reduction in body weight, accompanied by changes in body composition and alterations in the balance of the biological system, and causes progressive dysfunction. This article describes the results of the expert consensus and the responses of the panelists on the nutritional management in routine clinical practice of patients with diabetes/hyperglycemia hospitalized (non-critically ill) with cancer cachexia.
Published: 2022

43. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and concurrent pathologies

Author: García-Almeida, José Manuel, Matía‑Martín, Pilar, Palma, Samara, Sanz París, Alejandro, Zugasti, Ana, Burgos Peláez, Rosa, Institut Català de la Salut, [Burgos Peláez R] Unitat de Suport Nutricional, Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [García Almeida JM] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Matía Martín P] Departamento de Endocrinología y Nutrición, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. [Palma Milla S] Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, Madrid, Spain. [Sanz Paris A] Servicio de Nutrición, Hospital Universitario Miguel Servet, Zaragoza, Spain. Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain. [Zugasti A] Sección de Nutrición Clínica, Servicio de Endocrinología y Nutrición, Hospital Universitario de Navarra, Pamplona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia [ENFERMEDADES], instalaciones, servicios y personal de asistencia sanitaria::servicios de salud::asistencia al paciente::hospitalización [ATENCIÓN DE SALUD], enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES], Desnutrició, Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [DISEASES], enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición [ENFERMEDADES], Hiperglucèmia, Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [DISEASES], Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition [DISEASES], Diabetis no-insulinodependent, Health Care Facilities, Manpower, and Services::Health Services::Patient Care::Hospitalization [HEALTH CARE]
Abstract: Desnutrición; Diabetes; Tratamiento nutricional Malnutrition; Diabetes; Medical nutrition Desnutrició; Diabetis; Tractament nutricional La diabetes mellitus tipo 2 es una enfermedad muy prevalente en todo el mundo y genera una carga clínica y económica creciente debido a sus complicaciones micro- y macrovasculares. Con frecuencia, las personas con diabetes son hospitalizadas por diversas patologías. Estos pacientes tienen, por lo general, un mayor riesgo de complicaciones, de estancias prolongadas y de mortalidad. Un factor adicional que empeora el pronóstico en estos pacientes es la presencia de desnutrición, sobre todo en personas de edad avanzada. Todo ello hace que el manejo de estos pacientes sea complejo y requiera un abordaje nutricional específico, cuya finalidad sea cubrir los requerimientos nutricionales manteniendo siempre el control glucémico. La finalidad de este trabajo es generar, en base a los datos disponibles en la bibliografía y la experiencia clínica, recomendaciones consensuadas por parte de dieciocho expertos en Endocrinología y Nutrición sobre el abordaje nutricional de pacientes hospitalizados con diabetes/hiperglucemia y comparar el manejo óptimo basado en estas recomendaciones con la atención habitual a pie de cama, según un panel de médicos españoles encuestados sobre su práctica clínica diaria. En este primer artículo de este número extraordinario de la revista Nutrición Hospitalaria, se describe la metodología seguida y los resultados obtenidos sobre las cuestiones comunes para todas las patologías. Type 2 diabetes mellitus is a highly prevalent disease worldwide, generating an increasing clinical and economic burden due to its micro- and macrovascular complications. Frequently, people with diabetes are hospitalized for various pathologies. These patients generally have higher risk of complications, prolonged hospitalizations and mortality. An additional factor that worsens the prognosis in these patients is the concurrence of malnutrition, especially in elderly people. All this makes the management of these patients challenging and requires a specific nutritional approach, whose purpose is to cover the nutritional requirements while always maintaining glycemic control. The purpose of this work is to provide, based on the evidence available in the literature and clinical experience, consensus recommendations by eighteen experts in Endocrinology and Nutrition on the nutritional approach of hospitalized patients with diabetes/ hyperglycemia and compare the optimal management, based on these recommendations with bedside usual care according to a panel of Spanish doctors surveyed about their daily clinical practice. This first article of this extraordinary issue of the journal Nutrición Hospitalaria describes the methodology of the study and the results obtained regarding common issues for all pathologies.
Published: 2022

44. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and heart failure

Author: Zugasti, Ana, Chinchetru, María Jesús, García-Almeida, José Manuel, Matía‑Martín, Pilar, Palma, Samara, Burgos Peláez, Rosa, Institut Català de la Salut, [Zugasti Murillo A] Sección de Nutrición Clínica, Servicio de Endocrinología y Nutrición, Hospital Universitario de Navarra, Pamplona, Spain. [Chinchetru MJ] Servicio de Endocrinología y Nutrición, Hospital San Pedro, La Rioja, Spain. [Burgos R] Unitat de Suport Nutricional, Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [García Almeida JM] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Matía Martín P] Departamento de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, Spain. [Palma S] Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES], enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia [ENFERMEDADES], Cardiovascular Diseases::Heart Diseases::Heart Failure [DISEASES], Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [DISEASES], enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición [ENFERMEDADES], Hiperglucèmia, Insuficiència cardíaca, Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 [DISEASES], enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca [ENFERMEDADES], Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition [DISEASES], Diabetis no-insulinodependent, Malnutrició
Abstract: Diabetes; Insuficiencia cardíaca; Tratamiento nutricional Diabetis; Insuficiència cardíaca; Tractament nutricional Diabetes; Heart failure; Medical nutrition La insuficiencia cardíaca (IC) es una de las principales causas de morbilidad y mortalidad entre las personas mayores, lo que la convierte en un importante problema de salud pública. Las enfermedades cardiovasculares en general, y la IC en particular, son comorbilidades frecuentes en personas con diabetes tipo 2 (DM2). La presencia de DM2 e IC se asocia con síntomas y signos clínicos más graves, y peor calidad de vida y pronóstico. Además, debido al estado hipercatabólico y los trastornos de la absorción de nutrientes, la desnutrición está presente en muchos casos de IC. El presente artículo describe los resultados del consenso de expertos y las respuestas de los panelistas sobre el manejo nutricional en la práctica clínica habitual de los pacientes con diabetes/hiperglucemia hospitalizados en planta (no críticos) con IC. Heart failure (HF) is one of the leading causes of morbidity and mortality among older people, making it a major public health problem. Cardiovascular diseases in general, and HF in particular, are common comorbidities in people with type 2 diabetes (DM2). The concurrence of DM2 and HF is associated with more severe clinical symptoms and signs, and poorer quality of life and prognosis. Furthermore, due to the hypercatabolic state and nutrient absorption disorders, malnutrition is present in many HF cases. This article describes the results of the expert consensus and the responses of the panelists on the nutritional management in routine clinical practice of patients with diabetes/hyperglycemia hospitalized (non-critically ill) with HF.
Published: 2022

45. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and hip fracture

Author: Sanz París, Alejandro, Artero Fullana, Ana, García-Almeida, José Manuel, Matía‑Martín, Pilar, Palma, Samara, Burgos Peláez, Rosa, Institut Català de la Salut, [Sanz Paris A] Servicio de Endocrinología y Nutrición, Hospital Universitario Miguel Servet, Zaragoza, Spain. Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain. [Artero A] Unidad de Endocrinología y Nutrición, Hospital Universitario General de Valencia, Valencia, Spain. [Burgos R] Unitat de Suport Nutricional, Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [García Almeida JM] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Matía Martín P] Departamento de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, Spain. [Palma S] Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES], enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia [ENFERMEDADES], Articulació coxofemoral - Ferides i lesions, Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [DISEASES], enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición [ENFERMEDADES], Hiperglucèmia, Wounds and Injuries::Fractures, Bone::Femoral Fractures::Hip Fractures [DISEASES], Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 [DISEASES], Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition [DISEASES], Diabetis no-insulinodependent, Malnutrició, heridas y lesiones::fracturas óseas::fracturas del fémur::fracturas de cadera [ENFERMEDADES]
Abstract: Diabetes; Osteoporosis; Medical nutrition Diabetes; Osteoporosis; Tratamiento nutricional Diabetis; Osteoporosi; Tractament nutricional La incidencia de fractura de cadera cada año es muy alta, lo que genera una importante carga asistencial y socioeconómica. Estas fracturas pueden producirse a cualquier edad, pero la gran mayoría ocurren en personas mayores de 65 años y con predominancia del sexo femenino, debido al mayor riesgo de osteoporosis tras la menopausia. La diabetes mellitus tipo 2 (DM2), aparte de alterar el metabolismo glucídico, lipídico y proteico, también causa una desregulación del calcio, fósforo y magnesio, y alteraciones del metabolismo óseo. La prevalencia de desnutrición en pacientes con fractura de cadera es también elevada, por la edad avanzada, y la misma lesión aguda generar respuestas catabólicas e inflamatorias que resultan en desnutrición relacionada con la enfermedad y sarcopenia, lo que agrava el estado clínico del paciente. El presente artículo describe los resultados del consenso de expertos y las respuestas de los panelistas sobre el manejo nutricional en la práctica clínica habitual de los pacientes con diabetes/hiperglucemia hospitalizados en planta (no críticos) con fractura de cadera. The yearly incidence of hip fracture is very high, which generates significant healthcare and socioeconomic burden. These fractures can occur at any age, but the vast majority occur in people over 65 years of age and predominantly in women, due to the increased risk of menopause-associated osteoporosis. Type 2 diabetes mellitus (DM2), apart from altering glucose, lipid and protein metabolisms, also causes a deregulation of calcium, phosphorus and magnesium and dysfunction in bone metabolism. The prevalence of malnutrition in patients with hip fracture is also high, due to their advanced age, and the acute injury itself provokes catabolic and inflammatory responses that result in disease-related malnutrition and sarcopenia, which aggravates the patient’s clinical condition. This article describes the results of the expert consensus and the responses of the panelists on the nutritional management in routine clinical practice of patients with diabetes/hyperglycemia hospitalized (non-critically ill) with hip fracture.
Published: 2022

46. Sexualized drug use among men who have sex with men in Madrid and Barcelona: The gateway to new drug use?

Author: Guerras Moreira, Juan Miguel, Hoyos, Juan, Donat Lopez, Marta, Fuente, Luis de la, Palma Díaz, David, Ayerdi, Oskar, García-Pérez, Jorge N, García de Olalla, Patricia, Belza Egozcue, Maria Jose, Methysos Project Group, Institut Català de la Salut, [Guerras JM, Donat M] Escuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, Spain. CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain. [Hoyos J] Independent Researcher, Madrid, Spain. [de la Fuente L] CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain. Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain. [Palma Díaz D] CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain. Servicio de Epidemiología, Agència de Salut Pública de Barcelona, Barcelona, Spain. [Ayerdi O] Centro Sanitario Sandoval, Instituto de Investigación Sanitaria San Carlos, Hospital Clínico San Carlos, Madrid, Spain. [García-Pérez JN] Unitat d'Infeccions de Transmissió Sexual, Drassanes-Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, and Plan Nacional de Drogas (España)
Subjects: Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Male, Adult, Substance-Related Disorders, N-Methyl-3,4-methylenedioxyamphetamine, Sexually Transmitted Diseases, HIV Infections, Qüestionaris, Sildenafil Citrate, Methamphetamine, Behavior and Behavior Mechanisms::Behavior::Sexual Behavior::Sexuality::Homosexuality::Homosexuality, Male [PSYCHIATRY AND PSYCHOLOGY], Sexual and Gender Minorities, conducta y mecanismos de la conducta::conducta::conducta sexual::sexualidad::homosexualidad::homosexualidad masculina [PSIQUIATRÍA Y PSICOLOGÍA], Humans, Persons::Drug Users [NAMED GROUPS], Drug use, Homosexuality, Male, Malalties transmissibles - Transmissió, Homosexualitat masculina, virosis::enfermedades de transmisión sexual [ENFERMEDADES], Public Health, Environmental and Occupational Health, técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Drug initiation, Abús de substàncies, Men who have sex with men, personas::consumidores de drogas [DENOMINACIONES DE GRUPOS], Child, Preschool, Virus Diseases::Sexually Transmitted Diseases [DISEASES], Sexualized drug use, Chemsex
Abstract: Men who have sex with men; Sexualized drug use Homes que tenen sexe amb homes; Consum sexual de drogues Hombres que tienen sexo con hombres; Consumo sexual de drogas This original study compares the prevalences of drug use for any purpose and for sexualized drug use (SDU) among MSM. It also describes relevant characteristics of first SDU, analyzes to what extent SDU has been the first experience (the gateway) with different drugs by age and explores the correlates of SDU. Study participants included 2,919 HIV-negative MSM attending four HIV/STI diagnosis services in Madrid and Barcelona. They answered an online, self-administered questionnaire. Poisson regression models with robust variance were used. About 81.4% had ever used any drug, and 71.9% had done so in the last-12-months, while 56% had ever engaged in SDU, and 50% had done so in the last-12-months. Participants under 25 years old had the lowest prevalences of SDU, and the 25–39 age group the highest, except for Viagra, which was higher among those over age 40. The most frequently used drugs for first SDU were poppers (53.6%), cannabis (19.6%) and Viagra (12.2%). These drugs were also the most ever consumed for SDU. Among sexualized users, methamphetamine (78.3%) and Mephedrone (75.4%) were used always/most of the times for sex in the last-12-months. Around 72.2% of Mephedrone sexualized users and 69.6% of Methamphetamine vs 23.1% of ecstasy users' first consumption of these drugs involved use for sex. These drugs were provided to them free where they have sex for 66.8, 79.1, and 31.9%, respectively. On that occasion, 8.1% of Mephedrone, 6.8% of Methamphetamine and 18.4% of ecstasy users had sex only with steady partner; with 50.2, 56.2, and 26.2% respectively using a condom with any partner. SDU in the first use was associated with similar variables for recreational and chemsex drugs. The highest prevalence ratios were for having ever been penetrated by >20 men and having ever injected drugs. It can be concluded that the prevalence of SDU was more than half of the prevalence for any purpose. Thus SDU was the gateway to use for many drugs in an important proportion of users, who frequently consumed drugs that were free and had condomless anal sex with occasional and multiple partners. These circumstances were much more common for chemsex than for recreational drugs. This study was supported by the Delegación del Gobierno para el Plan Nacional sobre Drogas (2019I017).
Published: 2022
Full Text: View/download PDF

47. Time to decision in sepsis

Author: Ricard Ferrer, Juan González del Castillo, María Martínez-Martínez, Erika P. Plata-Menchaca, M. Nieves Larrosa, Institut Català de la Salut, [Ferrer R, Martínez-Martínez M, Plata-Menchaca EP] Servei de Medicina Intensiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [González Del Castillo J] Emergency Department, Heatlhcare Research Institute (IdISSC), Hospital Clínico San Carlos de Madrid, Spain. Complutense University, Madrid, Spain. [Larrosa MN] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents [CHEMICALS AND DRUGS], Microbiology (medical), Pharmacology, infecciones bacterianas y micosis::infección::enfermedades transmisibles [ENFERMEDADES], Otros calificadores::/uso terapéutico [Otros calificadores], Medicaments antiinfecciosos - Ús terapèutic, Otros calificadores::/diagnóstico [Otros calificadores], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos [COMPUESTOS QUÍMICOS Y DROGAS], infecciones bacterianas y micosis::infección::sepsis [ENFERMEDADES], General Medicine, Septicèmia - Diagnòstic, Other subheadings::/diagnosis [Other subheadings], Malalties transmissibles, Bacterial Infections and Mycoses::Infection::Sepsis [DISEASES], Bacterial Infections and Mycoses::Infection::Communicable Diseases [DISEASES], Other subheadings::/therapeutic use [Other subheadings]
Abstract: Código de sepsis; Gestión de la sepsis; Indicadores de calidad Codi de sèpsia; Gestió de la sèpsia; Indicadors de qualitat Sepsis Code; Sepsis management; Quality indicators Introduction. This study aimed to identify the common barriers leading to delayed initial management, microbiological diagnosis, and appropriate empirical antimicrobial treatment in sepsis. Patients and methods. A cross-sectional study was performed by the application of a population-based survey. Four different surveys were designed, targeting the healthcare personnel located in main hospital areas [emergency department (SEMES); infectious diseases and clinical microbiology-microbiological diagnosis (SEIMC-M); intensive care and infectious diseases, (SEMICYUC-GTEIS); and infectious diseases and clinical microbiology-clinical diagnosis, (SEIMC-C)]. Results. A total of 700 valid surveys were collected from June to November 2019: 380 (54.3%) of SEMES, 127 (18.1%) of SEIMC-M, 97 (13.9%) de SEMICYUC-GTEIS and 96 (13.7%) of SEIMC-C, in 270 hospitals of all levels of care. The qSOFA score was used as a screening tool. The most used biomarker was procalcitonin (n=92, 39.8%). The sepsis code was implemented in 157 of 235 participating centers (66.2%), particularly in tertiary level hospitals. The mean frequency of contaminated blood cultures was 8.9% (8.7). In 85 (78.7%) centers, positive results of blood cultures were available within the first 72 hours and were communicated to the treating physician effectively by phone or e-mail in 76 (81.7%) cases. The main reason for escalating treatment was clinical deterioration, and the reason for de-escalating antimicrobials was significantly different between the specialties. Quality indicators were not frequently monitored among the different participating centers. Conclusion. There are significant barriers that hinder adequate management processes in sepsis in Spanish hospitals. Introducción. Este estudio tuvo como objetivo identificar las barreras comunes que conducen al retraso en el manejo inicial, el diagnóstico microbiológico y el tratamiento antimicrobiano empírico adecuado en la sepsis. Pacientes y métodos. Se realizó un estudio transversal mediante la aplicación de una encuesta de base poblacional. Se diseñaron cuatro encuestas diferentes, dirigidas al personal de salud ubicado en las principales áreas hospitalarias [urgencias (SEMES); enfermedades infecciosas y microbiología clínica-diagnóstico microbiológico (SEIMC-M); cuidados intensivos y enfermedades infecciosas (SEMICYUC-GTEIS); y enfermedades infecciosas y microbiología clínica-diagnóstico clínico, (SEIMC-C)]. Resultados. Se recogieron un total de 700 encuestas válidas de junio a noviembre de 2019: 380 (54,3%) de SEMES, 127 (18,1%) de SEIMC-M, 97 (13,9%) de SEMICYUC-GTEIS y 96 (13,7%) de la SEIMC-C, en 270 hospitales de todos los niveles de atención. El qSOFA se utilizó principalmente como herramienta de detección. El biomarcador más utilizado fue la procalcitonina (n=92, 39,8%). El código sepsis estaba implementado en 157 de 235 centros participantes (66,2%), particularmente en hospitales de tercer nivel. La frecuencia media de hemocultivos contaminados fue del 8,9% (8,7). En 85 (78,7%) de los centros, los resultados de los hemocultivos positivos estuvieron disponibles en las primeras 72 horas y se comunicaron al médico responsable del paciente por teléfono o correo electrónico en 76 casos (81,7%). El motivo principal de la escalada del tratamiento fue el deterioro clínico y el motivo de la desescalada de los antimicrobianos fue significativamente diferente entre las especialidades. Los indicadores de calidad no se monitorizaban con frecuencia en los diferentes centros. Conclusión. Existen importantes barreras que dificultan los procesos de manejo adecuado de la sepsis en los hospitales españoles. This research has received an unrestricted grant Beckton, Dickinson and Company (BD), S.A.
Published: 2022

48. No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis

Author: Manuel Díaz-Llopis, Miguel Cordero-Coma, Ana Márquez, Blanca Molins, Ricardo Blanco, María José del Rio, J. Cañal, Marina Begoña Gorroño-Echebarría, Javier Martín, Agustin Martinez-Berriotxoa, David Díaz Valle, María Carmen Cenit, Norberto Ortego-Centeno, José Manuel Martín-Villa, Enrique de Ramón, José Luis García Serrano, Esperanza Pato, Alfredo Adán, Alejandro Fonollosa, [Cénti,MC, Márquez,A, Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, IPBLN, CSIC, Granada, Spain. [Cordero-Coma,M] Ophthalmology Department, Hospital de León, León, Spain. [Gorroño-Echebarría, MB] Ophthalmology Department, Hospital Universitario Principe de Asturias, Alcalá de Henares, Spain. [Fonollosa,A, Martínez-Berriotxoa,A] Internal Medicine Department, Hospital de Cruces, Bilbao, Spain. [Adán,A, and Molins,B] Ophthalmology Department, Hospital Clinic, Barcelona, Spain. [DÍaz Valle,D] Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain. [Pato,E] Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain. [Blanco,R] Rheumatology Department, Hospital Marqués de Valdecilla, IFIMAV, Santander, Spain. [Cañal,J] Ophthalmology Department, Hospital Marqués de Valdecilla, Santander, Spain. [Díaz-Llopis,M] Ophthalmology Department, Hospital Universitario La Fe, Valencia, Spain. [García Serrano,JL] Ophthalmology Department, Hospital Clínico San Cecilio, Granada, Spain. [Ramón de, E] Internal Medicine Department, Hospital Carlos Haya, Málaga, Spain. [Río del,MJ] Ophthalmology Department, Hospital Carlos Haya, Málaga, Spain. [Martín-Villa,JM] Immunology Department, Facultad de Medicina, Universidad Complutense de Madrid, Spain. [Ortego-Centeno,N] Internal Medicine Department, Hospital Clínico San Cecilio, Granada, Spain.
Subjects: Phenomena and Processes::Immune System Phenomena::Immunity::Autoimmunity [Medical Subject Headings], Male, Polimorfismo de nucleótido simple, Polimorfismo genético, Autoimmunity, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease_cause, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Gene Frequency, Genotype, STAT4, Multidisciplinary, Receptores de interleucina, Middle Aged, STAT4 Transcription Factor, Phenotype, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Interleukin [Medical Subject Headings], Medicine, Female, Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings], Alelos, Uveitis, Research Article, Adult, musculoskeletal diseases, Science, Check Tags::Male [Medical Subject Headings], Autoinmunidad, Biology, Polymorphism, Single Nucleotide, Factores de transcripción, IL23R protein, human, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], medicine, Genetic predisposition, Humans, Genetic Predisposition to Disease, Allele, Allele frequency, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleles [Medical Subject Headings], Alleles, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide [Medical Subject Headings], Polymorphism, Genetic, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Adaptor Proteins, Signal Transducing::STAT Transcription Factors [Medical Subject Headings], Receptors, Interleukin, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings], medicine.disease, Uveítis, Check Tags::Female [Medical Subject Headings], Immunology, Genotipo, Diseases::Eye Diseases::Uveal Diseases::Uveitis [Medical Subject Headings]
Abstract: OBJECTIVE: STAT4 and IL23R loci represent common susceptibility genetic factors in autoimmunity. We decided to investigate for the first time the possible role of different STAT4/IL23R autoimmune disease-associated polymorphisms on the susceptibility to develop non-anterior uveitis and its main clinical phenotypes. METHODS: Four functional polymorphisms (rs3821236, rs7574865, rs7574070, and rs897200) located within STAT4 gene as well as three independent polymorphisms (rs7517847, rs11209026, and rs1495965) located within IL23R were genotyped using TaqMan® allelic discrimination in a total of 206 patients with non-anterior uveitis and 1553 healthy controls from Spain. RESULTS: No statistically significant differences were found when allele and genotype distributions were compared between non-anterior uveitis patients and controls for any STAT4 (rs3821236: P=0.39, OR=1.12, CI 95%=0.87-1.43; rs7574865: P=0.59 OR=1.07, CI 95%=0.84-1.37; rs7574070: P=0.26, OR=0.89, CI 95%=0.72-1.10; rs897200: P=0.22, OR=0.88, CI 95%=0.71-1.08;) or IL23R polymorphisms (rs7517847: P=0.49, OR=1.08, CI 95%=0.87-1.33; rs11209026: P=0.26, OR=0.78, CI 95%=0.51-1.21; rs1495965: P=0.51, OR=0.93, CI 95%=0.76-1.15). CONCLUSION: Our results do not support a relevant role, similar to that described for other autoimmune diseases, of IL23R and STAT4 polymorphisms in the non-anterior uveitis genetic predisposition. Further studies are needed to discard a possible weak effect of the studied variant.
Published: 2013

49. Two functional variants of IRF5 influence the development of macular edema in patients with non-anterior uveitis

Author: José Luis García Serrano, María Carmen Cenit, María José del Rio, Miguel Cordero-Coma, Ana Márquez, Marina Begoña Gorroño-Echebarría, Alfredo Adán, Joseba Artaraz, Javier Martín, David Díaz Valle, Manuel Díaz-Llopis, Ricardo Blanco, J. Cañal, Victor Llorenç, Esperanza Pato, Norberto Ortego-Centeno, José Manuel Martín-Villa, Enrique de Ramón, Alejandro Fonollosa, [Márquez,A, Cénit,MC, Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, IPBLN, CSIC, Granada, Spain. [Cordero-Coma,M] Ophthalmology Department, Hospital de León, Spain. [Ortego-Centeno,N] Internal Medicine Department, Hospital Clínico San Cecilio, Granada, Spain. [Adán,A, Llorenç,V] Ophthalmology Department, Hospital Clínic, Barcelona, Spain. [Fonollosa,A, Artaraz,J] Ophthalmology Department, Hospital de Cruces, Bilbao, Spain. [Díaz Valle,D] Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain. [Pato,E] Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain. [Blanco,R] Rheumatology Department, Hospital Marqués de Valdecilla, IFIMAV, Santander, Spain. [Cañal,J] Ophthalmology Department, Hospital Marqués de Valdecilla, IFIMAV, Santander, Spain. [Díaz-Llopis,M] Ophthalmology Department, Hospital La Fe, Valencia, Spain.[Ramón,E de] Internal Medicine Department, Hospital Carlos Haya, Málaga, Spain. [Rio,MJ del] Ophthalmology Department, Hospital Carlos Haya, Málaga, Spain. [García Serrano,JL] Ophthalmology Department, Hospital Clínico San Cecilio, Granada, Spain. [Martín-Villa,JM] Immunology Department, Facultad de Medicina, Universidad Complutense de Madrid, Spain. [Gorroño-Echebarría,MB] Ophthalmology Department, Hospital Principe de Asturias, Alcalá de Henares, Spain., and Universitat de Barcelona
Subjects: Male, Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings], Polimorfismo de nucleótido simple, lcsh:Medicine, Interferó, Autoimmunity, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease_cause, Linkage Disequilibrium, Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Gene Frequency, Interferon, Diseases::Eye Diseases::Uveal Diseases::Uveitis::Panuveitis::Uveitis, Anterior [Medical Subject Headings], lcsh:Science, Multidisciplinary, Autoimmunitat, Middle Aged, Phenomena and Processes::Genetic Phenomena::Genetic Linkage::Linkage Disequilibrium [Medical Subject Headings], Uveitis, Anterior, Phenomena and Processes::Genetic Phenomena::Genotype::Genetic Predisposition to Disease [Medical Subject Headings], Modelos logísticos, Phenotype, Diseases::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration::Macular Edema [Medical Subject Headings], Oftalmologia, Interferon Regulatory Factors, Female, Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings], Fenotipo, Uveitis, Research Article, medicine.drug, Adult, Genotype, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Adaptor Proteins, Signal Transducing::Interferon Regulatory Factors [Medical Subject Headings], Check Tags::Male [Medical Subject Headings], Biology, Polymorphism, Single Nucleotide, Macular Edema, Genetic variation, Edema macular, medicine, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], Humans, Genetic Predisposition to Disease, Macular edema, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Models, Statistical::Logistic Models [Medical Subject Headings], Alleles, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleles [Medical Subject Headings], Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide [Medical Subject Headings], lcsh:R, medicine.disease, Uveítis anterior, Ophthalmology, Logistic Models, Factores reguladores del interferón, Haplotypes, Desequilibrio de ligamiento, Check Tags::Female [Medical Subject Headings], Genetic marker, Immunology, lcsh:Q, Phenomena and Processes::Genetic Phenomena::Gene Frequency [Medical Subject Headings], IRF5, Interferon regulatory factors
Abstract: Objective:Interferon (IFN) signaling plays a crucial role in autoimmunity. Genetic variation in interferon regulatory factor 5 (IRF5), a major regulator of the type I interferon induction, has been associated with risk of developing several autoimmune diseases. In the current study we aimed to evaluate whether three sets of correlated IRF5 genetic variants, independently associated with SLE and with different functional roles, are involved in uveitis susceptibility and its clinical subphenotypes.Methods:Three IRF5 polymorphisms, rs2004640, rs2070197 and rs10954213, representative of each group, were genotyped using TaqMan® allelic discrimination assays in a total of 263 non-anterior uveitis patients and 724 healthy controls of Spanish origin.Results:A clear association between two of the three analyzed genetic variants, rs2004640 and rs10954213, and the absence of macular edema was observed in the case/control analysis (PFDR=5.07E-03, OR=1.48, CI 95%=1.14-1.92 and PFDR=3.37E-03, OR=1.54, CI 95%=1.19-2.01, respectively). Consistently, the subphenotype analysis accordingly with the presence/absence of this clinical condition also reached statistical significance (rs2004640: P=0.037, OR=0.69, CI 95%=0.48-0.98; rs10954213: P=0.030, OR=0.67, CI 95%=0.47-0.96), thus suggesting that both IRF5 genetic variants are specifically associated with the lack of macular edema in uveitis patients.Conclusion:Our results clearly showed for the first time that two functional genetic variants of IRF5 may play a role in the development of macular edema in non-anterior uveitis patients. Identifying genetic markers for macular edema could lead to the possibility of developing novel treatments or preventive therapies. © 2013 Márquez et al.
Published: 2013

50. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry

Author: Laurent, Bertoletti, Sara, Quenet, Silvy, Laporte, Joan, Sahuquillo, Francisco, Conget, José, Pedrajas, Mar, Martin, Ignacio, Casado, Antonio Riera Mestre, Manuel, Monreal, Arcelus, Ji, Arcos, Mp, Ballaz, A, Barba, R, Barrón, M, Barrón Andrés, B, Blanco Molina, A, Bosco, J, Chaves, E, Cañas, I, Casado, I, Contra, A, Conget, F, de Miguel, J, del Campo, R, del Toro, J, Falgá, C, Fernández Capitán, C, Gabriel, F, Gallego, P, García Bragado, F, Gavín, O, Gómez, V, González, J, Gracia, V, Guil, M, Guillem, N, Gutiérrez, J, Hernández, L, Hernández Huerta, D, Jaras, Mj, Jiménez, D, Jiménez, S, Jiménez Gil, M, Lobo, Jl, Lecumberri, R, López Jiménez, L, Lorenzo, A, Macià, M, Madridano, O, Marchena, Pj, Martín, M, Martín Villasclaras JJ, Monreal, M, Morales, M, Morán, Lp, Nauffal, Md, Nieto, Ja, Núñez, Mj, Mascareño, Mc, Ogea, Jl, Otero, R, Pedrajas, Jm, Riera Mestre, A, Rodríguez Dávila MA, Román, P, Román Bernal, B, Roldán, V, Rosa, V, Royo, C, Ruíz, J, Ruiz Gamietea, A, Ruiz Giménez, N, Sahuquillo, Jc, Sánchez, R, Sánchez Muñoz Torrero JF, Soler, S, Soto, Mj, Tiberio, G, Tolosa, C, Trujillo, J, Uresandi, F, Valdés, M, Valle, R, Vela, J, Vida, G, Villalta, J, Zorrilla, V, Bertoletti, L, Bura Riviere, A, Debourdeau, P, Farge Bancel, D, Lamuraglia, M, Mahe, I, Merah, A, Quere, I, Babalis, D, Papadakis, M, Brenner, B, Barillari, G, Ciammaichella, M, Di Micco, P, Dalla Valle, F, Duce, R, La Regina, M, Maida, R, Orlandini, F, Pasca, S, Piovella, C, Poggio, R, Prandoni, Paolo, Quintavalla, R, Rota, L, Schenone, A, Tonello, D, Visonà, A, Zalunardo, B, Bosevski, M, Bounameaux, H, Malý, R, Hirmerova, J, Salgado, E., BMC, Ed., Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Service de Médecine Thérapeutique, CHU Saint-Etienne-Hôpital Nord - Saint Etienne, Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Saint Etienne, Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Internal Medicine, Hospital Municipal de Badalona, Department of Pneumonology, Hospital Clínico Universitario Lozano Blesa, Hospital Clínico San Carlos, Hospital Universitario Infanta Sofía, Hospital Universitario Virgen de las Nieves, Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL)-Hospital Universitari de Bellvitge-Hospital Duran i Reynals, Hospital Universitari Germans Trias I Pujol, The RIETE Investigators, Universitat de Barcelona, [Bertoletti,L, Quenet,S, Laporte,S] Thrombosis Research Group, EA3065, University Saint-Etienne, Saint-Etienne, France. [Bertoletti,L, Laporte,S] CIE3, INSERM, Saint-Etienne, France. Department of Therapeutic Medicine, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France. [Sahuquillo,JC] Department of Internal Medicine, Hospital Municipal de Badalona, Barcelona, Spain. [Conget,F] Department of Pneumonology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Pedrajas,JM] Department of Internal Medicine, Hospital Clínico San Carlos, Madrid, Spain. [Martin,M] Department of Internal Medicine, Hospital Infanta Sofía, Madrid, Spain. [Casado,I] Department of Pneumonology, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Riera-Mestre,A] Department of Internal Medicine, Hospital Univesitari de Bellvitge - IDIBELL, Barcelona, Spain. [Monreal,M] Department of Internal Medicine, Hospital Universitari Germans Trias I Pujol, Badalona, Spain., and Bayer Pharma AG for supporting this Registry. Bayer Pharma AG’s support was limited to the part of RIETE outside Spain
Subjects: Male, Internationality, Diseases::Respiratory Tract Diseases::Lung Diseases::Pulmonary Embolism [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis [Medical Subject Headings], Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Comorbidity, 030204 cardiovascular system & hematology, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Comorbidity [Medical Subject Headings], Prevalence, Tasa de Supervivencia, Registries, Young adult, Pneumology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings], Embòlia pulmonar, Aged, 80 and over, COPD, Venous Thromboembolism, Middle Aged, Prognosis, 3. Good health, Pulmonary embolism, Survival Rate, Embolia Pulmonar, Deep venous thrombosis, Female, Pneumologia, Venous thromboembolism, Cohort study, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings], Pronòstic mèdic, Análisis de Supervivencia, Check Tags::Male [Medical Subject Headings], Risk Assessment, 03 medical and health sciences, Young Adult, Internal medicine, Thromboembolism, medicine, Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Pulmonary Disease, Chronic Obstructive [Medical Subject Headings], Humans, cardiovascular diseases, Chronic obstructive pulmonary diseases, Intensive care medicine, Survival rate, Tromboembolisme, Survival analysis, Aged, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Survival Rate [Medical Subject Headings], Disciplines and Occupations::Social Sciences::Internationality [Medical Subject Headings], business.industry, Enfermedad Pulmonar Obstructiva Crónica, Research, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Assessment [Medical Subject Headings], equipment and supplies, medicine.disease, Survival Analysis, respiratory tract diseases, Check Tags::Female [Medical Subject Headings], 030228 respiratory system, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings], Estudios de Cohortes, Diseases::Cardiovascular Diseases::Vascular Diseases::Embolism and Thrombosis::Thromboembolism::Venous Thromboembolism [Medical Subject Headings], business, Medición de Riesgo
Abstract: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) have a modified clinical presentation of venous thromboembolism (VTE) but also a worse prognosis than non-COPD patients with VTE. As it may induce therapeutic modifications, we evaluated the influence of the initial VTE presentation on the 3-month outcomes in COPD patients. METHODS COPD patients included in the on-going world-wide RIETE Registry were studied. The rate of pulmonary embolism (PE), major bleeding and death during the first 3 months in COPD patients were compared according to their initial clinical presentation (acute PE or deep vein thrombosis (DVT)). RESULTS Of the 4036 COPD patients included, 2452 (61%; 95% CI: 59.2-62.3) initially presented with PE. PE as the first VTE recurrence occurred in 116 patients, major bleeding in 101 patients and mortality in 443 patients (Fatal PE: first cause of death). Multivariate analysis confirmed that presenting with PE was associated with higher risk of VTE recurrence as PE (OR, 2.04; 95% CI: 1.11-3.72) and higher risk of fatal PE (OR, 7.77; 95% CI: 2.92-15.7). CONCLUSIONS COPD patients presenting with PE have an increased risk for PE recurrences and fatal PE compared with those presenting with DVT alone. More efficient therapy is needed in this subtype of patients. Yes
Published: 2013
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

8,235 results on '"Hospital Clínico San Carlos"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources